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Figure 1.1: Overview of human diseases targeted by gene therapy clinical trials worldwide. 
As of June 2011, a total of 1714 gene therapy trials have been reported. A majority (64.6%) of trials 
were involved in the treatment of cancer, followed by cardiovascular disease (8.5%), inherited 
monogenic diseases (8.3%) and infectious diseases (8.1%). Modified from the Journal of gene 
Medicine, www.wiley.com/legacy/wileychi/genmed/clinical. 
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1. Introduction 
1.1. Gene therapy: the novel medical concept of the future  
1.1.1. Gene therapy and treated diseases  
Gene therapy is the use of a genetic element to correct a deficiency in an individual's 
cells and biological tissues to treat disease. The common form of gene therapy is the 
introduction of therapeutic nucleotides into target cells via different vectors as delivery 
vehicle, resulting in the cure of diseases (Anderson, 1992). As a medical concept, gene 
therapy first emerged in the 1960s, when thousands of human diseases were distinguished 
to be genetically determined (McKusick, 1970; Friedmann and Roblin, 1972). Gene therapy 
has long been considered as a promising technique to treat both inherited and acquired 
diseases. Since the first human gene therapy trial was conducted in 1989 (Rosenberg et al., 
1990), up to now over 1700 clinical studies have been completed, are ongoing or have been 
approved (Wiley, 2011). These trials deal with different human diseases, involving for 
instance cancer, cardiovascular disease, inherited monogenic diseases and infectious 
disease (Figure 1.1).  
Cancer treatments took a good portion of these clinical trials, because of the 
enormous prevalence, impact and potentially fatal outcomes. So far, different types of cancer 
have been targeted, including head and neck, lung, skin and breast tumors, as well as 
nervous system and gastrointestinal tumors (Edelstein et al., 2007; Bedognetti et al., 2010). 
Distinct approaches are being investigated, mainly dealing with the delivery of tumour-
suppressor genes, prodrug-activating genes and immunostimulatory genes into tumor cells 
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(McCormick, 2001; Wilson, 2002). An alternative option for cancer gene therapy is to 
harness the inherent ability of viruses to replicate and lyse cells, so called oncolytic viruses 
(Dalba et al., 2005). The proposed future application of the oncolytic viruses is the safe 
tumour-specific replication, which is enabled by the deletion of viral genes that are necessary 
for replication in normal somatic cells. Thus the virus can only replicate in tumour cells in 
which the missing function is supplied (Van Den Wollenberg DJ et al., 2009; Stanford et al., 
2010). 
Further diseases targeted in human gene therapy clinical trials are cardiovascular 
disease, inherited monogenic diseases and infectious disease. As cardiovascular diseases is 
nowadays one major cause of morbidity and mortality in human population, gene therapy is 
emerging as a potential alternative for patients who are not candidates for traditional 
revascularization procedures (Jazwa et al., 2007). The cardiovascular gene therapy is 
expected to show improvement in therapeutic angiogenesis, myocardial protection, 
regeneration and repair (Iverson et al., 2008; Jones and Koch, 2005). However, most of 
cardiovascular gene therapy trials have addressed therapeutic angiogenesis to increase 
blood flow to ischemic regions (Barbato et al., 2003; Edelstein et al., 2007). Recently, the 
combination of different angiogenic growth factors or simultaneous applications of genes and 
progenitor cells in order to obtain stable and functional blood vessels in ischemic tissue have 
achieved promising success (Losordo and Dimmeler, 2004; Stamm et al., 2008). 
Gene therapy is being investigated as an alternative treatment for a wide range of 
infectious diseases that are not amenable to standard clinical management (Walter, 1995; 
Bunnell and Morgan, 1998). Gene therapy for infectious diseases requires the introduction of 
transgenes designed to specifically block or inhibit some particular virus gene expression or 
function of essential gene products, thus the replication of the infectious agent is blocked or 
limited. The therapeutic material for treatment could be nucleic acids like antisense DNA and 
RNA, protein as single-chain antibodies or even genetic vaccines, with the aim of inhibiting 
multiple stages of the viral life cycle (Lorenzi et al., 2010; Liu, 2010). In clinical trials, human 
immunodeficiency virus (HIV) infected patients are the major research target (Gilboa and 
Smith, 1994; Sorg and Methali, 1997). However, most clinical trials aimed not at the 
treatment of AIDS or the HIV infection itself, but the secondary infection caused by tetanus, 
cytomegalovirus (CMV), hepatitis B/C and influenza virus (Edelstein et al., 2007). 
The treatment of monogenetic diseases, as an initial idea for gene therapy, is to 
correct the genetic disorder by replacing the defective gene with its functional counterpart 
(Kay and Woo, 1994). More than 20 different monogenic diseases have been targeted in 
clinical trials, mostly on cystic fibrosis, severe combined immunodeficiency syndromes 
(SCID), Duchenne muscular dystrophy and hemophilia (Edelstein et al., 2007). SCID gene 
therapy studies for example, have been conducted in several countries by different research 
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Figure 1.2: Overview of the vectors used in gene therapy clinical trials worldwide. Adenoviral 
(24.2%) and retroviral (20.7%) vectors were the most commonly used vectors in clinical gene 
therapy trials, while non-viral vectors, mainly naked/plasmid DNA (18.7%) and lipofection (6.4%), 
represent one quarter of all trials. Modified from the Journal of gene Medicine, 
www.wiley.com/legacy/wileychi/genmed/clinical. 
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Poxvirus 5.5% (n=94)
Adeno-associated virus 4.7% (n=81)
Herpes simplex virus 3.3% (n=57)
Lentivirus 2.3% (n=40)
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Unkonwn 3.2% (n=55)
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groups, showing lasting and clinically meaningful therapeutic benefit (Aiuti et al., 2002; 
Gaspar et al., 2004; Fisher et al., 1996). Another extensively studied monogenetic disease in 
the field of gene therapy is the clotting disorder- hemophilia, for which small and large animal 
models are available for preclinical testing (Evans et al., 1989; Lin et al., 1997; Jin et al., 
2004). Importantly, the efficiency of treatment can be easily quantified by well-defined and 
optimized assays. Therefore, hemophilia has been placed at the forefront of candidate 
diseases for gene therapy and also has been chosen by most researchers as a model 
disease for gene therapy studies (Kay, 1998; Herzog and High, 1998; Murphy and High, 
2008).  
 
1.1.2. Vectors used in gene therapy  
The fast development of the gene delivery vectors is a prerequisite for gene therapy 
applications. A successful gene therapy system should have the following features: efficient 
gene delivery, specific targeting and expression and in many cases long-term transgene 
expression (Lundstrom, 2003). Major improvements have been achieved during the past 
decades. However, as it is obvious that there are no universally applicable ideal vector 
systems available, no single vector can be suitable for all applications. The various features 
of each vector and types of disease to be treated should be well studied and defined before 
the final decision is made as to which vector type is used for a certain disease. 
So far, numerous vector systems have been developed, tested and applied in gene 
therapy clinical trials (Figure 1.2) (Wiley, 2011). They are usually divided into viral and non-
viral vectors. Viral vectors have the advantage of the million-year biology evolution for 
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efficient cellular delivery and long-term maintaining as an episome or integration in a 
chromosome (Walther and Stein, 2000; Young et al., 2006). However, immune responses to 
viral particles and the risk of insertional mutagenesis raise major safety concerns for the use 
of viral vectors (Hacein-Bey-Abina et al., 2003; Raper et al., 2003; Pien et al., 2009). As in 
gene therapy clinical trials, the most used viral vectors are adenoviral and retroviral vectors, 
followed by vaccinia virus, poxvirus, adeno-associated virus (AAV), herpes simplex virus 
(HSV) and lentivirus (Figure 1.2). On the other hand, non-viral vectors emerged quickly as a 
safe alternative to viral vectors (Edelstein et al., 2007; Edelstein et al., 2004). The simplest 
non-viral vector system utilizes „naked‟ DNA, which can be injected directly into certain 
tissues, particularly muscle, and can lead to significant levels of gene expression. However, 
the utility is limited by the absence of efficient cellular delivery and lack of long-term 
expression. Novel non-viral integration systems, such as transposons (Ivics and Izsvak, 
2006; Hackett et al., 2010; Claeys Bouuaert and Chalmers, 2010) and the bacteriophage 
integrases (Sauer, 2002; Calos, 2006; Smith et al., 2010) are also under development as 
alternative tools. It is clear that each of these vectors is characterized by a set of different 
properties that make it suitable for some applications and unsuitable for others (Table 1.1) 
(Thomas et al., 2003; Lundstrom, 2003).  
Recombinant adeno-associated viral vector (rAAV) for example, is unique among viral 
vectors that are being developed for gene therapy because the wild-type virus has never 
been shown to cause human disease (Daya and Berns, 2008). The small size and simplicity 
of the vector particle make it possible to administer high doses of vector systemically without 
eliciting acute inflammatory responses or toxic side effects (Carter, 2005; Schultz and 
Chamberlain, 2008). However, from another point of view, the small capacity of the vector 
(<5 kb) makes them unsuitable for some other applications that require incorporation of 
larger transgenes (Grieger and Samulski, 2005; Lai et al., 2010). Therefore, some larger viral 
vectors, as high-capacity adenoviral vectors (HC-AdVs) and herpes simplex virus-1 (HSV-1) 
(Table 1.1), with capacity to carry larger fragments of foreign DNA, are good alternatives.  
Furthermore, the vector tropism also determines its application. Wild-type HSV-1 is a 
neurotropic virus that can establish life-long persistence in sensory neurons. This natural 
tropism has made neuropathological disorders the reasonable target choice for replication-
defective HSV-1 vectors (Burton et al., 2001). The tropism of other vectors, like AAV and 
AdV, depends on their serotypes (Davidson et al., 2000). Thus, the serotype must be 
considered according to the target tissue/organ before therapeutic trials are initiated. 
In addition, AdVs, which elicite a strong immunoreponse (especially the earlier vector 
generations), may be not suitable for some gene therapy applications. However, 
immunogenic AdVs will probably find its niche in the treatment of cancer in which cellular 
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toxicity and immunogenicity might enhance anti-tumour effects (Alemany and Zhang, 2000; 
Toth et al., 2010).  
The vector status after delivery is another important factor that influences the 
suitability of the vector for specific therapeutic applications. The integrating viral vectors such 
as oncoretroviruses and lentiviruses which insert their genomes into host cellular chromatin 
are the tools of choice if stable genetic alteration needs to be maintained in dividing cells. On 
the other hand, the normally non-integrating vectors that persist with their genomes in the 
cell nucleus predominantly as extra-chromosomal episomes (AAVs, AdVs and HSVs) (Table 
1.1), can mediate persistent transgene expression in non-proliferating cells under certain 
circumstances. However, the insertional mutagenesis caused by oncoretroviruses  are still of 
high concerns (Cavazzana-Calvo and Fischer, 2004; Kustikova et al., 2010), thus, the 
development of non-viral integration machineries like Sleeping Beauty transposase (SB), 
bacteriophage integrases (phiC31) and zinc-finger nucleases (ZFNs) are of high interest.  
 
Table 1.1: Gene therapy vectors and their main properties. 
 Genetic 
material 
Packaging 
capacity 
Vector  
form 
Tropism Main limitations Main advantages 
viral vectors      
Retrovirus  RNA 10 kb integrated dividing  
cells 
transduce only dividing cells,  
preference for integration 
into 5' ends of genes 
persistent gene 
transfer in dividing 
cells 
Lentivirus RNA 10 kb integrated broad 
 
preference for integration 
into active genes 
persistent gene 
transfer in most 
tissues 
AAV ssDNA 5 kb episomal  
(>90%)  
Integrated 
 (<10%) 
broad small packaging capacity, 
transient expression 
non-inflammatory, 
non-pathogenic 
Adenovirus  dsDNA 36 kb episomal broad immunogenetic extremely efficient 
transduction of 
most tissues 
HSV-1 dsDNA 40 kb* 
150 kb# 
episomal strong  
for 
neurons 
Inflammatory Large packaging 
capacity, strong 
tropism for neurons 
non-viral vectors      
Naked 
plasmid 
dsDNA plasmid 
size 
Episomal/ 
integrated 
depends 
on 
delivery 
transient expression, 
absence of efficient cellular 
delivery 
non-inflammatory 
Sleeping 
beauty 
dsDNA 10 kb integrated depends 
on 
delivery 
random integration, absence 
of efficient cellular delivery 
 
low toxicity, 
persistent gene 
transfer 
Phic31 
integrase 
dsDNA not limited integrated depends 
on 
delivery 
induce deletions upon 
integration, chromosome 
rearrangements, absence of 
efficient cellular delivery 
low toxicity, persistent 
gene transfer, site-
specific integration (up 
to 15%) 
 
*Replication defective. #Amplicon. AAV, adeno-associated viral vector; HSV-1, herpes simplex virus-1. 
Modified from Thomas et al., 2003. 
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1.2. Adenovirus and its development as gene delivery vectors 
1.2.1. Adenovirus 
Adenovirus (Ad) was first discovered in 1953, isolated from cultures of human 
adenoid tissues (Rowe, 1953). Since then, 53 different serotypes of human adenoviruses 
have been isolated and characterized, and they are classified into six subgroups (A-F). 
Although human adenoviruses cause significant levels of respiratory, ocular, and 
gastrointestinal disease (Goncalves et al., 2010; Louie et al., 2008), highest incidence of 
severe diseases caused by Ads happens in immuno-compromised individuals (Ison, 2006; 
Echavarria, 2008). Among the general population these infections are usually resolved 
quickly and result in life long immunity to the virus (Lenaerts et al., 2008). Historically, Ads 
have been popular as model systems to study viral entry, transcription and replication of the 
DNA genome, mRNA splicing, viral assembly, transformation of cells in vitro, and 
tumorigenesis (Babiss and Ginsberg, 1984; Carr, 1993; Benson et al., 1999). 
Adenoviruses are medium-sized (70–100 nm in diameter), nonenveloped icosahedral 
viruses composed of a nucleocapsid and a double-stranded linear DNA genome with an 
average length between 27 and 36 kb (Russell, 2000). The virus replication origins are 
present in the first 50 base pairs of the 100–140 bp inverted terminal repeats (ITRs), which 
are located at each end of the genome. A terminal protein (TP) is covalently linked to each 5‟ 
terminus of the viral genome. Both ITRs and TPs play an essential role in viral DNA 
replication (Hearing et al., 1987; de Jong and van der Vliet, 1999). Adenoviral genes are 
encoded on both strands of the DNA in a series of overlapping transcription units (Figure 
1.3.a) (Curiel and Douglas, 2002).  
The current emphasis on therapeutic applications of adenoviruses has led to 
increased interest in the virion structure. In 2010, scientists achieved new insights into the 
structure of the human adenovirus by crystallization of a fiber-modified adenovirus type 5 
(Ad5) and cryo–electron microscopy (cryo-EM) single-particle analysis of Ad5. This helps our 
research using adenovirus as vaccines and gene therapy vectors in a great degree (Liu et 
al., 2010a; Reddy et al., 2010). 
 
1.2.2. Adenovirus as vector for gene delivery 
Adenoviral vectors (AdVs) are widely used for gene transfer into a broad variety of 
cell types (Shirakawa, 2009). This is evidenced by the fact that adenovirus is currently being 
used in roughly one quarter of all gene therapy clinical trials, resulting in the biggest vector 
group currently being used (Figure 1.2) (Wiley, 2011). 
To attain utility in patients, any gene therapy vector must deliver genes to the 
intended target organ and provide expression for an appropriate period of time to achieve a 
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therapeutic effect. When administered systemically it should infect only tissue in which gene 
delivery is desired, thus limiting toxicity to surrounding tissues and organs. Regarding AdVs, 
improvements along these lines have been obtained mostly through deletion of multiple 
adenovirus genes (Figure 1.3.b), thereby preventing or reducing certain protein expression 
and vector replication and the subsequent immune destruction of transduced cells (Campos 
and Barry, 2007; McConnell and Imperiale, 2004). 
1.2.3. Development of the early generation adenoviral vectors 
Genes in the E1 region are necessary for the activation of viral promoters and 
expression of both early and late genes. Thus, removal of the E1 coding sequence results in 
viruses that are severely impaired in their ability to replicate. Replacement of the E1 region 
with transgenes was the initial strategy used for construction of adenoviral vectors, giving 
rise to the so-called first-generation vectors (Chinnadurai et al., 1979). Removal of the E1 
region and optional E3 allow insertion of foreign DNA of up to 7.5 kb (Figure 1.3.b.i) 
(Berkner, 1988), because adenovirus serotype 5 can package up to 38 kb (105% of its 
original size) without affecting viral titer and growth rate (Bett et al., 1993).  
First-generation AdVs have proven to be highly promising as vehicles for gene 
delivery, however, challenges do exist. The most troublesome limitation associated with the 
use of first-generation vectors is represented by acute toxicity and strong immune response 
towards leaky expressed adenoviral proteins, resulting in rapidly fading transgene expression 
(Lochmuller et al., 1994). In addition, although the first-generation AdVs are generally 
considered replication defective, there is some low level expression of viral antigens, which 
eliminate the transduced cells by the cellular immune system, subsequently limiting the 
duration of transgene expression in vivo (McConnell and Imperiale, 2004). Another challenge 
is the recombination between the E1 region sequences in the producing cell line and the 
recombinant virus during vector production. This recombination gives rise to viral progeny 
with functional E1 genes that are replication competent (Yang et al., 1994; Yang et al., 1995; 
Dai et al., 1995). 
To prevent the immune response generated by low-level replication of E1-deleted 
viruses, vectors deleted for multiple genes have been created to inhibit viral gene expression 
more effectively. These so-called „second-generation vectors‟ have been constructed 
primarily by the removal of E2 and/or E4 coding sequences additionally to E1 and E3 
regions. These vectors show improved transgene persistence and decreased inflammatory 
response (Figure 1.3.b.ii) (Engelhardt et al., 1994). They also provide the benefit of a larger 
capacity for transgene insertion. However, the yielded amounts of these vectors during 
production are considerably decreased and toxic side effects were still observed (Gao et al., 
1996; Gorziglia et al., 1996). 
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Figure 1.3: Schematic overview of wild type adenovirus and recombinant adenoviral vector 
genomes. (a) Map of the wild type adenovirus genome and its transcription units. The central, 
solid line represents the viral genome. Positions of the left and right inverted terminal repeats (ITRs), 
the packaging signal (Ψ), the early transcription units (E1A, E1B, E2A, E2B, E3, and E4 in solid 
arrow), and the late transcription units (major late promoter [MLP], L1–L5 in hatched arrow) are 
shown. Arrows indicate the direction of transcription. (b) Different generations of recombinant 
adenoviral vectors used in gene therapy. Elements shown in red represent deletions providing 
space for insertion of transgene cassette. (i) First-generation adenoviral vectors lacking E1and/or E3. 
(ii) Second-generation adenoviral vectors with multi-deletions. (iii) Helper-dependent adenoviral 
vectors with all viral coding regions deleted. Adopted from Curiel and Douglas, 2002. 
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1.2.4. High-capacity adenoviral vectors (HC-AdVs)  
To avoid eliciting unwanted cellular immune responses, the third-generation 
adenoviral vector, helper-dependent adenoviral vectors (HD-AdVs), also called “gutless” 
vectors and high-capacity adenoviral vectors (HC-AdVs), have been developed (Kochanek et 
al., 1996; Parks et al., 1996; Parks and Graham, 1997; Ehrhardt and Kay, 2002). These HC-
AdVs devoid of all viral coding sequences consist solely of the ITRs flanking the virus 
genome at its termini and the packaging signal (Ψ) required for encapsidation (Figure 
1.3.b.iii) (Fisher et al., 1996).  
The elimination of Ad antigen expression in HC-AdVs permits long-term episomal 
expression of genes in quiescent cells by avoiding problems associated with the cellular 
immune response against viral gene products (Palmer and Ng, 2005; Brunetti-Pierri et al., 
2005). This type of vector has been shown to result in long-term transgene expression and 
phenotypic correction in animal models. Researchers have shown that after a single injection 
of HC-AdV, the vector genome can be maintained life-long in mice and for up to 2 years in 
rats (Ehrhardt and Kay, 2002; Toietta et al., 2005). In dogs and non-human primates, HC-
AdV liver transduction also led to long-term transgene expression (Brunetti-Pierri et al., 
2007). To date, the longest period of transgene expression (up to 964 days) after HC-AdV 
hepatic transduction was observed in baboons, using an improved balloon occlusion 
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catheter–based method which permits even greater hepatocyte transduction efficiency at 
clinically relevant low doses of vector infusion (1 × 1011, 3 × 1010, and even 1 × 1010 VPs/kg) 
(Brunetti-Pierri et al., 2009).  
A recent study demonstrated that HC-AdV genomes persist predominantly as 
replication-defective monomeric genomes (Jager and Ehrhardt, 2009). Moreover, the ability 
to grow recombinant viruses to high titers (Jager et al., 2009; Palmer and Ng, 2003) 
facilitates its further use in a broader research area. In addition, these vectors have a much 
higher packaging capacity of foreign DNA (36 kb), enabling the expression of large 
transgenes or the inclusion of human genomic regulatory elements (Palmer and Ng, 2005; 
Palmer and Ng, 2008). 
As adenoviral vectors are believed to integrate into host chromosomes at low 
frequencies (Harui et al., 1999; Hillgenberg et al., 2001; Stephen et al., 2008; Jager and 
Ehrhardt, 2009), episomal genomes are not able to segregate to daughter cells during 
subsequent mitoses. As a result, adenoviral vectors are not applicable in gene therapy 
applications in which the target tissue consists of dividing cells. As shown in a previous 
study, transgene expression levels from HC-AdV in vivo declined by 95% over a period of 
one year in mice (Ehrhardt and Kay, 2002). Furthermore, it was shown that an HC-AdV 
containing a canine coagulation FIX (cFIX) expression cassette injected into hemophilia B 
dogs at a nontoxic dose (8.6 × 1011 viral particles per kilogram, VPs/kg), exhibited no 
hepatotoxicity as shown by liver enzymes and liver histology, and had no dropping platelet 
counts. However, only transient phenotypic correction was achieved (therapeutic levels of 
cFIX for about 2 months) and the cFIX levels declined over time to undetectable levels 
(Ehrhardt et al., 2003). Another study with HC-AdV observed sustained cFIX expression for 
over a year at a high dose (3.57 × 1012, and 1.3 × 1013 VPs/kg), but induced transient mild 
liver enzyme elevations and a decrease in platelet counts (Brunetti-Pierri et al., 2005). 
To prolong the therapeutic effect after adenoviral gene transfer and to stabilize 
persistence of the therapeutic DNA at a lower dose, especially in targeted cells with a high 
replicative potential, one promising approach is to combine HC-AdV with tools for somatic 
integration. A variety of adenoviral hybrid-vectors that lead to somatic integration of the 
transgene from the episomal adenoviral vector genome into the host chromosome have been 
developed. These vectors combine the highly efficient DNA delivery of adenoviral vectors 
with the integration machineries of transposons (HC-AdV/retrotransposon, HC-AdV/Sleeping 
Beauty transposon) (Yant et al., 2002; Hausl et al., 2010; Soifer et al., 2001), phage 
integrases (HC-AdV/PhiC31) (Ehrhardt et al., 2007), retroviruses/lentiviruses (E1-deleted 
AdV/RV) (Soifer et al., 2002), or adeno-associated virus (HC-AdV/AAV) (Recchia et al., 
1999; Recchia et al., 2004), and resulted in stable transgene expression by somatic 
integration. 
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Figure 1.4: The chromosomal location of the 
human coagulation factor VIII (FVIII) and factor IX 
(FIX) genes on the X chromosome. The grey arrow 
shows the position of the FIX gene, while the black 
indicates the FVIII gene. The figure was modified 
from NCBI Map View. 
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1.3. Genetic disease and hemophilia B 
1.3.1. Genetic diseases 
Genetic factors play a crucial role in disease development. Genetic diseases, for 
example, are the disorders caused by abnormalities in an individual‟s genome. There are 
different types of genetic diseases, and the best studied ones among them are the 
monogenetic diseases, which are caused by changes or mutations that occur in a single 
gene. There are more than 6000 known single-gene disorders such as cystic fibrosis, sickle 
cell anemia, Marfan syndrome, Huntington‟s disease, hereditary hemochromatosis and 
hemophilia (Robin, 2008). 
 
1.3.2. Hemophilia and the current medical treatment 
Hemophilia A and B are blood clotting disorders caused by mutations in the genes 
encoding for blood coagulation factor VIII (FVIII gene) and factor IX (FIX gene). The human 
FVIII and FIX genes are located on the long arm of the X chromosome (chr Xq28 and chr 
Xq27) (Purrello et al., 1985), therefore both hemophilia A and B are X-linked recessive 
diseases (Figure 1.4) (Bolton-Maggs, 
2003; Cutler et al., 2004).  
The clinical features of 
hemophilia depend on the level of factor 
deficiency. Spontaneous hemorrhage 
occurs if factor levels are <1% of 
normal; hemorrhage and hemarthrosis 
occur following injuries if factor levels 
are 5%-30% of normal. There is usually 
no significant bleeding if factor levels 
are >30% of normal (Table 1.2) (Pagon 
RA, 2011). Current treatment for 
hemophilia involves protein (clotting 
factors) infusion therapy, which is based 
on intravenously injection of high-purity 
plasma-derived factors and recombinant 
products to hemophilia patients 
(Mannucci et al., 2001). Although this 
treatment has markedly improved the 
life expectancy of patients suffering from hemophilia, and some studies even showed 
Introduction 
 
11 
 
correction of the hemophilic phenotype with continuous prophylactic administration of the 
clotting factors (Manco-Johnson et al., 2007), most hemophilia patients worldwide are still at 
risk of life-threatening bleeding episodes and chronic joint damage (Darby et al., 2007). This 
is partly due to the limited availability and high cost (>$100,000 per patient per year for 
prophylactic replacement therapy) (Pipe, 2010) of purified proteins. The protein infusion 
therapy is therefore mostly used to treat acute bleeding on demand rather than to provide 
continuous prophylactic coverage (Roosendaal and Lafeber, 2007). In addition, especially 
the short half-life of the coagulation factors (e.g., 8 to 23 hours for FVIII and 18 to 24 hours 
for FIX) make the protein infusion therapy more complicated (van den Berg et al., 2007). An 
important side-effect is that some patients develop inhibitors, which are antibodies that block 
the function of a coagulation factor and make bleeding episodes difficult to treat (Lusher, 
2000; Hay, 2006; DiMichele, 2007). 
 
Table 1.2: Classification of hemophilia B based on in vitro clotting activity. Modified from Pagon 
RA, 2011. 
 
Clinical 
Severity 
 
Factor IX 
Clotting 
Activity 
Clinical Bleeding Symptoms 
 
Severe 
 
<1% 
 
Frequent spontaneous bleeding; excessive and/or prolonged 
bleeding after minor injuries, surgery, or tooth extractions 
Moderate 1%-5% 
 
Spontaneous bleeding rare; excessive and/or prolonged bleeding 
after minor injuries, surgery, or tooth extractions 
Mild 
 
>5%-30% 
 
No spontaneous bleeding; excessive and/or prolonged bleeding 
after major injuries, surgery, or tooth extractions 
 
 
1.3.3. Gene therapy as an alternative therapeutic approach for hemophilia B 
As a technique for correcting defective genes responsible for genetic diseases, gene 
therapy is well suited for hemophilia treatment, not only because hemophilia is due to a 
single gene defect, but also a slight increase in clotting factor levels can potentially convert 
severe hemophilia to a mild version of the disease. As shown in table 1.2, hemophilia B is 
associated with severe disease with <1% normal circulating levels of FIX activity, thus 
improvement of FIX activity into the range of >1% results in a profound improvement in 
symptoms and is sufficient to prevent spontaneous and life-threatening bleeding episodes. 
Activity improvement to up to 10% may result in near elimination of the bleeding diathesis. 
(Lofqvist et al., 1997; Chuah et al., 2004). Another advantage of hemophilia B in the 
development of gene therapy strategies is the relatively small size of FIX cDNA (~1.4 kb of 
coding sequence), which makes it suitable to many different vector types and provides the 
Introduction 
 
12 
 
possibility to add more regulatory elements to improve transgene expression (Pierce et al., 
2007). 
For these reasons, various vector systems such as retroviral (both gamma retroviral 
and lentiviral), recombinant adenoviral (AdV), recombinant adeno-associated viral (AAV), 
and non-viral vectors have been designed for expression of FIX in a gene therapy setting 
(Liras and Olmedillas, 2009; Matrai et al., 2010).  
 
1.3.4. The application of different vector systems for hemophilia B gene therapy 
Retroviral vectors integrate into the target cell genome, which ensures stable 
maintenance of the DNA and allows long-term transgene expression, but can also result in 
insertional mutagenesis (Hacein-Bey-Abina et al., 2003; Ott et al., 2006). An early study 
using retroviral vectors encoding canine FIX resulted in a successful long-term gene therapy 
in a canine model of hemophilia B and low levels of plasma FIX (~2-8 ng/ml). Notably, the 
whole blood clotting time (WBCT) decreased from nearly 50 minutes to as low as 15 
minutes, which led to a change in phenotype from severe hemophilia to a moderate form 
(Kay et al., 1993). Another researchers injected a murine leukemia virus (MLV) - based 
retroviral vector into neonatal hemophilia B puppies which resulted in high levels of cFIX (500 
ng/ml) and marked shortening of WBCT from over 60 minutes to 8-12 minutes (Xu et al., 
2003). A recent study using human immunodeficiency virus (HIV) – based lentiviral vectors 
expressing human FIX enabled sustained gene transfer in hemophilia B mice for more than 
280 days, with over 10% of normal FIX activity in treated mice (Brown et al., 2006). Although 
these preclinical results are very encouraging, enthusiasm has been damped by concerns 
about the risk of insertional mutagenesis with retroviruses (Hacein-Bey-Abina et al., 2003). 
Researchers are now exploring some alternative designs for a safer vector form, like self-
inactivating (SIN) retroviral or lentiviral vectors and integrase-defective lentiviral vectors 
(IDLVs) (Yu et al., 1986; Olson et al., 1994; Zufferey et al., 1998; Wanisch and Yanez-
Munoz, 2009), which hold great potential to further improve the gene therapy safety profile. 
As one of the most used vector in human clinical trials (Wiley, 2011) (Figure 1.2), 
adenoviral vectors were also explored in hemophilia B gene therapeutic studies. An earlier 
generation of adenovirus serotype 5 (Ad5) containing the canine FIX cDNA demonstrated the 
first successful somatic cell gene therapy approach in a canine model for hemophilia B, in 
which plasma cFIX levels were observed to be normal or super-physiological (>5000 ng/ml) 
for about a week, however, followed by a slow return to pre-treatment or baseline levels in 70 
to 100 days (Kay and Woo, 1994). It turned out that the success of adenovirus-mediated 
gene therapy for hemophilia B was limited by the host immune response to the adenoviral 
proteins. The adenoviral vector activates specific cytotoxic T lymphocytes (CTLs), T helper 
cells (both Th1 and Th2 subsets), and B cells, leading to inflammation, the destruction of 
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infected tissues, and the cessation of transgene expression (Arruda, 2006). Later on, 
important advancements have been reported after the use of helper-dependent adenoviral 
constructs that encode no viral proteins.  
Another vector that holds great promise for hemophilia gene therapy is represented 
by recombinant adeno-associated viral vector (rAAV). AAVs have a favorable safety profile 
because of their non-pathogenic nature, and are able to achieve persistent transgene 
expression by their predominately episomal maintained AAV genomes (Daya and Berns, 
2008; Nakai et al., 2001). Protocols to use rAAV–mediated gene therapy for hemophilia were 
established in several laboratories (Xiao et al., 1996; Snyder et al., 1997). The two main 
strategies utilizing muscle and liver as target organs showed promising results. Infusion of an 
adeno-associated viral vector serotype 2 (AAV2) into the muscle resulted in long-term (> 3 
years) and high FIX expression (circulating levels of 4%-14%) in a canine model for 
hemophilia B (Arruda et al., 2005), achieving complete correction of the bleeding disorder. 
Based on these results in animal models, a phase I clinical trial was performed in severe 
hemophilia B patients utilising intramuscular injection of AAV2-FIX vectors at multiple sites 
(Kay et al., 2000). Although there was evidence of gene transfer and expression in the 
treated patients for more than 3 years (Manno et al., 2003), however, the systemic FIX levels 
were below the therapeutic range. On the other hand, liver-directed AAV gene therapy 
resulted in sustained therapeutic FIX expression without inhibitor development in normal and 
hemophilic mice, hemophilia B dogs and nonhuman primates (Snyder et al., 1999; Mount et 
al., 2002; Nathwani et al., 2007). Recently, an 8-year study in inhibitor prone null mutation 
hemophilia B dogs treated with liver directed AAV2-FIX demonstrated long-term correction of 
the hemophilic phenotype with FIX activity stably remained between 4% and 10%, and 
without inhibitor development (Hasbrouck and High, 2008). A phase I clinical trial was 
therefore initiated in severe hemophilia B patients, who received infusion of liver-directed 
AAV2 vectors, expressing FIX from a liver-specific promoter (Manno et al., 
2006).Therapeutic FIX levels of up to 10% were obtained in the high dose group, however, 
transgene expression was lost after one month, most likely as a result of immune response 
against the AAV2 capsids (Pien et al., 2009). Therefore, as an alternative approach, 
scientists are trying to use alternative AAV serotypes (Wu et al., 2006) and transient 
immunosuppressive regimens (Jiang et al., 2006) to overcome these limitations. 
Non-viral vectors have the advantage of being less immunogenic and less toxic than 
its viral counterparts (Table 1.1), because no viral proteins are involved. However, the 
efficiency of non-viral DNA delivery is generally quite low compared to viral vector-mediated 
gene transfer (Douglas, 2008). Different strategies have been developed to introduce DNA 
into target cells, like ultrasound, electroporation, cationic liposomes conjugated with 
polyethylene glycol (PEG), polymers such as polyethyleneimine (PEI) or hybrid polymeric 
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lipids, or hydrodynamic transfection. In a preclinical study, a plasmid encoding human factor 
IX (hFIX) formulated with a protective, interactive, noncondensing (PINC) polymer was 
injected into the skeletal muscle followed by administration of multiple electrical pulses 
(electroporation). In mice long-term expression was achieved and the ability to re-
administrate formulated plasmid was also demonstrated. In normal dogs, expression of hFIX 
reached 0.5-1.0% of normal levels, however, only transient expression was observed due to 
the development of antibodies against hFIX (Fewell et al., 2001). Similarly, a phase I clinical 
trial for hemophilia A was conducted with FVIII-transfected autologous fibroblasts (Roth et 
al., 2001b). Although no long-term adverse effects occurred due to the transfected cells or to 
the implantation procedure, only a modest rise in FVIII activity was detected in seven out of 
12 patients and the FVIII expression levels were transient. To overcome this limitation of 
transient transgene expression, researchers then tried to combine non-viral therapy with 
chromosomal integration mediated by Sleeping Beauty transposase (Mates et al., 2009), or 
to increase episomal persistence by incorporating elements like matrix attachment regions 
(Harraghy et al., 2008), or by removing redundant bacterial backbone sequences like 
minicircle DNA (Mayrhofer et al., 2009). Furthermore, in combination with cell-based therapy 
as shown in the past (Tatsumi et al., 2008), non-viral vectors could be a promising option in 
the future (Lillicrap et al., 2006). 
The collective results from these hemophilia gene therapy studies indicate that the 
current approaches and doses are effective and safe, and long-term expression of clotting 
factors have been achieved in small and large animal models using multiple gene therapy 
strategies. However, these results have not yet been successfully translated into human 
patients. More efforts are needed to better understand the basic biology of gene therapy, and 
to further develop and improve these vectors for treatment of hemophilia and other inborn 
genetic disorders.  
 
1.3.5. Optimization with respect to the transgene encoding sequence 
The goal of hemophilia gene therapy is to effectively prevent bleeding and its 
associated complications in a relatively long-term period. Therefore, the ideal treatment of 
hemophilia B by gene therapy, on the one hand, requires the use of a gene delivery system 
that is efficient, safe, non or less-immunogenic and allows for long-term transgene 
expression (Petrus et al., 2010). On the other hand, the transgene itself also plays an 
essential role in therapeutic efficacy. For instance the improvement on the functional 
properties of the coagulation factors could not only enhance the therapeutic effect but can 
also reduce the vector dose needed, thereby significantly reduce the side effects caused by 
a high gene therapy vector dose infusion.  
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1.3.5.1 Bioengineering strategies to improve the functional properties of human 
coagulation factors 
With the fast development of recombinant DNA technology and deep understanding 
of the protein structure, bioengineering strategies have been used to improve the functional 
properties the coagulation proteins. These improvements have been directed at overcoming 
the recombinant coagulation factors‟ inherent limitations, like biosynthesis and secretion, 
functional activity, half-life, and antigenicity/immunogenicity. Some of these strategies have 
already reached commercialization, several are in ongoing clinical trials, and a number of 
strategies are in advanced preclinical development (Pipe, 2010). For example, the B-
domain–deleted (BDD)-FVIII cDNA, not only significantly improved the yield of recombinant 
FVIII production but also facilitated packaging within certain viral vectors facilitating its 
adoption for gene therapy strategies (Chao et al., 2000). Until now, BDD-rFVIII remains the 
first and only modified human rFVIII molecule getting commercialized.  
Another approach for improving properties of recombinant coagulation proteins would 
be the half-life extension. Prolonging the half-life of coagulation factors could greatly reduce 
the frequency and dose of infusions, thereby improving the efficacy, convenience and patient 
quality of life (Lillicrap, 2008). One strategy to extend the half-life of FIX is the fusion protein 
technology, which links FIX to another protein with a much longer plasma half-life. For 
instance, the constant region (Fc) of immunoglobulin G was fused to FIX (FIXFc). The 
presence of the Fc portion protects the fusion protein from catabolism through interaction 
with the neonatal Fc receptor (FcRn), thereby preventing the degradation in the lysosome. 
Preclinical data with FIXFc demonstrated a 3- to 4-fold longer terminal half-life in mice, rats, 
and cynomolgus monkeys (Peters et al., 2010). 
The most attractive area for improvements is modifying functional activity of human 
coagulation factor. For instance, the bioengineered FIX variants with increased catalytic 
activity may be useful for achieving therapeutic FIX activity with lower vector doses. Different 
strategies have been used to generate recombinant human FIX (rhFIX) variants with 
increased coagulating activity, for instance, by introduction of point mutations. By this 
approach a hyperactive variant was generated with a single point mutation changing arginine 
at 338 to alanine (hFIX-R338A), which showed a 3 times increased clotting activity than that 
of the wild type FIX (wt-hFIX) in the in vitro actived partial thromboplastin time assay (APPT) 
(Chang et al., 1998). Importantly, application of this hFIX-R338A in hemophilia B mice 
delivered by AAVs displayed a 2 to 6-fold higher specific activity (Schuettrumpf et al., 2005). 
Later on, based on this hFIX-R338A, more variants including some other mutants or domain 
exchange mutants demonstrated even higher clotting activities. When applied in in vivo gene 
therapy approaches, these further engineered variants resulted in up to 13-fold increased 
activity (Brunetti-Pierri et al., 2009; Lin et al., 2010; Kao et al., 2010).  
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Figure 1.5: Schematic view of the human coagulation Factor IX protein. The gene for human 
FIX consists of eight exons and seven introns, is approximately 34 kb long, and is located on the 
long arm of the X-chromosome at Xq27.1. Structurally, FIX contains an N-terminal γ-carboxy 
glutamic acid (Gla) domain (residues 1–40), a short hydrophobic stack (residues 41–46), two 
epidermal growth factor (EGF)-like domains (EGF1: residues 47–83, and EGF2: residues 88–127, 
which are connected by linker residues 84–87), an activation peptide (AP, residues 146–180), and a 
C-terminal protease domain (residues 181– 415) (top panel)  (Brandstetter et al., 1995; Hopfner et 
al., 1997). The truncated version used by Brandstetter et al. is depicted on the buttom panel. The 
red stars indicate the mutations to generate the hyperactive variants. 
 
Full-length hFIX
Truncated hFIX
Gla APEGF1 EGF2 protease domain 
APEGF2 protease domain 
Moreover, a gain-of-function mutation in FIX gene was recently identified from a 
family with a potent X-linked thrombophilia. This mutant R338L makes the plasma FIX 
activity 800% of normal activity, and it exhibited a 5- to 10-fold higher specific activity in vitro 
(Simioni et al., 2009). 
 The structure and function analyses offer a direct way to bioengineer novel and 
improved coagulation factors. From the sequence alignment and structural characteristics of 
the catalytic domain of hFIX with several homologous coagulation enzymes, researchers 
found that the segments exchange between FIX and FX can dramatically increase the 
activity up to 7000-fold based on a substrate selection assay (Figure 1.5)(Hopfner et al., 
1997; Sichler et al., 2003). 
These bioengineered FIX variants are not only valuable for recombinant FIX protein 
replacement therapy, but can also increase the therapeutic index of gene therapy vectors by 
permitting administration of lower vector doses to achieve the same therapeutic outcome. 
For instance, the hFIX mutants discovered by Hopfner (Hopfner et al., 1997) with up to 7000-
fold increased activity, are not been applied for gene therapy approaches so far. 
 
1.4. Adenovirus/Sleeping Beauty transposase hybrid-vectors 
1.4.1. Vectors for somatic integration 
To develop novel and safe vectors for therapeutic transgene expression in rapidly 
dividing cells is of great interest to the research community. Integrating viral vector systems 
based on retrovirus and on lentivirus are suitable tools, as the integration of viral vector 
genomes into the cellular chromosomal DNA allows for a more stable and long-lasting 
transgene expression than episomal gene-delivery models (Kustikova et al., 2010). However, 
the integrating viral vectors tested in preclinical and clinical settings revealed that integration 
site preferences may cause genotoxicity by changing the expression profile and properties of 
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the transduced target cells due to insertional mutagenesis (Haviernik and Bunting, 2004). For 
instance, retroviruses prefer the regulatory sequences for integration and lentiviruses 
integrate predominantly into transcribed gene regions. Therefore, to obtain stable gene 
transfer for therapeutic applications, alternative approaches have been explored based on 
Sleeping Beauty (SB) transposon system, phiC31 integrase and zinc-finger nucleases 
(ZFNs) for somatic integration. In contrast to viruses, these non-viral integration machinery 
lack direct mechanisms to gain entry to the cell across the membrane. However, viral hybrid-
vectors have been developed, by combining non-viral integration machineries with viruses for 
efficient delivery. 
The integrase from the Streptomyces phage PhiC31 was first described in 1991 
(Kuhstoss and Rao, 1991). It belongs to the serine recombinase family that includes the Tn3 
resolvase and a number of transposases. In contrast to other integration machineries, 
PhiC31 was shown to mediate unidirectional site-specific recombination between two DNA 
recognition sequences, the phage attachment site (attP) and the bacterial attachment site 
(attB) (Rowley and Smith, 2008). Expressed under the control of a mammalian promoter, 
PhiC31 integrase mediates integration of extra-chromosomal plasmids bearing an attB site 
into a limited number of „pseudo-attP‟ sites present in the native mammalian genomes (Groth 
et al., 2000; Chalberg et al., 2006). A remarkable feature of the PhiC31 integrase for gene 
therapy is the fact that integration is limited to „„hot spot‟‟ sites with up to 15% specificity in 
the mammalian genome (Chalberg et al., 2006; Ehrhardt et al., 2006) potentially decreasing 
the risk of insertional mutagenesis. Recently, more effort was spent on understanding the 
molecular mechanism of integrase in mammalian cells (Keravala et al., 2009; Liesner et al., 
2010; Liu et al., 2010b). Due to the low delivery efficiency of PhiC31 integrase to target cells 
by non-viral DNA (Table 1.1), researchers have also focused on combining the PhiC31 
system with viral vectors for high cell transduction efficiency. For instance, in a previous 
study, a hybrid-vector system that combines the high transduction efficiency of a HC-AdV 
and the integration machinery of the PhiC31 was developed for stable transduction and 
limited integration sites. Herein, the integration of the transgene expression cassette from the 
adenoviral vector resulted in 5-fold higher transgene expression levels in the active PhiC31 
group compared to the control group, which received a mutated and inactive version of 
PhiC31. Moreover, the previously described mpsL1 hot spot of integration was confirmed 
(Ehrhardt et al., 2007). 
Zinc-finger nucleases (ZFNs) are artificial restriction enzymes generated by fusing a 
zinc finger DNA-binding domain to a DNA-cleavage domain. Zinc finger domains can be 
engineered to target desired DNA sequences, which enable zinc-finger nucleases to induce 
double strand breaks at the desired DNA sequences, subsequently been repaired by the 
cellular repair mechanism (Durai et al., 2005). Therefore, in gene therapy application, ZFN 
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Figure 1.6: Sleeping beauty transposase-mediated somatic integration. A two-component 
system is shown in which a gene of interest flanked by transposon-derived inverted repeats (IRs) is 
mobilized by the transposase protein provided in trans. For gene transfer application, the tranposon 
is usually excised from a plasmid or a viral vector and integrated into a genomic target site (TA). 
This system is commonly referred to as „cut-and-paste‟ mechanism. 
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IR Gene of interest IR TA
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IR Gene of interest IR
SB SB
enables the replacement of the defective gene at its natural chromosomal location, which 
offers an ideal strategy for site-specific integration (Urnov et al., 2010). To take advantage of 
the high efficiency of viral vectors for cell delivery, ZFNs were combined with AdVs and 
integrase-defective lentiviral vectors (IDLVs) (Lombardo et al., 2007; Perez et al., 2008). 
IDLVs were used to deliver ZFNs directed at the human IL-2Rγ gene, a combination vector 
that carried one ZFN and one copy of the donor DNA was produced to reduce the number of 
separate viruses that had to infect the same cell. However, the efficiency of gene targeting 
varied widely among different types of cells, for example this system achieved targeting 
frequencies up to 39% in K562 cells, but lower efficiencies in other cell types (Lombardo et 
al., 2007). 
 
1.4.2. The Sleeping Beauty (SB) transposon system 
The Sleeping Beauty (SB) transposon system was first molecularly reconstructed 
from ancient inactive copies of Tc1/mariner-like elements found in several fish genomes in 
1997 (Ivics et al., 1997). The wild-type transposon consists of the SB transposase and 
inverted terminal repeats (IRs) flanking the transposase encoding sequence. For 
transposition, SB transposase recognizes the IRs and mediates the insertion into a TA site of 
the host genome by a „cut-and-paste‟ mechanism (Figure 1.6). In gene therapy approaches, 
SB components are split into an artificial transposon containing the therapeutic cargo 
sequence flanked by the IRs and the transposase provided in trans for mobilization of the 
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transposon (Izsvak and Ivics, 2004). Due to the high transpositional activity in vertebrates, 
SB transposase is an attractive tool for human gene therapy. It has been shown to provide 
long-term transgene expression in vitro with a random integration profile in the context of 
plasmid design (Yant et al., 2000; Yant et al., 2005). However, also for the SB system, 
delivery presents a major hurdle and methods such as hydrodynamic delivery (Bell et al., 
2007) are not suitable in humans. Therefore, much effort was spent on designing virus/SB 
hybrid-vector systems to deliver the SB transposon system efficiently. Until now, the SB 
transposase machinery was combined with several different viral vectors, like AdV, herpes 
simplex virus (HSV), lenti- and retroviral vectors (Yant et al., 2002; Peterson et al., 2007; 
Vink et al., 2009; de Silva et al., 2010; Heinz et al., 2011), and showed efficient delivery and 
long-term transgene expression. 
 
1.4.3. Previous work on adenovirus/SB transposase hybrid-vectors 
To combine efficient delivery and high transduction efficiency of adenoviral vectors 
with the long-term expression of a transgene expression cassette after SB-mediated somatic 
integration, the first AdV/SB hybrid-vector system was generated in 2002 (Yant et al., 2002). 
This hybrid-vector system consisted of two independent HC-AdVs, in which one contained 
the integration machinery and the other encoded the transposon. This particular molecular 
design was called “two-vector-system”. Herein, one adenoviral vector contained SB 
transposase and Flp recombinase encoding sequences, and the second vector contains the 
transposon which encompasses the transgene expression cassette bordered by inverted 
repeats (IRs) for SB recognition and the FRT sites for Flp recognition (Figure 1.7)  
Therefore, after co-transduction of a single cell with both HC-AdVs the transgene 
expression cassette integrates into the cellular genome by a two-step mechanism. Initially, 
Flp recombinase interacts with the FRT sites and excises the transposon from the HC-AdV 
genome generating a circular intermediate. Subsequently, the SB transposase recognizes 
the IRs in the excised circular DNA and integrates the transposon by a „cut-and-paste‟ 
mechanism into the genomic DNA (Figure 1.7).  In that study, stable FIX expression levels 
were obtained in murine liver even after inducing rapid cell cycling of hepatocytes with 
carbon tetrachloride (CCl4) (Yant et al., 2002). However, further optimization of the vector 
design and multi-experiments setting are needed before it is ready for clinical application.  
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Figure 1.7: Principle of the adenovirus/transposase hybrid vector system. Schematically shown is 
a “two-vector strategy” based on two HC-AdVs co-infecting one cell. The first HC-AdV acts as 
transposon-donor vector and encodes the transgene flanked by transposon-derived inverted repeats 
(IR) and FRT sites for Flp recombinase mediated excision; the other HC-AdV provides SB transposase 
and Flp recombinase and plays the role as a „Transposition actor‟, initializing circularization by Flp-FRT 
recognition essential for SB functionality and transgene insertion into TA sites of the host genome by 
the „cut-and-paste‟ mechanism. HC-AdV, high-capacity adenoviral vectors; SB, Sleeping Beauty. 
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1.5. Potential improvements of the adenovirus/transposase hybrid-vector system 
and future challenges 
The previous study which introduced an adenovirus/SB transposase (AdV/SB) hybrid-
vector system (Yant et al., 2002) provided a potential new mean to treat genetic diseases. 
However, also this system has some limitations to be overcome before considering clinical 
studies.  
For instance, the conventional system was wild type SB for somatic integration. 
However, the intrinsic activity of the SB system has been enhanced through a variety of 
measures including the creation of a series of hyperactive SB transposases and engineering 
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of transposons with identical 3´ and 5´ inverted repeats (IR). For instance, the hyperactive 
version of SB transposases like SB11, HSB5 and SB100x (Zayed et al., 2004; Yant et al., 
2004; Mates et al., 2009) which showed increasing enzymatic activities in vitro. These could 
be introduced into the AdV/SB hybrid-vector system to increase the integration efficiency and 
potentially enhance the therapeutic effect. 
Furthermore, it is essential to explore the dose effects of the AdV/SB hybrid-vectors. 
In almost all clinical trials, multiple ascending dose studies need to be conducted to better 
understand the pharmacokinetics and pharmacodynamics of the drug. Therefore, multi-dose 
settings in animals would be beneficial to better understand the AdV/SB hybrid-vector 
system, and this had not been performed in the previous study.  
In addition, the development of gene transfer strategies, similar as the traditional 
research procedure for any new medication, usually begins with evaluation of the gene 
transfer effect in tissue culture. Then the efficacy and safety of the vector system need to be 
addressed in small animals (usually mice, rats and rabbits), in large animals (dogs, sheep, 
pig and non-human primates), and finally in humans. The direct translation from mice to 
human is usually challenging, mainly due to the huge body size difference (approximately 
3500-fold body weight scale-up from mice to human), necessary changes of the 
administration route, target tissue or organ and more importantly vector amount (Figure 1.8) 
(Hausl et al., 2011; High, 2005). Moreover, the short life span of mice compared to human 
and the less predictive immune responses of inbred mice make the outcome in humans less 
predictable. Therefore, up-scaling approaches from treating small animal models to large 
animal models are essential before going into clinical studies. It is of note that at the 
beginning of this study, the adenovirus/SB transposase hybrid-vectors had not been explored 
in large animals.  
Importantly, safety is an essential issue when new medical agents are evaluated in a 
pre-clinical or any clinical setting. As to gene therapy, there are several aspects to be 
considered. Firstly, high doses of any vector type can result in acute inflammatory responses 
with potentially lethal consequences (Brunetti-Pierri et al., 2004). Therefore, the vector load 
is one primary issue to be considered. Secondly, with respect to immune responses, 
immune-toxicity caused by both transgene product and vector protein need to be monitored 
as the immune-response against the transgene product counteracts the therapeutic effect 
due to the vector elimination (Manno et al., 2006). Additionally, this kind of host immune-
response results in inflammation at the injection sites or the target organ leading to the final 
failure of the therapy (Raper et al., 2003). Furthermore, the over-production of the transgene 
product can sometimes also be toxic. For example, some enzyme products may cause 
unwanted side effects such as over-activity of coagulation factors which may turn hemophilia 
to thrombosis (Dargaud et al., 2005). Considering the genome level, potential genotoxicity 
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Figure 1.8: Translation of the medicines from tissue culture to clinical trials. The figure shows 
the procedure of drug discovery. It may begin with tissue culture, and then go on to different animal 
models, finally achieve in human beings. For preclinical studies, translation into the clinic and 
research on human diseases especially in the area of gene therapy, large animals (cat, dog, pig, 
primate) are preferred models compared to mice. One important aspect to consider is the increasing 
body weight which automatically requires a scale-up of the required vector dose. For instance from a 
large animal to human the scale-up would be approximately 1- to10-fold, whereas the scale-up from 
mouse to human could be as much as 3500-fold. 
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needs to be analyzed, especially for integrating vector systems. After somatic integration of 
the transgene, stable transgene expression can be obtained and long-term therapy effect is 
achievable. However, any insertion of foreign segments could change the genetic 
composition of the cell. This kind of toxicity has raised researchers‟ attention since the cases 
of leukemia happened to the patients who received oncoretroviral vectors transduced stem 
cells (Hacein-Bey-Abina et al., 2003; Ott et al., 2006; Howe et al., 2008). A recent clinical 
study showed a monosomy of chromosome 7 after retroviral vector therapy (Stephen et al., 
2010) and even more frequently toxicity caused by the insertion of the transgene was 
observed after retroviral infection (Li et al., 2002; Kustikova et al., 2005; Donsante et al., 
2007). There are also other types of genotoxicity, such as genome deletions and other 
rearrangements observed after PhiC31-mediated integration (Ehrhardt et al., 2006), and in 
AAV integration (Miller et al., 2002). Therefore, the evaluation of genotoxicity is of high 
importance. Notablely, SB-mediated integrations have been shown to cause neglectable 
genotoxicity with a fairly random integration profile in plasmid context (Liu et al., 2005; Yant 
et al., 2005). However, the SB integration profile via adenoviral vector is still need to be 
characterized. 
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Aims of this work 
One of the best studied and the most utilized vectors in gene therapy are adenoviral vectors 
(AdVs). Especially the advanced version represented by high-capacity adenoviral vectors 
(HC-AdVs) attracted researchers, because these vectors display a low toxicity profile and 
result in long-term transgene expression in quiescent cells. In proliferating cells, the 
combination of HC-AdV with the integration machinery of Sleeping Beauty transposase (SB) 
demonstrated also great potential in gene therapeutic applications. The aim of this study was 
to evaluate this novel adenovirus/Sleeping Beauty transposase (AdV/SB) hybrid-vector 
system with respect to the following aspects: 
1. The first aim was to evaluate the dose effect of this novel AdV/SB hybrid-vector 
system in mice in order to define the appropriate amount, which is sufficient to obtain long-
term transgene expression and only with limited side-effects in regenerating tissue. Towards 
this end, in depth viral vector titration and characterization are required. Also, focusing vector 
dose dependency, in vivo studies in male and female mice should be performed. 
2. The second aim was to evaluate the safety profile of this novel AdV/SB hybrid-vector 
system in detail. Therefore, the potential genotoxicity caused by SB-mediated integration as 
well as the acute liver toxicity after in vivo application of the AdV/SB hybrid-vectors need to 
be analyzed. With respect to genotoxicity, the integration profile of the AdV/SB hybrid-vectors 
should be determined.  
3. As a further step, this novel adenovirus/SB transposase hybrid-vector system was 
explored in a canine model for hemophilia B. Herein, gene transfer efficiencies, the somatic 
integration pattern after transposition and anti-adenoviral immune responses needed to be 
evaluated. 
4. To further improve adenovirus-based gene therapy approaches for hemophilia, it was 
planned to explore the potential of a previously described hyperactive variant of human 
coagulation factor IX (hFIX-K265A/Y345A), which was generated from structure comparison 
and sequence alignment. 
In total, this work will provide important information about the underlying mechanisms and 
the features of this novel AdV/SB hybrid-vector system. Thus, this system can be optimized 
to be more suitable for human applications. 
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2. Material and methods 
2.1. Material 
2.1.1. Plastic ware 
All sterile plastic wares were supplied by Peske and Falcon, if not stated otherwise. 
 
2.1.2. Chemicals and enzymes 
All chemicals were obtained from Roth or Sigma, respectively. All enzymes were 
purchased from New England Biolabs, if not stated otherwise. 
 
2.1.3. Equipment 
Bacteria incubator    wtc Binder 
Bench top centrifuge Biofuge fresco, Heraeus 
Chemistry bench              Kottermann 
Clinical centrifuge Rotanta 460, Hettich 
Coagulation analyser                        MC 1, ABW Medizin und Technik GmbH 
Electronic balance             Kern 
Electroporator  Gene Pulser II, Biorad 
ELISA reader Sunrise, Tecan 
Humidified incubator                           Thermo electron  
Isofluran machine Eickemeyer 
Magnetic stirrer  Bellco 
Microscope Zeiss Axiovert-25, Spectra     
PCR cycler T professional basic, Biometra 
PIPETBOY acu                                    IBS - INTEGRA Biosciences 
Phosphoimager FLA-3000, Fujifilm 
pH Meter                                               pH 526, Bachofer 
Refrigerator Liebherr 
Rotor for ultracentrifuge SW 41, Beckman Coulter 
Spectrophotometer  Ultrospec 3000, Pharmacia 
Taqman-Cycler 7500 Fast Real-time PCR System, Applied Biosystems 
Thermomixer comfort                           Eppendorf 
Tissue culture hood        LaminAir HBB 2448, Heraeus 
Ultracentrifuge Optima LE-80K, Beckman Coulter 
Vortexer   MS1 Minishaker, Ika 
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2.1.4. Kits 
Advantage™ 2 PCR Kit                                                   BD Biosciences Clontech 
ALT Kit                                                                          Randox 
APPT liquid reagent                                            MediRox AB 
FastStart Universal Probe Master (ROX)                             Roche  
FastStart Universal SYBR Green Master (ROX)            Roche 
FuGENE® HD Transfection Reagent                                   Roche 
FuGENE® 6 Transfection Reagent                                      Roche 
GenomeWalker™ Universal Kit                                           BD Biosciences Clontech 
KOD Hot Start DNA Polymerase                                         Novagen 
Phase Lock Gel light/heavy                                                 5 Prime 
PureYield™ Plasmid Midiprep System                                Promega 
ProtoScript® First Strand cDNA Synthesis Kit                    NEB 
QIAquick Gel Extraction Kit                                                 QIAGEN 
SuperFect Transfection Reagent                                         QIAGEN 
TRIZOL Reagent                                                                    Invitrogen 
Vivapure AdenoPACK 20                                                     Sartorius Stedim Biotech 
Zero Blunt® TOPO® PCR Cloning Kit                                 Invitrogen 
  
2.2. Viruses, viral vectors, oligonucleotides and plasmids  
2.2.1. Viruses and viral vectors 
Table 2.1: Overview over viruses and viral vectors used 
Virus/vector            Relevant characteristics Reference          Figure   
Adenovirus 
serotype 5 wild 
type (Ad5 wt) 
Wild type virus occurring in the human 
population 
(Garnett et 
al., 2002) 
Figure 
1.3 A 
Ad-RSV/lacZ First generation adenovirus expressing LacZ 
with   Rous sarcoma virus (RSV) long terminal 
repeat promoter 
(Kay and 
Woo, 1994) 
              
 
Helper virus 
(AdNG163R-2) 
Ad5-based, inverted packaging signal Ψ is 
flanked by loxP-sites; promotes replication of 
HC-AdVs 
(Palmer and 
Ng, 2003) 
 
HC-AdV-HSB5 High-capacity adenoviral vector (HC-AdV) 
containing a transgene expression cassette for 
the HSB5 and Flp  
(Hausl et al., 
2010) 
Figure 
1.7; 3.1a 
HC-AdV-mSB The control vector of HC-AdV-HSB5 containing 
the inactive version of SB (mSB) 
(Hausl et al., 
2010) 
HC-AdV-TcFIX HC-AdV containing a transposon determined 
by inverted repeats (IRs) of SB at each end of 
transgene cFIX, the transposon is flanked by 
two FRT sites 
(Hausl et al., 
2010) 
HC-AdV-
luciferase 
HC-AdV containing a luciferase expression 
cassette under the control of hAAT promoter  
(Jager and 
Ehrhardt, 
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2009) 
HC-AdV-wt- 
hFIX 
 
HC-AdV containing a wild type human 
coagulation factor IX (wt-hFIX) expression 
cassette under the control of hAAT promoter 
This study Figure 
3.21 
HC-AdV-hy- 
hFIX 
 
HC-AdV containing a hyperactive human 
coagulation factor IX (hy-hFIX) expression 
cassette under the control of hAAT promoter 
This study 
 
 
2.2.2. List of oligonucleotides 
Table 2.2: Overview over the oligonucleotides used in this study. All primers were obtained from 
operon, while all probes were from Ella Biotech.   
Target/Name Orientation Sequence 5’ to 3’ Reference 
ASP1 Forward GTAATACGACTCACTATAGGGC BD 
ASP2 Reverse ACTATAGGGCACGCGTGGT 
Dog B2M-F Forward GGATGAGTTTAGCTGCCGTG  This study 
Dog B2M-R Reverse TATCTGAGCACAGGCACAGC 
E1-F Forward GGGTGAGGAGTTTGTGTTAGATTATG (Puntel et al., 
2006) E1-R Reverse TCCTCCGGTGATAATGACAAGA 
E1-specific 
probe 
 [6-FAM] AGC ACC CCG GGC ACG GTTG 
[TAMAR] 
GSP1 Forward CCTTAAGACAGGGAATCTTTACTCGGA This study 
GSP2 Reverse GGCTAAGGTGTATGTAAACTTCCGACT 
hAAT-cFIX f Forward CTG ACC TGG GAC AGT GAA TGA T 
hAAT-cFIX r Reverse GCC TGG TGA TTC TGC CAT GAT 
hFIX-forw Forward ATGCAGCGCGTGAACATGATCA 
hFIX-OL1 Reverse ACTGCTGGTTCACAGGACTTCTG 
hFIX-OL2 Forward CAGAAGTCCTGTGAACCAGCAGT 
hFIX-rev Reverse AGCTCACTTAATGAAAGCTTGCGG 
hFIX qPCR f  TGGAAGCAGTATGTTGATGGAGA 
hFIX qPCR r  CCTTGCAACTGCCGCCATTT 
Human B2M f Forward TGCTGTCTCCATGTTTGATGTATCT  (Vandesompel
e et al., 2002) Human B2M r Reverse TCTCTGCTCCCCACCTCTAAGT 
L3-F Forward GAG TTG GCA CCC CTA TTC GA (Puntel et al., 
2006) L3-R Reverse ATG CCA CAT CCG TTG ACT TG 
L3-specific 
probe 
 [6-FAM] CCA CCC GTG TGT ACC TGG 
TGG ACA [TAMAR] 
Linker for 
genome walker 
PCR 
 GTAATACGACTCACTATAGGGCACGCG
TGGTCGACGGCCCGGGCTGGT–3' 
                     3'–H2N-CCCGACCA-PO4–5' 
BD 
Mouse TBP f Forward CCCCACAACTCTTCCATTCT This study 
Mouse TBP r Reverse GCAGGAGTGATAGGGGTCAT  
SB-L Forward GGTGGCAGCATCATGTTGTG This study 
SB-R Reverse CCTTCCTCATGATGCCATCTATT 
 
DB, BD GenomeWalker
TM
 Kit from BD Biosciences 
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2.2.3. Plasmids  
Table 2.3: List of plasmids used in this study 
Plasmids name Characteristics Reference 
pAAV-EF1a-wthFIX human elongation factor 1a (EF1a) gene 
enhancer/promoter-driven wild type (wt) hFIX 
expression cassette 
(Nakai et al., 
2001) 
pAdFTC HC-AdV cloning plasmid, AmpR (Ehrhardt and 
Kay, 2002) 
pAdFTC-hAAT-
(wt/hy)-hFIX 
pAdFTC containing wt or hy hFIX under the 
control of  hAAT promoter 
This study 
pAdFTC-hAAT-cFIX pAdFTC containing cFIX under the control of  
hAAT promoter 
This study; 
(Hausl et al., 
2010) pAdFTC-PGK-HSB5 pAdFTC containing HSB5 under the control of 
the phospho-glycerate kinase promoter (PGK)  
pAdFTC-PGK-mSB pAdFTC containing mSB under the control of the 
PGK promoter  
pCMV-HSB5 A helper plasmid encoding a hyperactive 
transposase (HSB5) under the control of  CMV 
promoter 
(Yant et al., 
2007) 
pCMV-mSB A helper plasmid encoding inactive transposase 
(mSB) under the control of  CMV promoter  
(Yant et al., 
2000) 
pCI-hAAT-2xMAR pCI vector with hAAT promoter and two stuffer 
DNA fragments (ChMAR: matrix attachment 
region from chicken lysozyme gene, 2.8 kb of 
each), AmpR 
Generated by 
Hausl M 
pCI-hAAT-(wt/hy)-
hFIX 
pCI-hAAT-2xMAR containing wt or hy hFIX under 
the control of  hAAT promoter 
This study 
pCR-Blunt II-TOPO for the cloning of blunt end PCR fragments, KanR Invitrogen 
pET22b-
(K265T/Y345T) hFIX 
pET22b vector containing the truncated human 
coagulation factor IX (hFIX) variant 
(K265T/Y345T) 
(Hopfner et al., 
1997) 
pGL3-Control Luciferase expression, SV40 promoter, AmpR Promega 
pGL3-hAAT (∆SV40 
and Luc) 
pGL3-Control with liver specific human alpha-1-
antitrypsin promoter (hAAT) promoter, w/o 
∆SV40 promoter and Luciferase expression  
This study 
pGL3-hAAT-(wt/hy)-
hFIX 
pGL3 vector containing wt or hy hFIX under the 
control of  hAAT promoter 
This study 
pHM5 Shuttle vector, KanR  (Mizuguchi and 
Kay, 1999) 
pHM5-hAAT-cFIX pHM5 containing canine coagulation factor IX 
(cFIX) under the control of  hAAT promoter 
(Hausl et al., 
2010) 
pHM5-hAAT-(wt/hy)-
hFIX 
pHM5 containing wt or hy hFIX under the control 
of  hAAT promoter 
This study 
pTnori KanR/NeoR- marked transposon ori to permit 
recovery of transposon insertions 
(Yant et al., 
2000) Figure 3.6 
pTOPO-(wt/hy)-hFIX pTOPO vector containing the full-length wild type 
(wt) or hyperactive (hy) hFIX 
This study 
pTOPO-mTBP pTOPO vector containing mouse TBP gene 
(TATA box binding protein) fragment 
pTOPO-dB2M pTOPO vector containing dog B2M gene (Beta-2-
microgloblin) fragment  
pTOPO-hB2M pTOPO vector containing human B2M gene 
(Beta-2-microgloblin) fragment 
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pTOPO-SB pTOPO vector containing SB gene (Sleeping 
Beauty transposase) fragment 
pTOPO-L3 pTOPO vector containing L3 gene fragment of 
Ad 5   
pZAC2.1 For AAV2/8 production, ITR, 4543 bp, AmpR Wilson Lab 
pZAC-CMV-(wt/hy)-
hFIX 
pZAC vector containing the full-length wt or hy 
hFIX under the control of  cytomegalovirus 
(CMV) immediate early promoter 
This study 
 
 
2.3. Molecular genetic methods 
2.3.1. Plasmid preparation 
For cloning selection and integration site analysis, a small amount (3~5 ml) of bacteria 
was cultured over night in Luria-Bertani (LB) medium (1% tryptone, 0.5% yeast extract, 0.5% 
NaCl). To isolate plasmid DNA, 1.5~3 ml bacterial culture were spun down at 15.000 x g for 2 
min in a bench top centrifuge. The supernatant was discarded and the bacterial cell pellet 
was resuspended with 100 µl of resuspension buffer (50 mM Tris-HCl, pH 7.5; 10 mM EDTA, 
pH 8.0; 100 μg/ml RNase A). Then 100 µl of lysis buffer (0.2 M NaOH, 1 % SDS) were added 
and the samples were mixed thoroughly and incubated at room temperature for 3 min. After 
addition of 100 µl of neutralisation buffer (4.09 M guanidine hydrochloride, pH 4.8; 759 mM 
potassium acetate; 2.12 M glacial acetic acid), the samples were mixed and centrifuged for 5 
min at 15.000 x g. The supernatant was transferred to a new Eppendorf tube, which contains 
30 µl of sodium acetate (3 M NaAc, pH 5.0) and 900 µl of ice cold 100% ethanol were added. 
The solution was mixed and the tube was centrifuged at 15.000 x g for 8 min. Then the 
supernatant was removed and the pellet was washed once with 500 µl of 70% ethanol. After 
completely removing the supernatant, the DNA pellet was dried and resuspended in 100 µl 
dH2O. 
For a large amount of plasmid DNA preparation, a plasmid midiprep kit from Promega 
was used, according to the manufacturer‟s instructions. 
The concentration of DNA was determined using spectrophotometry. 2 µl of DNA 
solution were measured in 98 µl dH2O using the Ultrospec 3000 spectrophotometer 
(Pharmacia Biotech). The concentration of the DNA was calculated using Lambert Beers 
Law which states concentration of double-stranded DNA in µg/ml = A260 x 50 x dilution factor, 
whereby A260 is the adsorption coefficient of DNA at 260 nm. The solution was also 
measured to determine the absorption at 280 nm for proteins. Only DNA samples with an 
A260/A280 ratio of 1.8-2.0 were used for experiments. 
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2.3.2. Manipulation of plasmid DNA 
2.3.2.1. Restriction digestion of DNA and agarose gel electrophoresis 
Plasmid DNA or DNA fragments generated by PCR were digested with the respective 
restriction endonuclease in a total volume of 20 µl for analytic digests or 100 µl for 
preparative digests. Digests were performed for 1 h or overnight at the respective cleaving 
temperature. Cleaved DNA samples were loaded on to 1 % agarose gels containing ethidium 
bromide (EtBr) for visualization and separation.   
 
2.3.2.2. Isolation of DNA fragments from agarose gels 
After running the 1% agarose gel, the respective band of DNA was cut out under UV 
light. Exposure of the DNA to UV light was reduced to a minimum to avoid mutations. The cut 
out gel slices were transferred to Eppendorf tubes and the DNA was isolated using a gel 
extraction kit (Qiagen) according to the manufacturer‟s instructions.  
 
2.3.2.3. Ligation of DNA fragments and plasmids 
To prevent self-ligation, the digested vector DNA was dephorphorylated. 1U of calf 
intestinal phosphatase (CIP) was used and incubated at 37ºC for 1 h. CIP was then 
inactivated by incubation at 75 ºC for 10 min. The dephosphorylated DNA was subsequently 
extracted with phenol: chloroform: isoamylalcohol and ethanol precipitation. The precipitated 
DNA was re-suspended in 20 μl of dH2O. 
According to the size of the respective fragments/plasmids used in the ligation 
reaction, an excess of insert DNA was added (plasmid: insert = 1:4). 400 units of T4 DNA 
ligase (NEB) were used in an as small as possible reaction volume. Ligation was performed 
for overnight at 16 ºC.  A control ligation without insert was always included. 
 
2.3.3. Transformation of bacteria  
2.3.3.1. Electrotransformation  
Electrocompetent E. coli cells were thawed on ice, and then the DNA was added and 
gently mixed. For re-transformations, 1 μl of the plasmid DNA were used. For newly ligated 
plasmids, up to 2 µl of the ligation mixture were used. 50 μl of competent cells containing the 
plasmid DNA were then transferred to 0.2 cm cuvettes. Samples were electroporated with a 
BioRad GenePulser® II electroporator using the following conditions: 2.5 kV, 200 Ω, 25 μF. 
600 µl of room temperature S.O.C. medium (2% tryptone, 0.5% yeast extract, 8.56 mM NaCl, 
2.5 mM KCl, 10 mM MgCl2, and 20 mM glucose) were immediately added after 
transformation and the suspension was transferred to a 1.5 ml Eppi. The transformed 
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bacteria were shaken for 1 h at 37°C , subsequently 10-50 µl were plated on the appropriate 
solid agar, flowing by a over night incubation at 37°C. For further culture and analysis, ~10 
colonies were picked. 
 
2.3.3.2. Chemical transformation 
Chemically competent E. coli cells were thawed on ice, and then the DNA was added, 
followed by 5 to 30 minutes incubation on ice. For re-transformations, 1 μl of the plasmid 
DNA were used. For newly ligated plasmids, up to 5 µl of the ligation mixture were used. 
Cells were heat-shocked for 30 seconds at 42°C without shaking. Then the tubes were 
transferred immediately to ice. After addition of 250 μl room temperature S.O.C. medium, the 
transformed bacteria were shaken for 1 h at 37°C, followed by a similar procedure as in the 
Electrotransformation (2.3.3.1). 
 
2.3.4. DNA-sequencing and bioinformatic analysis 
To control the correctness of cloned DNA fragments and to obtain DNA-sequences 
for the design of oligonucleotides, respective plasmids were sequenced by Eurofins (MWG 
Operon, Ebersberg). Obtained sequences were uploaded in VectorDesigner Database 
browser (Invitrogen) for further analyses.  Briefly, the sequences were analyzed by sequence 
alignments to known DNA sequences and/or certain species genome database. All 
programmes were provided by the National Center for Biotechnology Information (NCBI). 
The database and the respective algorithms are available at 
http://blast.ncbi.nlm.nih.gov/Blast.cgi. 
In case of integration sites location in genomic DNA and genomic strand decision, the 
genomic data base and the BLAT search program for mouse and dog from the Center for 
Biomolecular Science & Engineering (UCSC) was used (http://genome.ucsc.edu/cgi-
bin/hgBlat) (Fujita et al., 2011). For evaluation of the potential cancer formation of the 
integration sites, all genes located in and near the integration sites were checked to one 
Cancer Gene Expression Database (CGED, http://lifesciencedb.jp/cged/) (Kato et al., 2005). 
 
2.3.5. Isolation of DNA from mammalian cells 
2.3.5.1. Isolation of genomic DNA from cell pellets 
The cell pellet was resuspended in 200 µl DPBS and vortexed for complete 
resuspension. Then 200 µl lysis buffer (10 mM Tris, 10 mM EDTA, 0.5% SDS) were added, 
supplemented with 30 µl 10% SDS and 15 µl proteinase K (Qiagen, 600 mAU/ml = 20 
mg/ml). The suspension was mixed thoroughly and shaken over night at 55°C. On the next 
day, 2 µl RNase A (10 mg/ml) were added and the suspension was incubated for 30 min at 
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37°C. Genomic DNA was then purified by phenol: chloroform: isoamylalcohol (PCI, 25:24:1) 
extraction. Herein, the suspension was mixed thoroughly with PCI and subsequently 
centrifuged for 2 min at high speed in a bench top centrifuge. Then the supernatant was 
transferred to a fresh tube. The PCI extraction was repeated once as described above. The 
DNA was then precipitated by addition of 50 µl NaAc (pH 5.0, 3 M) and 1 ml ice cold 100% 
ethanol. The DNA was pelleted by centrifugation for 10 min at high speed in a bench top 
centrifuge. The supernatant was removed and the pellet was washed twice with 500 µl of 
70% ethanol. Afterwards, the supernatant was discarded, and the pellet was dried and 
subsequently dissolved in 120 µl of dH2O. For determination of DNA concentration and purity 
a test gel was run and the A260/A280 was measured. 
 
2.3.5.2. Isolation of genomic DNA from liver 
2 ml lysis buffer (40 mM NaCl, 10 mM Tris pH 7.5, 10 mM EDTA) were filled into 50 
ml tubes (Falcon) and 300 µl of 10% SDS were added. Approximately 0.1 g of liver tissue 
was used. Small pieces of tissue were immediately transferred to the prepared lysis buffer 
and homogenized with a syringe (needle gauge: 20G). Then 10 µl of Proteinase K (20 
mg/ml) were added and the samples were incubated at 55°C for 2 h with permanent gentle 
shaking. Subsequently, 15 µl RNase A (10 mg/ml) were added and the samples were 
incubated over night at 37°C on a shaking platform. On the next day the samples were 
extracted twice with 500 µl phenol: chloroform: isoamylalcohol (25:24:1). After centrifugation 
at 3000 rpm for 2 min, the supernatant was transferred to a 15 ml Falcon tube. For 
precipitation of the DNA, three volumes of ice cold 100% ethanol were added and the 
samples were mixed thoroughly. Subsequently, the samples were centrifuged at 2000 rpm 
for 10 min. Afterwards, the supernatant was discarded and the DNA-pellet was briefly air-
dried. To solve the DNA 600 µl freshly prepared TE buffer (10 mM Tris pH 7.5, 1 mM EDTA, 
10 µg/ml RNase A) were added and the samples were gently shaken for 2 h at room 
temperature. For long-time storage the samples were frozen at -20°C. 
 
2.3.6. Isolation of RNA from mammalian cells 
2.3.6.1. Isolation of RNA from cells grown in monolayer 
Cells from 6-well plates were resuspended in 200 µl TRIZOL Reagent (Invitrogen), 
homogenized with a 21-gauge needle (or pipette) and RNA was isolated following the 
manufacture‟s instructions. The concentration of isolated RNA was determined using a 
spectrophotometer (Pharmacia). The integrity of the isolated RNA was evaluated by agarose 
gel electrophoresis. All work was done on ice. Isolated RNA was stored at -80°C. 
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2.3.6.2. Isolation of RNA from liver 
Liver tissue was stored at -80°C and was transferred in liquid nitrogen. Approximately 
0.05~0.1 g of liver tissue was used. 1 ml TRIZOL Reagent (Invitrogen) was added directly 
into the store tube before the tissue sample was thawed. The sample was homogenized with 
the help of glass balls in mixer mill MM 200 (Retsch) and RNA was isolated following the 
manufacture‟s instructions. 
 
2.3.6.3. Reverse transcription of mRNA into cDNA  
Transcription of mRNA into cDNA was done according to the NEB First Strand 
Synthesis Protocol using 2 µg of purified total RNA. 5 μl of cDNA were directly used for PCR. 
 
2.3.7. Polymerase chain reactions (PCR) 
2.3.7.1. Standard PCR 
Reaction components 
Components Amount Final concentration 
10 x KOD buffer 5 μl 1 x 
MgSO4 (25 mM)   3 µl 1.5 mM 
dNTPs (2 mM) 5 μl 0.2 mM (each) 
Oligonucleotide 1 (10 µM) 1.5 μl 0.3 µM 
Oligonucleotide 2 (10 µM) 1.5 μl 0.3 µM 
Template DNA 10-100 ng  
KOD Hot Start DNA Polymerase (1 U/μl) 1 μl 0.02 U/µl 
deionized H2O  add to 50 μl  
Total  50 µl  
 
Cycling parameters:  
Parameters Temperature Time Cycles 
Initial Denaturation 95°C 2 min 1 x  
Denaturation 95°C 20 sec 30-35 x 
Annealing x°C 10 sec         
Elongation 70°C            y sec 
Final extension 70°C          10 min 1 x 
 
x: Annealing temperature is dependent on the Tm (melting temperature) of oligonucleotides. 
y: Elongation is typically 30 second per kb of amplified DNA using KOD polymerase. 
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2.3.7.2. PCR for GenomeWalkerTM DNA walking  
1) First PCR 
Reaction components 
Components Amount 
Template DNA 1 μl of each DNA library 
AP1 (10 µM)   1 μl 
GSP1 (10 µM) 1 μl 
dNTPs (10 mM) 1 μl 
10X Advantage 2 PCR buffer 5 μl 
Advantage 2 Polymerase Mix (50X)         1 μl 
deionized H2O  40 μl 
Total  50 µl 
 
Cycling parameters:  
Parameters Temperature Time Cycles 
First Denaturation 94°C 25 sec 7 x 
First Elongation 72°C            3 min 
Second Denaturation 94°C 25 sec 32 x 
Second Elongation 67°C            3 min 
Final extension 67°C            7 min 1 x 
 
2) Nested PCR 
Reaction components 
Components Amount 
Template DNA 1 μl of 10 x diluted primary PCR product 
AP2 (10 µM)   1 μl 
GSP2 (10 µM) 1 μl 
dNTPs (10 mM) 1 μl 
10X Advantage 2 PCR Buffer 5 μl 
Advantage 2 Polymerase Mix (50X)         1 μl 
deionized H2O  40 μl 
Total  50 µl 
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Cycling parameters:  
Parameters Temperature Time Cycles 
First Denaturation 94°C 25 sec 5 x 
First Elongation 72°C            3 min 
Second Denaturation 94°C 25 sec 20 x 
Second Elongation 67°C            3 min 
Final extension 67°C            7 min 1 x 
 
2.3.7.3. Quantitative real-time PCR (qRT-PCR)  
Up to 100 ng of genomic DNA or 20 ng of plasmid DNA was used in a final volume of 
20 µl. Oligonucleotides were designed with primerExpress3.0 software (Applied Biosystems) 
and obtained from Operon. The Taqman Fast Universal PCR Master Mix (Applied 
Biosystems) was used in corporation with a Taqman 7500 Fast Real Time PCR System 
(Applied Biosystems) with 7500 Standard program. Table 2.2 shows all oligonucleotides, 
which were used for qPCR.  
(1) Without probe 
Components Volume Final Conc. 
Template DNA 5 µl Up to 100 ng of genomic DNA or 20 ng of plasmid 
DNA 
FastStart Universal SYBR 
Green Master (ROX) 
10 µl 1 x 
Forward primer (10 µM) 0.6 µl 300 nM 
Reverse primer (10 µM) 0.6 µl 300 nM 
deionized H2O 3.8 µl  
Total 20 µl  
 
Cycling parameters:  
Parameters Temperature Time Cycles 
AmpErase UNG reaction 50°C 2 min 1 x 
DNA Polymerase activation 95°C 10 min 1 x 
Amplification and real-time analysis 95°C 15 sec 40 x 
60C 1 min 
Dissociation 95°C 15 sec 1 x 
 60°C 1 min 
95°C 15 sec 
60°C 15 sec 
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Amplification and data collection were at 60 °C for 1 min 
 
(2) With probe 
Components Volume Final Conc. 
Template DNA 5 µl Up to 100 ng of genomic DNA or 20 ng of plasmid 
DNA 
FastStart Universal Probe 
Master (ROX)                            
10 µl 1 x 
Hydrolysis probe (10µM) 0.625 µl 250 nM 
Forward primer (40 µM) 0.5625 µl 900 nM 
Reverse primer (40 µM) 0.5625 µl 900 nM 
deionized H2O 3.25 µl  
Total 20 µl  
 
Cycling parameters:  
Parameters Temperature Time Cycles 
AmpErase UNG reaction 50°C 2 min 1 x 
DNA Polymerase activation 95°C 10 min 1 x 
Amplification and real-time 
analysis 
95°C 15 sec 40 x 
60°C 1 min 
 
Amplification and data collection were at 60°C for 1 min 
 
2.4. Enzyme activity assays 
2.4.1. Measurement of alanine aminotransferase (ALT) 
For the quantitative determination of ALT in murine serum as signal for liver toxicity, 
the ALT kit (Randox) was used according to the manufacturer‟s instructions. 10 µl of fresh 
murine serum were applied to each reaction. The measurement was conducted in the 
Ultrospec 3000 spectrophotometer (Pharmacia Biotech). 
 
2.4.2. Enzyme linked immunosorbent assay (ELISA) 
2.4.2.1.  Detection of canine factor IX (cFIX) in murine serum 
Detection of cFIX in murine serum was performed in a sandwich ELISA. 96-well 
plates (Greiner Bio-One) were coated with an anti-cFIX antibody (Affinity Biologicals). The 
anti-cFIX antibody was 1:500 diluted in coating buffer (0.1 M NaHCO3, pH 9.4). The plates 
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were incubated using 50 µl per well at 4°C over night. For blocking, plates were washed with 
200 µl TBST (10 mM Tris-HCl, 150 mM NaCl, 0.05% Tween 20) per well. After removal of 
the TBST solution, 200 µl dilution buffer (TBST + 5% FBS) per well were added and the 
plates were incubated 1 h at room temperature. Following twice washes with TBST, samples 
were diluted with dilution buffer (TBST + 5% FBS) in appropriate relations. For generation of 
a standard curve, normal dog plasma was used. 50 µl of standard or detected sample per 
well were loaded and the plates were incubated for 2 h at 37°C. Afterward, the plates were 
washed 3 times with TBST. For detection, an anti-cFIX-HRPO antibody (Affinity Biologicals) 
was used. The anti-cFIX-HRPO antibody was applied in a 1:1000 dilution, and loaded 50 µl 
per well followed by incubate for 1 h at 37°C and 4 times washes with TBST. For 
development, 100 µl substrate solution (Sigma Fast OPD) per well were used and the plates 
were incubated for 10 min at room temperature. To stop and enhance the reaction, 50 µl of 2 
M H2SO4 were added to each well. The samples were finally read at 492 nm in a plate reader 
(Tecan, Magellan3 software). 
 
2.4.2.2. Detection of human factor IX (hFIX) in tissue culture supernatant and murine 
plasma 
Detection of hFIX was performed in a similar procedure as cFIX. Briefly, an anti-hFIX 
antibody (Sigma) was used for coating with 1:1000 dilution, purified hFIX (ProSpec-Tany 
Technogene) was used for generation of a standard curve and an anti-hFIX-HRPO antibody 
(1:1000 diluted) (Biozol) was used for detection. 
 
2.4.3. Detection of human coagulation factor IX (hFIX) activity by activated partial 
thromboplastin time (APPT) 
The APTT tests were performed on the Merlin MC 1 table coagulation analyser                       
(ABW Medizin und Technik GmbH), which is a semi-automatic mechanical coagulation 
detection system. The sample was thawed at 37°C immediately prior to performing the 
assays, Owren‟s buffer (11 mM sodium citrate, 132 mM NaCl, pH7.3, with 4mM Sodium 
pyrophosphate as a conservative. MediRox AB) was used for plasma dilution when needed. 
50 µl (diluted) sample were mixed with an equal volume of human FIX-deficient plasma (Hart 
Biologicals) without shaking. This mixture was added in the 12 o‟clock position of the cuvette 
on the machine. After two-minute incubation at 37°C, 100 µl 37°C pre-warmed APPT liquid 
reagent (MediRox AB) were added to the cuvette in the same position. After another 
incubate at 37°C for 5 minutes, the clotting was induced by dispensing 100 µl 37°C pre-
warmed Calcium Chloride (0.025 mol/L, MediRox AB) in the 9 o‟clock position of the cuvette. 
The clotting time and activity can then be recorded and calculated. For generation of a 
standard curve, normal human plasma (Hart Biologicals) was used.  
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2.5. Cell culture 
2.5.1. Prokaryotic cells 
All bacteria (Table 2.4) were routinely grown in Luria-Bertani (LB) medium (1% 
tryptone, 0.5% yeast extract, 0.5% NaCl). Liquid media were sterilised by autoclaving (121 
°C at 1 bar for 20 min). For solid agar, 1.5% agar was added. If required, media were 
supplemented with the respective antibiotic (Table 2.5). Bacteria on LB-agar were cultivated 
over night at 37°C, if not stated otherwise. Bacteria in liquid culture were cultivated over night 
at 37°C on a shaking platform.  
 
Table 2.4: Bacterial strains 
E. coli strain 
 
Characteristics Reference 
DH10B F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 
recA1 endA1 araD139 Δ(ara, leu)7697 galU galK λ- rpsL 
nupG 
Invitrogen 
DH5α endA1 hsdR17(rk-mk+) supE44 thi-1 recA1 gyrA relA1 
Δ(lacZYAargF) U169 (φ80lacZΔM15) 
(Hanahan, 
1983) 
TOP10 F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 
recA1 araD139 Δ(araleu) 7697 galU galK rpsL (StrR) endA1 
nupG 
Invitrogen 
Stabl-2 F- endA1 glnV44 thi-1 recA1 gyrA96 relA1 Δ(lac-proAB) 
mcrA Δ(mcrBC-hsdRMS-mrr) λ- 
Invitrogen 
 
 
Table 2.5: Antibiotics used for selection of prokaryotic and eukaryotic cells 
Antibiotic 
 
Abbreviation  Dissolved in Working 
concentration 
Ampicillin Amp H2O 100 µg/ml 
Kanamycin Kan H2O 20 µg/ml 
Hygromycin B Hyg H2O 100 µg/ml 
Geneticin G418 H2O 500 µg/ml 
 
2.5.2. Eukaryotic cells 
2.5.2.1. Cell culture media 
1) Growth medium: 
Modified eagle medium (MEM, PAA) or Dulbecco‟s modified eagle medium (DMEM, 
PAA), supplemented with 10% (v/v) fetal bovine serum (FBS, PAA). For liver cell 
lines, non-essential amino acids (PAA) were added. 
2) Freezing medium: 
DMEM or MEM supplemented with 20% (v/v) FBS and 5% (v/v) filter sterilised 
dimethylsulfoxide (DMSO).  
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2.5.2.2. Cultivation of eukaryotic cell lines 
All cells were grown in a humidified incubator at 37°C and 5% CO2.  
Human embryonic kidney 293 cells (ATCC CRL-1573) and HeLa cells (ATCC CCL-2) 
were grown in DMEM supplemented with 10% FBS.  
Huh7, Sk-Hep-1 (ATCC HTB 52) cells were kept in DMEM containing 10% FBS and 
0.1 mM non-essential amino acids.  
116 cells (Palmer and Ng, 2003) were used for production of HC-AdVs. This cell line 
carries a hygromycin resistance gene, expresses Cre recombinase, and was grown in MEM 
supplemented with 10% FBS and 100 µg/ml hygromycin B.  
 
2.5.2.3. Establishment of cell cultures from cryostocks 
The cells were thawed at 37°C and transferred immediately into a 15 ml tubes 
(Falcon) containing 5 ml of growth medium. Cells were collected by centrifugation at 200 g 
for 3 min at room temperature. After removing the supernatant, the cell pellet was re-
suspended with 5 ml of fresh growth medium and transferred to cell culture dishes containing 
the appropriate growth medium. 
 
2.5.2.4. Preparation of permanent cell culture stocks in liquid nitrogen  
80% confluency cells were trypsinized and collected by centrifugation at 200 g for 3 
min at room temperature. After removing the supernatant, the cell pellet was re-suspended in 
freezing medium. 500 µl of the cell suspension were aliquoted into cryovials and kept in liquid 
nitrogen for long-term storage. 
 
2.5.2.5. Passaging of eukaryotic cell lines 
At a confluence of 50-80%, cells were split at a ratio of 1:4. Cells were detached from 
the dish with trypsin-EDTA solution (PAA). Trypsinised cells were immediately transferred to 
new cell culture plates containing the appropriate growth medium. 
 
2.5.2.6. Transfection of eukaryotic cells 
For transfection of eukaryotic cells, commercial transfection agents (FuGENE® HD/6 
Transfection Reagent, SuperFect Transfection Reagent) were used according to the 
manufacturer‟s instructions. Briefly, one day before the transfection experiment, the cells 
were trypsinized and seeded in the chosen cell-culture vessel. On the day of transfection, 
plasmids DNA to be transfected were diluted in OPTI-MEM I reduced serum medium 
(Invitrogen), mixed with respective transfection agent and added to the cells. After a certain 
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length of incubation period (normally 48 hrs), the respective cells and supernatant were 
collected and measured.  
 
2.6. Adenovirus production, purification and titration 
2.6.1. Production and purification of viral vectors and viruses 
2.6.1.1. Production of helper virus 
AdNG163R-2 helper virus was amplified in adherent 293 cells (Palmer and Ng, 2003; 
Jager et al., 2009). Three serial passages using 60-mm (one in total), 100-mm (two in total) 
and 150-mm (six in total) tissue culture dishes were first performed as pre-amplification. 
Afterward, a large-scale amplification of the virus was produced on 30 confluent 15 cm cell 
culture plates. 48 hours after each infection, a cytopathic effect (CPE) should be observed 
because of helper virus replication (cells are rounded up and loosely or completely detached 
from the tissue culture dish). Then the cells were harvested for virus purification (see also 
2.6.1.3).  
 
2.6.1.2. Production of high-capacity adenoviral vectors (HC-AdVs) 
To produce of high-capacity adenoviral vectors, the linearised FTC plasmid DNA was 
transfected with Superfect (Qiagen) into the producer cell line 116 according to the 
manufacturer‟s instructions. 16 to 18 h post transfection, the cells were co-infected with 
helper virus AdNG163R-2 (HV) (Palmer and Ng, 2003) applying 5 transducing units (TUs) 
per cell. Cells and supernatant (= passage P0) were harvested 48 h post-infection and frozen 
at -80°C. Then, 3 to 5 serial passaging steps (P1 - P5) on 6 cm, 10 cm and 15 cm dishes are 
required for pre-amplification of HC-AdV. Usually, two third of the three-time frozen-thawed 
lysate of the previous passage was applied to infect the next plate. Co-infection with HV was 
always at 2 TUs/cell. Lysate was generally harvested when complete cytopathic effect was 
observed. 
After the pre-amplification steps, large-scale HC-AdV production was performed with 
a 3000 ml spinner flask (Bellco) as described (Figure 2.1) (Parks et al., 1996; Palmer and 
Ng, 2003; Jager et al., 2009). Herein, 116 cells were flushed off with 10 ml fresh media from 
10 confluent 15 cm dishes and transferred into a spinner flask containing 900 ml of pre-
warmed fresh MEM (Gibco) supplemented with 10% FBS (Sigma) and 100 µg/ml hygromycin 
B (Invitrogen). Over the next days, the same growth medium with all necessary 
supplementals was added to a final volume of 3 litres (500 ml on days 2 and 3, 1000 ml on 
day 4). On day five, 3 litres of 116 cells at 3 to 4x105 cells/ml were harvested by 
centrifugation (8 min at 1500 rpm in a clinical centrifuge), resuspended in 120 ml volume 
medium and co-infected with 100% of the crude lysate from the 15 cm dishes of the last 
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serial passaging step and HV at an MOI of 1 TU/cell. In an alternative simplified protocol, 
when an HC-AdV is to be re-amplified from excited stock, purified HC-AdV instead of crude 
lysate was used as inoculum at an MOI of 100 for co-infection of 3 litres of 116 cells. Virus 
adsorption was performed at 37°C on a magnetic stir plate (Bellco) for 2 h, after which 
medium (MEM supplemented with 5% FBS, Sigma) was added to a final volume of 2 litres. 
Co-infected cells were harvested 48 h later for adenoviral vector purification. 
 
2.6.1.3. Purification of adenoviruses and adenoviral vectors 
At the end of virus amplification, cells and supernatant of infected dishes or suspend 
cells from spinner flask were collected in conic 500 ml bottles. Cells containing the virus were 
spun down for 10 min at 200 x g. Supernatant was removed and the cell pellet was 
resuspended in 28 ml DPBS. This suspension can be stored at -80°C. To release the virus 
from the cells, the suspension was four times frozen in liquid nitrogen and thawed in a 37°C 
water bath. The lysate was spun down for 8 min at 200 x g and the supernatant containing 
the virus was collected. 
For purification of adenovirus and adenoviral vectors, the suspensions obtained 
above were loaded onto one step and one continuous gradient. The step gradient was 
established by pipetting cesium chloride (CsCl) solutions with different densities in the 
following order: 
 
0.5 ml   1.5 g/cm3 CsCl 
3 ml   1.35 g/cm3 CsCl 
3.5 ml   1.25 g/cm3 CsCl 
5 ml    virus/vector 
 
This step gradient was spun for 1.5 h at 35000 rpm (226000 x g)/ 12°C in an 
ultracentrifuge (Beckman Coulter). The lower bluish band containing the virus was collected 
and mixed with 1.35 g/cm3 CsCl (final volume 12 ml). This continuous gradient was spun for 
at least 20 h at 35000 rpm (226000 x g)/ 12°C. The virus band was collected in an as little 
volume as possible. The purified virus was dialysed over night at 4°C in 2 l dialysis solution 
(10 mM Tris pH 7.5, 10% Glycerol, 1 mM MgCl2) at very low stir speed and then aliquotted.  
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Figure 2.1: Schematic outline for the production of HC-AdV. The transgene is usually cloned 
from a shuttle vector pHM5 into pAdFTC. The linearized pAdFTC with transgene is then transfected 
into 116 cells and is co-infected with helper virus AdNG163R-2 at a multiplicity of infection (MOI) of 5. 
Helper virus provides all necessary gene products for HC-AdV production, while its own genome is 
not efficiently packaged due to excision of their packaging signal Ψ in Cre-expressing 116 cells. 3-5 
serial passages are used to pre-amplify HC-AdV in adherent 116 cells before going to suspend 116 
cells in a 3-liter spinner flask. HC-AdV is purified by cesium chloride centrifugation, dialysed and 
titrated by quantitative Real-Time PCR with primers specifically detecting each transgene (black 
arrows). ITR: Inverted terminal repeat; HV: helper virus; HC-AdV: High-capacity adenoviral vector; Ψ: 
packaging signal. Modified from Jager et al. 2009. 
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2.6.2. Adenovirus DNA isolation 
50 µl CsCl-purified virus were incubated in 150 µl lysis buffer (10 mM Tris, 10 mM 
EDTA, 0,5% SDS) supplemented with 10 µl proteinase K (Qiagen, 600 mAU/ml = 20 mg/ml) 
for 2 h at 55°C. Subsequently, the solutions were purified with phenol: chloroform: 
isoamylalcohol extraction. The DNA was precipitated with ice cold 100% ethanol for 20 min 
at -20°C and centrifuged with full speed at 4°C for 10 min. Precipitated DNA was 
resuspended in 50 µl dH2O.  
 
2.6.3. Titration of adenoviral vector preparations 
2.6.3.1. Determination of the physical titer 
Viral DNA was released from virions obtained from CsCl gradients in dilution buffer 
(100 mM Tris, 10 mM EDTA, 0.1% SDS). The A260 was measured to determine the viral titer. 
The viral particle concentration was determined by the well-characterized absorption of pure 
adenovirus DNA at 260 nm (Maizel et al., 1968), an OD260nm unit corresponds to of 1.1 x 10
12 
VPs/ml based on a 36 kb size of the wild type particle genome. Thus, the optical particle 
units (OPU) for HC-AdV and other adenoviruses were calculated using the following formula: 
OPU/ml = (absorbance at 260 nm) × (dilution factor) × (1.1 × 1012) × (36)/(size of HC-AdV in 
kb).  
In brief, 475 µl of dilution buffer were added to a 25 µl aliquot of the CsCl purified 
virus. Suspensions were vigorously shaken at 1200 rpm for 15 min in a table top shaker. 
Subsequently, samples were briefly centrifuged and subjected to OD260nm measurement. 100 
µl of each 5 aliquots were used for determination. 
 
2.6.3.2. Determination of the infectious titer by quantitative real-time PCR 
The number of infectious genomes was determined by quantitative real-time PCR 
(qPCR) employing the oligonucleotides described in table 2.2. Infectious particles were 
determined by analyzing two different diluted (10–2 and 10–3) genomic DNA of infected (2 µl, 
0.4 µl or 0.08 µl virus infect 6-cm diches) 293 cells in a total volume of 20 µl. These infected 
293 cells were harvested with trypsin after 4 h of incubation, and washed twice with PBS to 
remove unabsorbed virions. Genomic DNA was isolated as described (2.3.5.1). The Taqman 
7500 Fast Real Time PCR System (Applied Biosystems) was used for detection. The 
programme of the Taqman 7500 was set as described in 2.3.8.3. Universal Fast PCR Master 
Mix (Applied Biosystems) was used for Taqman qPCR. Primers were designed by Primer3 
when not found from literature. 
Each sample was normalized to genomic hB2M gene level. Quantification was 
performed by calculating known hB2M levels from the plasmid pTOPO-hB2M by the 
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following term:  
Copies/g plasmid= (6.02 x 1023 copies/mol) / [plasmid size (bp) x (330 Da 
(g/mol)/nucleotide) x 2 nucleotide/bp] 
 
2.6.3.3. Determination of helper virus contamination and back-recombination of E1 
sequences 
The determination of the helper virus contamination in HC-AdV preparations was 
performed using two differently diluted (10–2 and 10–3) genomic DNA preparations isolated 
from virus infected cells. While the detection of E1 back-recombination was analyzed using 
purified adenoviral DNA in three different dilutions per assay: 10–1 to 10–3. For generation of a 
standard curve for qPCR, 102–108 genome copies of a purified wild-type adenovirus serotype 
5 with known plaque-forming units were used. Adenovirus DNA was isolated according to 
step 2.6.2. Universal Fast PCR Master Mix (Applied Biosystems) was used for Taqman 
qPCR. Oligonucleotides, probes and protocol parameters were chosen according to Puntel 
et al. 2006. In a total volume of 20 µl per reaction, 5 µl of the template DNA was added. 
Quantitative real-time PCR was carried out by the Taqman 7500 Fast Real Time PCR 
System (Applied Biosystems) amplifying a 67 bp area of the adenoviral late gene 3 (L3) and 
a 436 bp area of the adenoviral early gene 1 (E1), respectively.  For L3 quantification, the 
oligonucleotides L3 forward and L3 reverse together with an L3 specific probe were used. 
The PCR was run with the program described in 2.3.8.3. For E1 quantification, the same 
program was used but with its own relative primers and probe, as shown in table 2.2. 
 
2.7. Animal studies  
2.7.1. Mice studies 
All mice (C57Bl/6) were kept and treated according to the regulations of the 
Government of Upper Bavaria. 6- to 8-week old C57Bl/6 mice were used for all studies. 
 
2.7.1.1. Transduction of C57Bl/6 mice with viral vectors and plasmid vectors 
For viral vectors delivery, all mice were injected via the tail vein with a total volume of 
200 µl containing different transducing units of HC-AdVs diluted in Dulbecco´s phosphate 
buffered saline (DPBS, Gibco).  
For delivery of plasmids to murine liver, the hydrodynamic injection procedure was 
utilized. Herein, all mice were injected via the tail vein with 20-80 µg of plasmid DNA in a total 
volume of 2 ml PBS within 5 to 8 seconds (Bell et al., 2007). 
Rapid cell cycling of murine liver cells was induced by intraperitoneal administration of 
50 µl carbon tetrachloride (CCl4, Sigma) solution (1:1 dilution in mineral oil, Sigma). 
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2.7.1.2. Blood sample collection from mice 
For serum sample, blood was collected via periorbital puncture, using heparin coated 
glass capillaries (micro-haematocrit-tubes, Assistent). Serum was subsequently separated 
from blood cells by centrifuge for 15 min at 4°C and 9000 rpm. All serum samples were 
stored in -80ºC before use. 
For plasma collection, it‟s important not to damage the coagulation factors. For this 
purpose, the mice were first anesthetized with isofluran (Eickemeyer), and then pre-warmed 
for 5 min by a red light lamp. It is important that the head is covered with one or more tissues 
while pre-warming. The eye was stitch with a normal glass capillary without soaking in the 
blood, after discarding the first drop of blood the following blood drops were directly collected 
into a tube with 3.8% of sodium citrate solution at a ratio of 1:10. After the collection, the 
samples were mixed and put immediately on ice. Finally the plasma is separated by 
centrifugation for 15 min at 4°C and 9000 rpm. The plasma can be stored in -80ºC for 
months. 
 
2.7.2. Dog studies 
Inbred hemophilia B dogs were obtained from the University of North Carolina at 
Chapel Hill (Chapel Hill, NC). These hemophilia B dogs carry a missense mutation in the 
catalytic domain of the FIX-coding sequence resulting in undetectable FIX protein product 
and activity (Evans et al., 1989). Dog studies were performed under the guidelines of the 
University of North Carolina. For vector administration, dogs were sedated with Domitor 
(750 µg/m2 body surface area) and the vector dilution (~18.5 ml) followed by ~10 ml PBS for 
vector wash was infused by peripheral vein injection at 0.5 ml/minute into the right foreleg. 
During injection heart rate, blood pressure, and body temperature were monitored. Routine 
laboratory measurements before and after adenoviral vector administration were performed. 
 
2.7.2.1. Detection of neutralizing anti-adenoviral antibodies in canine serum 
The principle of this test is to analyze at which dilution the canine serum potentially 
containing anti-adenoviral antibodies is able to inhibit 50% of the transduction of a reporter 
virus into 293 cells.  
293 cells were cultured in Dulbecco modified Eagle medium (DMEM) supplemented 
with 10% FBS. One day before performing the assay, 293 cells were seeded into 96-well 
tissue culture plates containing 100 μl of medium. To destroy heat-sensitive complement 
components, both dog serum and all FBS used for cell culture were incubated at 56°C for 40 
minutes. Briefly, the serum samples were diluted in 2-fold steps in DMEM with 10% heat-
inactivated FBS in a total volume of 50 μl. Then 50 μl of the lacZ-expressing reporter virus 
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Figure 2.2: Schematic outline for the detection of neutralizing anti-adenoviral antibodies in 
treated dogs. The anti-adenoviral antibodies can recognize the LacZ expressing virus (Ad-
RSV/lacZ) and inhibit its infection and LacZ expression. Therefore, the inhibition rate is determined 
by which dilution the antibody contained in blood serum can inhibit the infectivity of the reporter virus 
by 50%. The neutralizing-antibody titer was defined as the reciprocal of this dilution. 
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Ad-RSV/lacZ were added to the diluted serum samples at a concentration of 1 x 109 plaque-
forming units/mL (diluted in DMEM with 10% heat-inactivated FBS). After an incubation of 1 
hour at 37°C, the serum-virus mixture was applied to 80% confluent monolayer of 293 cells. 
Cells were incubated for 24 hours, and then fixed with 0.5% glutaraldehyde for 5 minutes, 
washed with PBS, and stained in PBS containing 3 mM potassium ferricyanide, 3 mM 
potassium ferrocyanide, 2 mM MgCl2, and 1 mg/mL 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-gal). As a negative control untreated dog serum and PBS were used 
for the experiment, respectively. The neutralizing anti-adenovirus antibody titer was defined 
as the reciprocal of the highest dilution of serum at which the infectivity of the reporter virus 
was decreased by at least 50% (Figure 2.2). 
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3. Results 
3.1. Virus characterization and titration 
To evaluate the gene-transfer effect and safety profile of adenovirus/Sleeping Beauty 
(SB) transposase hybrid-vectors after systemic application, high-quality viral vector 
productions are needed and the viral vectors need to be titrated for their transducing ability. 
Moreover, some other unwanted side effects from the virus production, like helper virus 
contamination and back-recombination of the deleted viral genome region, should be 
carefully checked and excluded. 
 
3.1.1. Production of high-capacity adenoviral vectors (HC-AdVs) 
Three HC-AdVs were generated for the adenovirus/Sleeping Beauty (SB) transposase 
hybrid-vector system (Figure 3.1.a). The transposon-donor vector HC-AdV-TcFIX contains a 
transposon, which encodes a cassette for liver-specific expression of canine factor IX (cFIX). 
The transposon is flanked by SB specific inverted repeats (IRs) and Flp recognized FRT 
sites. The transposon-actor vector HC-AdV-HSB5 provides the components of the integration 
machinery, which include the cDNA for Flp recombinase and the hyperactive SB transposase 
mutant HSB5. HSB5 demonstrated 10-fold higher activity in cell culture in comparison to the 
wild type transposase (Yant et al., 2007). As a negative control for the integration machinery, 
the vector HC-AdV-mSB containing an inactive version of the Sleeping Beauty transposase 
(mSB) (Yant et al., 2004) was used. Several independent viral preparations of each HC-AdV 
were produced and amplified following a protocol for large-scale production of HC-AdV in 
spinner flasks and subsequent purification by cesium chloride (CsCl) ultracentrifugation 
(Figure 2.1) (Palmer and Ng, 2003; Jager et al., 2009). The viral vectors used for the dog 
study and in part viruses for mouse studies were prepared by Martin Hausl. 
 
3.1.2. Determination of infectious titers and total physical titers of high-capacity 
adenoviral vectors (HC-AdVs) 
All virus preparations were characterized with respect to total physical titers and 
infectious titers. It was found in previous studies that the ratios of physical titer compared to 
infectious titer (virus particle/transducing unit, VP/TU) vary for different HC-AdV preparations 
(Palmer and Ng, 2003; Crettaz et al., 2008). Therefore, it is important to carefully measure 
both parameters. 
Infectious titers of final vector preparations for animal studies were determined by 
quantitative real-time PCR (qPCR) with the primer pairs specific for the respective 
transgenes (HSB5/mSB and cFIX) described in Table 2.2 and Figure 3.1a with horizontal 
arrows. The genomic DNA isolated from virus infected 293 cells was used as templates. The 
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human B2M (Beta-2-microgloblin) gene was used as internal control (Vandesompele et al., 
2002). Herein, it was found that the infectious titers measured by qPCR were generally non-
equal to the physical titers quantified by OD260nm measurements for all three viruses (HC-
AdV-TcFIX, HC-AdV-HSB5 and HC-AdV-mSB) (Figure 3.1.b). Figure 3.1 b shows 
representative virus preparations that were used for murine studies. The VP/TU ratios were 
13.6 and 10.1 for the two cFIX viruses, 4.2 and 4.6 for the two HSB5 viruses; 18.9 and 47.8 
for the two mSB viruses. The second mSB virus with the VP/TU ratio 47.8 was excluded from 
further studies, because a high VP/TU ratio means low percentage of infectious HC-AdV 
virions. 
 
3.1.3. Determination of the helper virus (HV) contamination and exclusion of 
replication competent adenovirus (RCA) 
 In the HC-AdV production system, the Cre/loxP system is used to excise the 
packaging signal (Ψ) from the helper virus (HV) genome, resulting in unpackaging of the HV 
genome (Palmer and Ng, 2003). However, the excision efficiency of Cre/loxP is not 100%, 
thus the HVs are packaged to some extent. The physical separation of the HC-AdV from the 
HV by CsCl ultracentrifugation can significantly reduce the level of HV contamination but is 
still not 100% efficient. Therefore, it is important to figure out the level of HV contamination in 
each HC-AdV preparation. The level of helper virus contamination was determined by 
quantitative real-time PCR using the genomic DNA isolated from virus infected cells. The 
PCR specifically detected the helper virus genome by primers and probe binding to the late 
protein 3 (L3) of adenovirus serotype 5 (Figure 3.1.a). The helper virus (infectious units) 
contamination levels of purified HC-AdVs were lower than 0.03% compared to the infectious 
titers of HC-AdV. For example, the infectious units ratio of HV to HC-AdV were 0.013% and 
0.011% for the two cFIX viruses, 0.006% and 0.011% for the two HSB5 viruses and 0.021% 
and 0.0266% for the two mSB viruses (Figure 3.1.b). 
Homologous recombination between the genomes of the helper virus and producing 
cell line which expresses the complementary E1 sequence during vector amplification has 
been reported to yield replication competent adenovirus (RCA)(Sandig et al., 2000; Palmer 
and Ng, 2003). Therefore, it is important to rule out whether replication competent 
adenovirus is present in the HC-AdV preparations and the helper virus stocks (Puntel et al., 
2006). The E1 back-recombination was checked by quantitative real-time PCR using isolated 
virus genomic DNA from purified virus preparations. The PCR primers and probe specifically 
detected the E1 region (Figure 3.1.a). As expected, the E1 sequence was undetectable in all 
virus preparations, indicating that there were no replication competent adenovirus present in 
the purified HC-AdV particles and the helper virus stock (data not shown).
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Figure 3.1: Characterization of the viruses for in vivo application. (a) Schematic outline of the 
viral vector constructs and location of real-time PCR primers. HC-AdV-TcFIX represents the 
transposon-donor vector, expressing canine coagulation factor IX under control of the liver specific 
human alpha-1-antitrypsin promoter (hAAT) including two liver specific enhancers (HCR: hepatocyte 
control region; ApoE: Apolipoprotein E). It contains a transposon determined by inverted repeats 
(IRs) at the ends and is flanked by two FRT sites for Flp-mediated excision. The HC-AdV-HSB5 
contains a transgene expression cassette for the hyperactive Sleeping Beauty (SB) transposase 
(HSB5) under the control of the phospho-glycerate kinase promoter (PGK) and an expression-
cassette for the Flp recombinase driven by the elongation factor-1-alpha promoter (EF1α). The 
control vector HC-AdV-mSB contains the inactive version of SB (mSB). All HC-AdVs include 22 kb 
stuffer DNA derived from human/mouse chromosomal DNA to optimize packaging of viral vectors. (A 
detailed description for the principle of the adenovirus/transposase hybrid-vector system can be 
found in Figure 1.7 from introduction part). The helper virus (HV) AdNG163R-2 used for the HV-AdV 
production is an E1-deleted first generation adenoviral vector. Arrows inside the circles show the real-
time PCR primers binding sites. For the HC-AdV-TcFIX vector, one 150 bp PCR product was 
amplified; for vectors HC-AdV-HSB5 and HC-AdV-mSB, the same primer sets were used to amplify a 
141 bp PCR product, for HV, a primer pair and probe binding to L3 gene was used to amplify and 
detect a 67 bp PCR product, and for the detection of E1 back-recombination, primers and probe 
specific to E1 gene were used to amplify and detect a 436 bp PCR product. (b) Titer and purity of 
the final adenoviral vector preparations. The table summarizes the titration results and 
contamination levels with the helper virus used for vector production. Shown are six representative 
preparations of the HC-AdV which were used for hepatic infusion into C57Bl/6 mice. Physical titers 
were determined by OD260nm measurements. Molecular titration using qPCR was carried out to 
measure infectious titers and HV contamination by analyzing genomic DNA of virus infected 293 
cells. The level of helper-virus contamination was defined as the percentage of transducing helper-
virus particles contained in the total amount of transducing HC vector units. 
 
b
Virus HC-AdV-TcFIX HC-AdV-HSB5 HC-AdV-mSB
Prep 1 Prep 2 Prep 1 Prep 2 Prep 1 Prep 2
VP/µl 3.5x108 7.9x108 4.2x109 2.9x109 6.6x108 6.5x108
TU/µl 2.6x107 7.9x107 9.9x108 6.4x108 3.5x107 1.4x107
VP/TU 13.6 10.1 4.2 4.6 18.9 47.8
% HV 0.013 0.011 0.006 0.011 0.021 0.026
a
HV
PGK HSB5 EF1 FlpstufferHC-AdV-HSB5 
stuffer FRT IR hAAT IR FRTHC-AdV-TcFIX cFIX
PGK mSB EF1 FlpstufferHC-AdV-mSB
loxP  E1 L3loxP
Ψ
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After the titration and characterization, most of the HC-AdV preparations were found 
to contain high transducing unit numbers (107-108 TUs/µl), low helper virus contamination 
levels (<0.03%) and undetectable RCA. Otherwise the virus would be excluded from the 
further in vivo studies (e.g. the second mSB virus preparation, Prep2).  
 
3.2. In vivo application of the novel adenovirus/transposase hybrid-vectors  
3.2.1. Application of the hybrid-vector system in small animals 
After systemic administration of high-capacity adenoviral vectors (HC-AdVs), the 
severity of the acute toxicity is vector dose dependent (Brunetti-Pierri et al., 2004). This 
phenomenon represents the most essential obstacle currently hindering the usefulness of 
this otherwise promising gene therapy technology. Therefore, it is important to optimize the 
vector dose in a pre-clinical setting. Herein three different vector doses were chosen for 
C57Bl/6 mice: a low dose with 1.6x108 transducing units (TUs), a medium dose with 8x108 
TUs or a high dose with 4x109 TUs per mouse, respectively. The two vectors HC-AdV-TcFIX 
and HC-AdV-HSB5 were co-injected at a ratio of 3:1 (Figure 3.2.a). As negative controls for 
somatic integration, mice of the control group were treated with HC-AdV-mSB encoding an 
inactive version of SB or using HC-AdV-Luc as an irrelative vector control instead of HC-
AdV-HSB5 at medium and high vector doses (8x108 or 4x109 TUs per mouse) (Figure 3.2.a). 
In groups which received the highest dose (4x109 TUs per mouse), high levels of 
transgene expression were obtained (~10000 ng/ml cFIX measured by ELISA). However, 
this dose was accompanied by cases of death (9 mice died from 15) one week post vector 
administration. And the reasons for these fatalities remain to be elucidated. At the lowest 
dose, only low levels of serum cFIX were detected (~100 ng/ml). This was in sharp contrast 
to the medium-dose group, in which serum cFIX levels ~1000 ng/ml were measured until 4 
weeks post-vector infusion (Figure 3.2.b). 
 
3.2.1.1. Stable transgene expression after the hybrid-vectors administration into mice  
To test in which extent SB-mediated integration from the episomal adenoviral genome 
can facilitate the stability of transgene expression levels in vivo, mice with different vector 
infusions (Figure 3.2.a) were further treated intraperitoneally with carbon tetrachloride (CCl4). 
CCl4 is a liver-toxic substance and leads to death of affected hepatocytes by necrosis (Weber 
et al., 2003). Therefore, the total size of the liver and number of hepatocytes will be reduced. 
The amount of CCl4 injected (25µl) leads to loss of about 70% of the whole liver (Das et al., 
2007). To reconstruct a normal liver size, the hepatocytes need to divide. When the 
hepatocytes are actively dividing, only genes which integrate stably into chromosomal DNA  
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Figure 3.2: In vivo application of the AdV/SB hybrid-vector system in mice. (a) Vector 
administration. Female C57Bl/6 mice were co-injected with HC-AdV-TcFIX and HC-AdV-HSB5 at a 
ratio of 3:1 with three different vector doses (1.6x10
8
, 8x10
8
 or 4x10
9
 TU per mouse). Mice of the control 
groups were treated with HC-AdV-mSB (expressing inactive SB) or HC-AdV-Luc (as an irrelevant 
vector control) instead of HC-AdV-HSB5 with the vector doses (8x10
8
 or 4x10
9
 TU per mouse). (b) 
Dose-effect of the AdV/SB hybrid-vector in mouse. Dose-dependent transgene expression levels of 
the AdV/SB hybrid-vector were found in mouse (n=5 for medium and low dose; n=3 for high dose). 
Canine FIX expression levels were measured weekly by ELISA.  
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can be replicated under the control of the parental chromosome. Following each cell division, 
the integrated gene will be stably inherited to both daughter cells (Strachan et al., 1999). As 
a result, all hepatocytes that descend from a single cell in which stable integration took place 
will contain the integrated gene; thereby the transgene can continue its stable expression 
after CCl4 injection. In contrast, episomal genes which do not integrate can not segregate to 
all daughter cells during subsequent mitoses. As a result, the non-integrated transposon 
forms will be diluted and get lost quickly after CCl4 treatment and cell division, resulting in the 
decrease of transgene expression levels. 
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All experimental groups (HC-AdV-TcFIX co-injected with HC-AdV-HSB5 at three 
doses: 1.6x108, 8x108 or 4x109 TUs per mouse; HC-AdV-TcFIX co-injected with HC-AdV-
mSB or HC-AdV-Luc at two doses: 8x108 or 4x109 TUs per mouse) were monitored for 
transgene (cFIX) expression levels for more than three months. Canine FIX expression 
levels in blood circulation were measured by ELISA one day before CCl4 injection and at later 
time points every other week. Although the transgene expression levels were slightly 
decreased after the first CCl4 injection, mice which received the high dose (4x10
9 TUs per 
mouse) of the HC-AdV-TcFIX/HSB5 remained stable at physiological cFIX levels 
(3000~5000 ng/ml) during the whole time course of the experiment. This was in contrast to 
the control group which received the same dose of vectors but instead of HSB5 a vector 
expressing inactive SB (mSB). In this group the transgene expression levels were most likely 
derived from non-integrating vectors, and therefore the cFIX levels dropped quickly after 
induction of cell division by CCl4 treatment (Figure 3.3.a). However, probably due to the 
toxicity caused by the high vector dose, many infused mice died due to dose-dependent 
toxicity one week post-injection. Therefore, this high viral load (4x109 TUs per mouse, 
referring to 2x 1011 TUs per kilogram body weight) could be a limitation for in vivo application. 
In the medium vector dose group (8x108 TUs per mouse), the same stability of 
transgene expression as in the high vector dose group was observed after 
adenovirus/transposon hybrid-vectors infusion and CCl4 treatment. Although the cFIX levels 
decreased after the first CCl4 injection, stable levels of cFIX (300-800 ng/ml) were detected 
throughout the whole experiment. As a control group, mice received the same dose of the 
cFIX vector but instead an irrelative vector (HC-AdV-Luc) was co-delivered. As expected, in 
this group the serum cFIX expression levels decreased quickly after induction of cell cycling 
(Figure 3.3.b). 
Regarding the group which received the lowest dose of vector infusion (1.6x108 TUs 
per mouse), low serum cFIX levels (~100 ng/ml) were observed in the first few weeks, which 
dropped to undetectable levels after CCl4 administration (data not shown). 
To compare stability of transgene expression from episomal HC-AdV (TcFIX/luc), HC-
AdVs from which the transgene is excised (TcFIX/mSB), and HC-AdVs from which the 
transgene is excised and subsequently integrated into the host genome (TcFIX/HSB5), 
transgene expression levels before and after CCl4 administration were determined. The loss 
rates of transgene expression levels for all systems with and without induction of rapid cell 
cycling in murine liver were determined. The integrating HC-AdV system utilizing HSB5 for 
somatic integration was found to be superior in cycling cells compared to episomal HC-AdVs 
(Figure 3.3.c). Moreover, comparable levels of relative transgene expression were observed 
in the HC-AdV- TcFIX/mSB group and HC-AdV- TcFIX/Luc group after CCl4 treatment, 
indicating that the transgene expression is independent of excision of the transposon from 
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Figure 3.3: In vivo cFIX expression levels in actively dividing mouse hepatocytes. HC-AdV-TcFIX 
was co-delivered with either HC-AdV-HSB5 (HSB5), HC-AdV-mSB (mSB) or the irrelevant vector HC-
AdV-luc (Luc) at a ratio of 3:1. Persisting transgene expression levels were found in mouse which 
received TcFIX/HSB5 hybrid-vector, compared to mice that received inactive SB (TcFIX/mSB) or 
irrelevant vector (TcFIX/Luc). (n=5 for all group, except for high dose HSB5 n=3). Canine FIX 
expression levels were measured weekly by ELISA. Arrows indicate when animals received 
intraperitoneal injections of CCl4 to promote hepatic cell cycling. (a) Mice received high dose (4x10
9
 
TU per mouse) of vector infusion. (b) Mice received medium dose (8x10
8
 TU per mouse) of 
vector infusion. (c) Relative transgene expression levels. Mice were treated three times with CCl4 
and serum levels of cFIX before CCl4 treatment (white bar) were defined as 100% for each group. Black 
bar, post-CCl4 treatment; gray bar: no CCl4 treatment. Serum cFIX levels were determined one day 
before and 3 weeks after CCl4 treatment for all groups. 
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the adenoviral vector (Figure 3.3.c) (Hausl et al., 2010). These results are in concordance 
with historical data utilizing AdV/SB hybrid-vectors (Yant et al., 2002). In both studies stable 
transgene expression levels were obtained after CCl4 administration. 
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3.2.2. Application of the adenovirus/transposase hybrid-vectors in large animals 
Several biological differences exit between mouse and human, such as the body size, 
life span and immune responses (Figure 1.8). All these elements make it necessary to 
address the treatment effect in large animals before going to human clinical trials. For the 
present study using the novel adenovirus/transposase (HSB5) hybrid-vector system, after 
verifying its efficiency in mice, it is of importance to check whether transposition can also 
enable somatic integration and subsequent phenotypic correction in a preclinical animal 
model for hemophilia B.  
Therefore, three hemophilia B dogs carrying a missense mutation in the catalytic 
domain of the genomic cFIX coding sequence (Evans et al., 1989) were intravenously 
injected with the same vector system (Figure 3.1.a). All dogs (D1, D2 and D3) were co-
injected with the canine factor IX transposon donor vector and the transposase delivery 
vector at a 2:1 ratio. For the experimental setting, dog D1 received a total dose of 9.4x1011 
VPs/kg of the TcFIX/HSB5 system while dog D2 received a 2.6-fold increased dose (2.4x1012 
VPs/kg). As a control, dog D3 was injected with the inactive version of the transposase 
system (TcFIX/mSB) at a total dose of 1.2 x1012 VPs/kg, which was equivalent to the virus 
dose applied in dog D1 (Hausl et al., 2010).  
 
3.2.2.1. Phenotypic correction after administration of the hybrid-vectors in hemophilia 
B dogs 
For dog D1, which received the TcFIX/HSB5 hybrid-vector system, the whole blood 
clotting time (WBCT) was shortened to 18.5 minutes and stabilized for the total study length 
of 960 days (Figure. 3.4.a). This clearly demonstrated that phenotypic correction of the 
coagulation factor IX deficiency occurred and suggested that in contrast to the historical 
study utilizing a comparable dose of the cFIX encoding vector (Ehrhardt et al., 2003), 
stabilization of transgene expression occurred. In sharp contrast, systemic administration of 
the inactive transposase system (TcFIX/mSB) in dog D3 at a similar viral dose resulted in 
transient phenotypic correction (Figure. 3.4.b) (Hausl et al., 2010). Surprisingly, dog D2 
which was also treated with the TcFIX/HSB5 hybrid-vector system but with an increased 
dose showed only transient phenotypic correction (Figure. 3.4.b). This may indicate that 
toxic side effects associated with the incoming viral proteins or a robust immunological 
response against incoming viral particles or against one of the transgene products may have 
occurred. 
In order to monitor transgene expression, cFIX levels in canine plasma samples were 
monitored. Supraphysiological plasma cFIX levels of up to 40 000 ng/ml were detected for 
dog D1 on days 3-9 post-injection (Figure. 3.4.a). During 9-27 days post-injection, a rapid 
decline of canine factor IX (cFIX) plasma levels was observed. However, after 4 weeks, 
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Figure 3.4: Summary of the therapeutic effect of the adenovirus/transposase hybrid-vectors in a 
canine model for hemophilia B. The whole blood clotting time (WBCT) is an indicator for phenotypic 
correction in treated hemophilia B dogs. The WBCT for hemophilia B dogs is longer than 60 min. The 
grey shadow shows the WBCT range for normal dogs. The expression level of canine coagulation factor 
IX (cFIX) was measured by ELISA. Normal levels of healthy dogs are between 500 and 12000 ng/ml, 
but even a cFIX level of about 50 ng/ml is sufficient for effective coagulation (therapeutic level). (a) 
Therapeutic effect in a hemophilia B dog (D1) receiving low dose vector infusion (9.4 x 10
11
 viral 
particles per kilogram body weight [VPs/kg]). (b) The therapeutic effect in a hemophilia B dog 
(D2) receiving high dose vector infusion (2.4x10
12 
VPs/kg) and the control dog (D3) receiving 
inactive transposase system (TcFIX/mSB). ▲/∆, cFIX expression levels of the dog D2 and D3, 
respectively; ■/□, the WBCT of the dog D2 and D3, respectively. 
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plasma cFIX levels stabilized within a therapeutic range (60 ng/ml) for up to 295 days (latest 
time point analyzed by cFIX ELISA; this ELISA experiment was performed by Christina 
Rauschhuber). For dogs D2 and D3 high physiological cFIX plasma levels were observed 5-
10 days post-injection, which declined to undetectable levels 40 and 20 days post-injection 
for dogs D2 (Figure 3.4.b) and D3 (Figure 3.4.b), respectively (Hausl et al., 2010). 
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Figure 3.5: Neutralizing antibodies directed against adenoviral vectors in treated hemophilia B 
dogs. As an indicator for the adaptive immune response challenged by the HC-AdVs, neutralizing 
antibodies directed against the vector were measured. Therefore the highest dilution of canine serum 
was determined, which is able to inhibit 50% transduction efficiencies of a reporter virus in 293 cells. 
The neutralizing-antibody titer was defined as the reciprocal of this dilution. 
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3.2.2.2. Detection of neutralizing anti-adenoviral antibodies 
To further investigate the potential reasons for the transient phenotypic correction in 
dogs D2 and D3, as well as the rapid decrease of cFIX plasma levels in dog D1 during the 
first weeks post injection, I searched for anti-cFIX inhibitors and measured neutralizing anti-
adenoviral antibody levels. The Bethesda inhibitor assay was used to detect anti-cFIX 
inhibitors in dog plasma before and after injection, but no antibodies against the transgene-
encoded product were detected in either dog (data not shown). Thus, the decrease in cFIX 
transgene expression was not caused by a humoral immune response directed against the 
recombinant cFIX protein. 
For analysis of the humoral immune response directed against the adenoviral vector, 
dog serum at various time points was examined for the presence of anti-adenoviral 
neutralizing antibodies. For this purpose, a neutralization assay was used, measuring the 
inhibitory effect of anti-adenoviral antibodies contained in canine serum samples by infection 
of 293 cells with an adenoviral vector encoding a reporter gene (see also Figure 2.2). 
Neutralizing antibodies for dog D1 were monitored until the end of the experiment (960 days 
post injection) and for dogs D2 and D3 up to 80 days post injection (latest time points 
measured). Highest levels were measured 2–3 weeks post-treatment (Figure 3.5). Although 
the biological relevance of this finding is not clear at the time, injection of HC-AdVs at a 
similar dose resulted in comparable or even higher levels of neutralizing antibodies in a 
previous study (Ehrhardt et al., 2003), indicating that these neutralizing antibodies levels are 
normal for this injected vector dose. 
The efficient phenotypic corrections in these hemophilia B dogs (especially dog D1) 
hold promising potential of this novel AdV/SB hybrid-vectors for hemophilia B gene therapy. 
The hemophilia B dog study serves also as an example for translation from a small animal to 
a large animal model. 
Results 
 
56 
 
 
 
Figure 3.6: Overview of the transposition from plasmids in cultured mammalian cells. pTnori, 
the transposon donor plasmid; pCMV-HSB5, the helper plasmid encoding hyperactive transposase; 
pCMV-mSB, control vector encoding an inactive transposase. IR, inverted repeat; SV40, simian virus 
promoter; neo, neomycin-phosphotransferase gene; CMV, cytomegalovirus promoter. 
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3.3. Analyzing safety issues of the adenovirus/Sleeping Beauty transposase 
hybrid-vectors 
Safety is an essential issue to be considered for gene therapy when analyzing its 
efficacy in a pre-clinical or any clinical setting. Therefore, after in vivo application of the 
adenovirus/transposase hybrid-vectors genotoxicity related to insertional mutagenesis was 
analyzed in detail, as well as the acute liver toxicity. 
 
3.3.1. Integration site analyses 
After stable transgene expression was obtained from the AdV/SB hybrid-vector 
system for in vivo application in mice and dogs (Chapter 3.2), the next step was to confirm 
the existence of somatic integration by identification of integration sites. Moreover, the 
genotoxicity found in the other vector systems make it a requirement to characterize the 
genomic insertion pattern for each vector system being explored. Thus, it was of great 
importance to carefully analyze the integration sites after SB-mediated transposition from the 
adenoviral vector context. 
 
3.3.1.1. Establishment of a GenomeWalker-based method to determine integration 
sites 
The BD GenomeWalkerTM Kit from BD Biosciences was adopted to detect integration 
sites. In a previous study this strategy was used to analyze integration sites after PhiC31-
mediated integration from an adenoviral vector (Ehrhardt et al., 2007). In the current study, 
the BD GenomeWalkerTM Kit was adjusted to analyze the integration sites after Sleeping 
Beauty transposase-mediated integration. To establish the protocol, a tissue culture based 
study was first initiated (Figure 3.6), which detected SB-mediated integration sites in a 
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Figure 3.7: Schematic outline of the GenomeWalker-based method to determine integration 
sites. (a) DNA digest: highly purified genomic DNA was digested with four blunt-ended restriction 
enzyme nucleases: SspI, PvuII, StuI, EcoRV. (b) Linker ligation:  linker from BD GenomeWalker
TM
 kit 
was ligated to both ends of the genomic DNA fragments to create GenomeWalker libraries. (c) Two-
step PCR: a two-step PCR was performed with gene-specific primers (GSPs) binding to the transposon 
flanked sequence IR, and adaptor primers which specifically amplify from the 5‟ end of the adaptor-
ligated genomic fragments. (d) Subcloning and sequencing of PCR products (chromosomal DNA): 
the PCR products were subcloned into pCR-blunt II-TOPO vector, after restriction enzyme digestion 
screening, the genomic-transposon complex was sequenced and analyzed. 
a. Digest genomic DNA
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c. Two-step PCR
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DNA
Genomic
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Neor IR
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plasmid-based context. Herein the donor plasmid pTnori carrying a transposon for neomycin-
phosphotransferase gene expression was co-transfected with a second plasmid containing 
either hyperactive SB transposase (pCMV-HSB5) or a control vector with inactive SB 
(pCMV-mSB). The transfected Hela cells were then selected with G418 for two weeks to get 
pools of drug resistant cells (Figure 3.6). Subsequently, cell genomic DNA was isolated and 
integration sites were characterized (Figure 3.7).  
The GenomeWalker-based method for integration site analysis was established and 
evaluated at each single step (Figure 3.7 and 3.8). The construction of GenomeWalker DNA 
libraries should begin with clean, high-molecular weight genomic DNA which requires a high 
quality DNA preparation. To ensure that the genomic DNA is of adequate quality, the 
genomic DNA was visualized on a 0.6% agarose/EtBr gel (Figure 3.8.a). To avoid potential 
biases for detection of integration sites, 4 blunt-end digestions with different restriction 
enzymes were set up (Figure 3.7.a and 3.8.b). Importantly, these enzymes should not digest 
the sequence from the first PCR primer to the 3‟-end of the IR. After phase lock gel  
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Figure 3.8: Control Gels to check quality of the GenomeWalker procedure. (a) Quality of 
Genomic DNA:  the size of genomic DNA was checked by loading on a 0.6% agarose/EtBr gel, 
genomic DNA should be bigger than 50 kb with minimum smearing. M, 1kb DNA marker; Lanes 1-3, 
genomic DNA from three independent dishes for pools of transgene integrated Hela cells. (b) 
Completed digestion of genomic DNA: digestion was controlled by loading on a 0.6% 
agarose/EtBr gel, a smooth smear in each lane shows that the genomic DNA can be completely 
digested by the restriction enzymes (SspI, PvuII, StuI, EcoRV). (c) Results of primary PCR: 20µl 
and 5 μl of the primary PCR products were loaded on a 1.5% agarose/EtBr gel, in all lanes except for 
negative controls, a multiple banding or a smearing pattern could be observed, the size ranging are 
from about 500 bp to 5 kb. The red arrows indicate the bands. (d) Results of secondary PCR: 5 μl 
of the secondary PCR products were loaded on a 1.5% agarose/EtBr gel, products of secondary 
PCR ranged from 200 bp to 6 kb with some strong major bands. (e) Integration site library 
visualized on agarose gel. The size differences of these plasmids containing the sub-cloned PCR 
products indicate the different integration events. (f) Integration site library from restriction 
enzyme digest screening. As is shown, in the digest library, unique bands were identified to be 
DNA segments of different sizes visualized on agarose gel (Valid PCR products should be bigger 
than 0.2 kb). (g) Analysis of Sleeping Beauty mediated transposition events in the genome of 
Hela cells. The nested primer sequences are underlined, sequences at the end of the inverted-
repeat (IR) are in italic letters, the target sites property (TA) is in the central shaded box. The 
sequences analyzed in HSB5 transposed cells contained all these elements. * non-specific PCR 
product; # random integration; § back ground. 
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purification, the BD GenomeWalker™ adaptors were ligated to the blunt ends of the genomic 
DNA fragments to create GenomeWalker libraries (Figure 3.7.b). To facilitate the PCR-
walker reaction, two gene-specific primers, one for the primary PCR (GSP1) and one for the 
nested PCR (GSP2) were designed. These primers bind specifically to the left inverted 
repeat sequences of Sleeping Beauty transposon (see also in Table 2.2). The primary and 
nested PCRs were performed according to the two-step PCR program described in the 
method part (Figure 3.7.c). The efficiencies of PCR reactions were visualized on a 1.5% 
agarose/EtBr gel (Figure 3.8.c, 3.8.d), where a multiple banding or a smearing pattern could 
be observed. The PCR products were finally subcloned using the Zero Blunt™ TOPO™ PCR 
Cloning Kit (Invitrogen) (Figure 3.7.d) and pre-screened by EcoRI restricted enzyme 
digestion (Figure 3.8.e, 3.8.f). The EcoRI double digest can excise from the pTOPO vector, 
and only plasmids containing a unique insert bigger than 100bp were sequenced by T7 
and/or SP6 primers. 
 
3.3.1.2. Features of rescued Sleeping Beauty transposase-mediated integration events 
The first step to analyze the sequences contained in the Topo vector is to identify and 
remove vector- and linker-related sequences. The PCR products subcloned into the TOPO 
vector consist of three parts: the IR sequence from the nested primer GSP2, the genomic 
DNA sequence flanking the vector integration sites and the linker sequence from the other 
nested primer ASP2 (Figure 3.8.g, 3.9.a). Since the sequence primers bind to the TOPO 
vector, the integration site sequences include also part of the sequence from pTOPO vector 
(Figure 3.9.b).  
Integration events were considered authentic only if they (1) contained the sequence 
from the nested primer GSP2 (underlined) until the end of the inverted-repeat (IR) (bold) (5‟ 
GGCT AAGGT GTATG TAAAC TTCCG ACT TC AACTG 3‟), (2) matched a genomic 
location starting immediately after the end of IR (TCAACTG) and starting with a TA-
dinucleotide sequence, (3) showed >95% identity to the genomic sequence, and (4) matched 
no more than one genomic locus with the highest identity. Only the sequences having these 
features described were used for further analyses. Some examples of sequences rescued 
from HSB5 or mSB transduced Hela cells are shown in Figure 3.8.g. These sequences from 
HSB5 transduced cells contained all the required elements, therefore were identified as 
Sleeping Beauty transposase-mediated integrations. As a contrast, the sequences from mSB 
transduced cells are shown. They either lack the TA site or have an incomplete IR sequence 
or show no homology to the chromosomal DNA. These events are therefore not considered 
SB-mediated integrations. 
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Figure 3.9: Features of rescued sequences after SB-mediated integration. (a) DNA sequences 
in the rescued integration library contained in the pTOPO vector. SP6/T7: sequence primers 
binding to TOPO vector; IR, inverted repeat; TA, dinucleotide sequence, genomic target site. (b) 
The normal pattern of an integration site (IS) sequence. The genomic DNA sequences are 
flanked by the vector sequence, the IR and the Linker sequence. The IR sequence is a 34-bp 
fragment containing the sequence from the nested primer GSP2 to the end of the IR. The sequence 
immediately after the end of the 5' IR matches a genomic location and normally begins with a TA-
dinucleotide sequence. The linker, which demonstrates a 36-bp fragment containing the sequence 
from the nested primer ASP2 to the end of the linker, the genomic sequence connects to the linker 
shows part of a restriction enzyme (RE) site from the digestion step during the build-up of the 
integration library. 
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3.3.1.3. Integration site analysis in female C57Bl/6 mice 
After the GenomeWalker-based integration site analyzing method was established 
with plasmid-based transposition, the major focus was to characterize the transposition 
profile from the adenovirus/transposase hybrid-vectors in vivo. Therefore, the SB-mediated 
integration site analysis was performed in female C57Bl/6 mice. The group which received a 
high dose of the AdV/SB hybrid-vectors (4x109 TUs per mouse), high transgene expression 
levels were obtained (Chapter 3.2). After the second CCl4 administration, serum cFIX levels 
of around 4 500 ng/ml were detected in mice which received the HSB5 expressing virus, 
while the cFIX levels decreased to 750 ng/ml in the control group that received the mSB 
expressing virus. One mouse from each group, HSB5 mouse 1 (f1) with serum cFIX levels of 
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4800 ng/ml and mSB mouse 1 (mSB) with serum cFIX levels of 700 ng/ml were sacrificed 9 
weeks post-vector injection to isolate liver genomic DNA for integration site analysis (Figure 
3.10.a). After an additional CCl4 administration at week 13 post-vector injection, integration 
sites from a second mouse (female mouse 2, f2) of the HSB5 group with serum cFIX levels 
of about 3100 ng/ml was analyzed. Notably, at this time the control group which received the 
mSB expressing virus had serum cFIX levels that decreased to 150 ng/ml (Figure 3.10.a). In 
addition, one mouse (female mouse 3, f3) from the medium vector dose group (8x108 TUs 
per mouse) (Figure 3.3.b), with serum cFIX levels of 520 ng/ml was scarified at 14 weeks 
post-vector infusion for integration site analysis. Serum cFIX levels in the control group 
(TcFIX /Luc) of the same vector dose were around 70 ng/ml (Figure 3.10.a). 
Integration site analysis was then performed with the method described above 
(Figure 3.7). Briefly, adaptors for genome walker was ligated to digest genomic DNA isolated 
from respective mouse liver, PCR reaction was performed and PCR products were 
subcloned. Before each unique clone was sequenced, they were pre-screened by restriction 
enzyme digestion with EcoRI, which rescue the PCR products with a double digest from the 
Topo vector at the multiple cloning site. Thus the sizes of the DNA bands shown on the gel 
refer to the sizes of the cloned PCR products. As shown, in the library derived from the 
mouse (f1) that received the TcFIX/HSB5 viruses, more unique bands could be identified 
compared to the mSB group (valid PCR products range from 0.2 to 6 kb) (Figure 3.10.b). 92 
SB-mediated unique integration sites (ISs) were identified from female C57Bl/6 mice which 
received high dose and medium dose of the AdV/SB hybrid-vectors infusion (38 ISs from 
female mouse 1, f1; 35 ISs from female mouse 2, f2; 19 ISs from female mouse 3, f3). 
 In a previous study, insertional patterns and preferences of the SB transposon in 
mouse liver have been analyzed in plasmid-based approaches, which showed a random-like 
distribution among chromosomes (Yant et al., 2005). In order to obtain insight into the target 
site properties of AdV/SB hybrid-vector system in vivo in the present study, all 94 integration 
sites (92 unique ISs) were mapped in the murine chromosomes (Appendix Figure 2.a, 2.b 
and 2.c). Unlike the evenly chromosomal distribution of ISs after plasmid-based SB 
transposition, the SB-mediated integration from AdV/SB hybrid-vector system showed a bias 
towards the X-chromosome for all investigated mice (Figure 3.11). There were 18 (18/38) 
integration sites located in the X-chromosome in mouse f1, 13 (13/35) integration sites 
located in the X-chromosome in mouse f2 and 5 (5/19) integration sites located in the X-
chromosome in mouse f3 (Figure 3.11). Although a large amount of integration sites remains 
to be analyzed to draw clear conclusions with respect to the genome-wide integration profile, 
the high percentage of X-chromosome integrations was different compared to the plasmid 
based studies.  
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Figure 3.10: SB-mediated integration sites in female C57Bl/6 mice. (a) Serum cFIX levels of 
the mice used for integration site analysis. From the high vector dose group (Figure 3.3a), at 9 
weeks post vector infusion, one mouse from HSB5 group (HSB5-mouse1) with serum cFIX level of 
4800 ng/ml was sacrificed, liver genomic DNA was used for setting up the first integration site library 
(female mouse 1, f1). At the same time point, the serum cFIX levels of the control group (mSB 
group) were around 750 ng/ml, one mouse with serum cFIX level of 700 ng/ml was then used as 
control. At a second time point, 13 weeks post vector infusion another mouse from HSB5 group 
(HSB5-mouse2) with serum cFIX level of 3100 ng/ml was sacrificed for the second integration site 
library (female mouse 2, f2), while the serum cFIX levels of the control group (mSB group) was 
around 150 ng/ml. From the medium vector dose group (Figure 3.3b), at 14 weeks post vector 
infusion, one mouse from HSB5 group with serum cFIX level of 520 ng/ml was sacrificed for the third 
integration site library (female mouse 3, f3), while the serum cFIX levels of the control group (Luc 
group) was around 70 ng/ml. (b) Integration site library after restriction enzyme digestion. As is 
shown, in the HSB5 library, more unique bands were identified compared to the mSB group (Valid 
PCR products should be bigger than 0.2 kb). 
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Figure 3.11: Genome-wide distributions of SB-mediated integration events in female C57Bl/6 
mice. Integration sites analyzed from three HSB5 co-delivered mice. Mouse 1 was sacrificed 9 
weeks post-vector infusion, while mouse 2 and 3 was 13 and 14 weeks post-vector infusion (Figure 
3.10a). The distribution of SB-mediated integration events was compared to that of a computer-
simulated random integration profile (Yant et al., 2005). The Y axis shows the percentage of 
integration events from each individual chromosome. 
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3.3.1.4. Integration site analysis in male C57Bl/6 mice 
Due to the distinct bias of integration events towards the X-chromosome found in 
female mice after AdV/SB hybrid-vectors administration (Figure 3.11), it is of great interest to 
check the chromosomal distribution pattern also in male mice containing only one X-
chromosome. Therefore, male mice were infused with the same vector system (HC-AdV-
TcFIX co-injected with HC-AdV-HSB5 at the ratio of 3:1) at both high dose (4x109 TUs per 
mouse) and medium dose (8x108 TUs per mouse). Mice which received the medium vector 
dose showed stable transgene expression, although the serum cFIX level decreased after 
the first CCl4 administration, stable transgene expression levels were observed after the 
second and third CCl4 administration (Figure 3.12). However, as for the high dose group in 
previous experiments all mice died probably due to dose-dependent toxicity. To build up an 
integration site library, two mice with serum cFIX levels of ~460 and ~850 ng/ml from the 
medium vector dose group were sacrificed at 14 weeks post-vector infusion.  
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Figure 3.12: Stability of cFIX expression in male mice which received the AdV/SB hybrid-
vector. Male C57Bl/6 mice were co-injected with HC-AdV-TcFIX and HC-AdV-HSB5 at a ratio of 3:1 
with two different vector doses (8x10
8
 or 4x10
9
 transducing units (TU) per mouse). For the high dose 
group (4x10
9 
TU/mouse, n=5) all mice died within 2-3 weeks post vector infusion. The transgene 
expression levels in the medium vector dose group (8x10
8
 TU/mouse, n=5) are shown. Red vertical 
arrows indicate carbon tetrachloride (CCl4) injection. 
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Of the 44 unique transposon insertions found in male mice, three X-chromosomal 
integrations were identified from male mouse 1 (m1) and two were from male mouse 2 (m2). 
This preference is almost similar to random integration. Notably, although there was a Y 
chromosome present in these male mice, no integration site was located there (Appendix 
Figure 2.d, 2.e). With a total of 44 integration sites, it is not surprising that some 
chromosomes may be hit more than once, while some may not be hit at all (e.g., 
chromosomes 9, 18 and 19 were not hit) (Appendix Figure 2.d, 2.e).  
 
3.3.1.5. Summary of the chromosomal distribution profile on X-chromosome  
To show the relative position of all integration sites on a chromosomal level, all 136 
integration sites from 5 mice were mapped on the respective mouse chromosomes 
(Appendix Figure 2.a, 2.b, 2.c, 2.d and 2.e).  
In order to look inside the chromosomal distribution profile on the X-chromosome in 
more detail, all 41 independent integration sites from all 5 mice on the X-chromosome are 
schematically shown in different colors in Figure 3.13. The X-chromosome band XA1.1 was 
found to be the most preferred location with 6 integration sites in total, followed by band XE3 
with 4 events. No integration site was observed on bands A7.2, A7.3, B, C3, E2, and F5. The 
average distribution profile was found to be not related to the location of the mouse FIX gene 
(Band XA6), although the canine FIX cDNA is highly homologous to it, which may lead to 
homologous recombination.  
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Figure 3.13: SB transposition site mapping of the X-chromosome. The relative positions of 42 
independent integration sites from all 5 mice for SB-mediated transposition from the adenoviral 
vectors (AdV/SB hybrid-vector system) are shown. The colored squares next to the chromosome 
figure indicate the number of integration sites that located in the corresponding chromosomal bands. 
The blue arrows indicate single integration events; the gray arrow indicates the location of the 
murine coagulation factor IX (mFIX) gene. No integration site located in bands A7.2, A7.3, B, C3, 
E2, and F5. 
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3.3.1.6. Frequencies of transposon insertions within or outside genes 
The mutagenic potential of any given integrating vector system is one of the most 
essential considerations for gene therapy applications. Normally, the integrations in genes 
display a higher risk to cause genotoxicity than those which hit an intergenic region. Thus, 
the relation of transposon insertions to transcriptional units was analyzed, aiming to 
determine the mutagenic potential associated with AdV/SB hybrid-vectors mediated 
integrations isolated from the three female mice and the two male mice. 31 of all the 136 
transposon integrations in mice liver (23%) were mapped within at least 1 of the 18,090 
mouse RefSep genes (Figure 3.14.a). When compared to the computer-simulated random 
integrations (26%) (Yant et al., 2005), these data revealed a similar or lightly less preference 
for SB-mediated integration into mouse genes. Notably, this frequency is much lower when 
compared to murine leukemia virus (MLV, retroviral vectors) with 50.7% and human 
immunodeficiency virus derived vectors (lentiviral vectors) with 83.4% (Wu et al., 2003; 
Schroder et al., 2002). Among the 31 total integrations that occurred in genes, which were 
distributed evenly amongst the transcript units, 27 mapped within intron sequences, only 4 
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Figure 3.14: Frequencies of insertions within or outside of genes. (a) Percentage of integration 
sites. f1: female mouse 1; f2: female mouse 2; f3: female mouse 3; m1: male mouse 1; m2: male 
mouse 2; total: all integration sites from five mice; random: computer predicted data. (b) Proximity of 
integration sites to genes.  
 
a
b
f1           f2            f3           m1          m2        total      random
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
 intragenic
exons
introns
intergenic
0
2
4
6
8
10
12
14
16
18
P
e
rc
e
n
ta
g
e
(%
) 
o
f
in
te
g
ra
ti
o
n
si
te
s
p
e
r 
k
b
up stream integration sites down stream
-50         -10            -5            -1           +1            +5          +10          +50     distance (kb)
2
8
19
46
P
e
rc
e
n
ta
g
e
(%
) 
o
f
in
te
g
ra
ti
o
n
si
te
s
p
e
r 
k
b
were on exons (Figure 3.14.a). The bias towards introns is probably due to the larger overall 
size of introns when compared to exon sequences. 
As to the 105 integration sites in intergenic sequences, 8 (7.6%) were found near 
genes (±5kb), while >70% were located 50kb far away from genes (Figure 3.14.b). This is in 
sharp contrast to AAV vectors, for which over 38.3% of integrations were found near genes 
(Nakai et al., 2005). 
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Table 3.1: Transposon insertions in or near cancer related genes. 
mouse chromosomal 
location 
Band gene symbol & name   cancer type 
 chr5: 92880283  5 E2 SCARB2: scavenger receptor class B, 
member 2 
  gastric (GC) 
f1 chrx: 49859131 XA5 GPC3: glypican 3    hepatocellular (HCC) 
 chrx: 13341506 XA1.1 CASK: calcium/calmodulin-dependent 
serine protein kinase 
  hepatocellular (HCC) 
 chr2: 154999131 2H1 ITCH: itchy, E3 ubiquitin protein ligase   hepatocellular (HCC) 
f2 chrx: 138774886 XF2 ACSL4: acyl-CoA synthetase long-chain 
family member 4  
   breast (BC) 
 chr19: 43843935  19C3  1.1kb up to CUTC: cutC copper 
transporter homolog 
   gastric (GC) 
 chr1: 37535572 1B MGAT4A: mannoside 
acetylglucosaminyltransferase 4, 
isoenzyme A  
   thyroid (TC) 
m1 chr11: 21917357 11A3.1 EHBP1: EH domain binding protein 1     gastric (GC) 
 chrx: 20425116 XA1.3 1.99kb down after ARAF: v-raf murine 
sarcoma 3611 viral oncogene homolog  
   colorectal (CC) 
m2 chr5: 36106310 5B3 ABLIM2: actin-binding LIM protein 2      gastric (GC) 
 
3.3.1.7. Transposon insertions in or near cancer related genes 
To evaluate the risk of neoplastic changes that could be potentially induced by the 
integrating vector system, those genes which were hit by integration events or near (±5kb) 
the integration sites were checked in Cancer Gene Expression Databases (CGED, 
http://lifesciencedb.jp/cged/) (Kato et al., 2005)  
Although no neoplastic change was observed macroscopically in all treated animals, 
10 cancer related genes were found to be affected by transpositions from the AdV/SB hybrid-
vectors (Table 3.1). Three cancer related genes were identified in the treated female mouse 
1 (SCARB2, GPC3 and CASK). SCARB2 locates in chromosome 5 and relates to gastric 
cancer, while both GPC3 and CASK locate in chromosome X and relate to hepatocellular 
cancer. Of the integration events in female mouse 2, two located in the cancer related genes 
ITCH (relate to hepatocellular cancer) and ACSL4 (breast cancer), one located near to the 
CUTC gene (gastric cancer). No cancer related gene was found in the transposition events 
of female mouse 3. 
In the male mouse 1, two integrations were identified in the cancer related genes 
MGAT4A (thyroid cancer) and EHBP1 (gastric cancer) and one was near the ARAF gene 
(colorectal cancer). Moreover, one integration site was found to locate to the ABLIM2 gene 
(gastric cancer) in male mouse 2. 
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Figure 3.15: Transposition into extra-chromosomal target sequences. The upper panel 
schematically shows the vector constructs of the transposition-actor vectors HC-AdV-HSB5/mSB 
and the transposon-donor vector HC-AdV-TcFIX. A detailed description of these vectors can be 
found in Figure 3.1. The lower panel shows a detailed map of the stuffer DNA and the transgene. 
The stuffer DNA consists of two parts: IgkMAR (the matrix attachment region of the murine 
immunoglobulin κ locus) and alphoid repeat DNA (alphoid repeat DNA sequences from human 
chromosome 17).  The core transgene represented by the canine coagulation factor IX cDNA (cFIX) 
and contained a portion of the first intron from the human FIX gene. The red triangles show the 
relative positions of the extra-chromosomal integrations identified in mouse liver genomic DNA. 
 
IgMAR Alphoid repeat DNA
stuffer FRT IR hAAT cFIX IR FRTHC-AdV-TcFIX
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3.3.1.8. Transposition into extra-chromosomal target sequences 
In addition to the 136 incidences of genomic integration, 27 transposon integration 
events (with 12 unique sites) were found to localize within the HC-AdV genome used in this 
study. These insertion sites were evaluated in more detail and it turned out, that they were 
located in the stuffer DNA contained in the HC-AdV genome (IgkMAR and alphoid repeat 
DNA) and the transgene. Multiple insertions were observed at two of these sites. Four were 
located at one site of the IgkMAR sequence (location: mouse chromosome 6, 70675584) and 
8 were within human FIX gene intron 1 (location: human chromosome x, 138612987), which 
was added to the transgene region in the expression cassette and located before the cFIX 
cDNA sequence. Extra-chromosomal targets for SB transposes were also described in a 
plasmid-based study (Yant et al. 2005), in which the promoter region and the polyadenylation 
signal region were found to be a “hot spot” including 85% of all extra-chromosomal 
transposition events. The present study, however, showed no bias towards promoter or 
signal regions (Figure 3.15).  
 
 
3.3.1.9. Summary of all integration events  
For all the five SB transposed mice (f1, f2, f3, m1 and m2), 60~80 clones from each 
library were analyzed, of which ~40 clones were shown to contain unique PCR products 
visualized by unique DNA bands (Figure 3.16). Briefly, amongst these sequence results, the 
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Figure 3.16: Number of different transposition events in all five mice. mSB: female mouse 
which received inactive transposase (TcFIX/mSB); f1: female mouse 1; f2: female mouse 2; f3: 
female mouse 3; m1: male mouse 1; m2: male mouse 2; f1, f2, f3, m1 and m2 received the 
hyperactive transposase HSB5 (TcFIX/HSB5). Clones identified referred to the number of clones 
that were screened by restriction enzyme (EcoRI) digestion. Transposon integrations are the 
confirmed integration events mediated by Sleeping Beauty transposase. Non-specific PCR products 
are those sequences, which did not contain an intact IR or TA. Extra-chromosomal target events 
were those transposition events which mapped to the vector genome used for delivery (Figure 3.15). 
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majority of sequences obtained from the two female mice (f1 and f2), which received a high 
dose of vector infusion (4x109 TUs per mouse), were identified to be real transposon 
integrations. This was in contrast to the other three treated mice (f3, m1 and m2) that 
received a medium dose vector infusion (8x108 TUs per mouse), in which more than half of 
the clones sequenced were not real transposition events. Extra-chromosomal transposition 
events and non-specific PCR products were obtained from all treated groups, especially in 
the mouse receiving mSB encoding virus, in which no real transposition event was observed. 
Interestingly, I observed that those mice in which most of the transposon insertion 
sites could be identified, relatively high transgene expression levels were detected. For 
female mouse 1 and 2, which had high levels of serum cFIX (4800 and 3100 ng/ml) (Figure 
3.10.a), 40 of 47 and 35 of 50 clones sequenced turned out to be real transposition events. 
In contrast, in the other three mice (female mouse 3, male mouse 1 and 2) which had relative 
low transgene expression levels (less than 1000 ng/ml) (Figure 3.10, 3.12), the real 
transposition events also take low percentage of all clones that were sequenced (Figure 
3.16). 
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3.3.1.10. Detection of transposition events from treated canine liver genomic 
DNA  
To demonstrate that the cFIX transposon underwent transposition in canine liver and 
to analyze the fate of transduced vector DNA, detailed molecular analysis of liver-derived 
canine genomic DNA was performed with dog D1. The GenomeWalker-based integration site 
analyzing method was used to determine integration sites (Figure 3.7). Briefly, an adaptor 
for the GenomeWalker method was ligated to pre-digested genomic DNA, PCR reaction was 
performed and PCR products were subcloned. From more than 100 clones analyzed, 40 
were identified to contain unique bands after performing a restriction enzyme digest screen. 
Analyzing of the sequences rescued, 4 unique transposon insertions were identified 
(Appendix Table), although one integration site in the synaptophysin gene was found more 
than once. Similar to the observation in mice (Figure 3.15), five transposon insertions were 
found in extra-chromosomal target sequences. Two were in the vector stuffer DNA 
containing alphoid repeat DNA sequence, one was in the FRT sequence, and other two were 
in the cFIX cDNA.  
 All the other sequences were catalogued to be non-specific PCR products due to 
their lack of an intact IR. Since the dog-specific genomic DNA sequences database is not as 
complete as human and mouse at the moment, the number of insertion sites may be not 
representative. However, these transposon insertions identified evidenced the fact that the 
novel adenovirus/transposase hybrid-vectors can also facilitate somatic integration in large 
animals. 
 
3.3.2. Genome status of the hybrid-vectors in different animals 
To further understand the transposon mechanism related to this novel 
adenovirus/transposase hybrid-vector system, the genome copy numbers of each vector 
from liver genomic DNA of all animals (mice f1-f3, m1, m2 and mSB virus treated mice, and 
dog D1) was checked by real-time PCR.  
For analyses of cFIX and SB encoding sequences analyses, the same primer pairs as 
for vector titration (Figure 3.1.a) were used. To normalize the different samples, the same 
amount of genomic DNA was analyzed by real-time PCR using a house keeping gene as an 
internal control. For mouse samples, mouse TBP gene (TATA box binding protein) was used 
and for dog samples the dog B2M gene (Beta-2-microgloblin) was determined. 
In contrast to the results obtained from a semi-quantification PCR (Hausl et al., 2010), 
the SB transposase gene was detectable by real-time PCR in all animals (Figure 3.17) 
ranging from 0.004 to 0.106 copies per cell. However, in all AdV/SB transposase hybrid-
vectors treated animals except for the mouse which received the inactive version of 
transposase (mSB), the cFIX gene copy numbers per cell were one log higher than the 
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Figure 3.17: Vector genome copy numbers in liver after in vivo application. The upper figure 
shows the vector genome copy numbers and serum cFIX levels of each treated subject. Liver 
genomic DNA was analysed by real-time PCR using primers detecting cDNAs of the two main 
functional genes cFIX and SB, and the house keeping genes (TBP for mouse, B2M for dog) were 
used as internal control. The lower figure indicates the dose of each vector infused. mSB: female 
mouse receiving inactive transposase (TcFIX/mSB); f1: female mouse 1; f2: female mouse 2; f3: 
female mouse 3; m1: male mouse 1; m2: male mouse 2; f1, f2, f3, m1 and m2 received hyperactive 
transposase HSB5 (TcFIX/HSB5) (Figure 3.10 and 3.12). Dog indicates dog D1 which received a 
low dose (9.4x10
11
 vps/kg, equals to 4.7x10
10 
TU/kg) vector infusion. 
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measured SB gene copies. Moreover, in the two female mice f1 and f2, which received a 
high dose vector infusion (4x109 transducing units (TUs) per mouse, equals to 2x1011 
TUs/kg), high genome copy numbers (0.811 and 0.581 copies/cell for transposon-encoding 
sequence, 0.106 and 0.080 copies/cell for transposase-encoding sequence), as well as high 
cFIX expression levels (4500 and 3100 ng/ml at the last time point measured) could be 
measured. In contrast, in mice which received a medium vector dose (f3, m1 and m2, 8x108 
TUs per mouse, equals to 4x1010 TUs/kg) low genome copy numbers and transgene 
expression levels were detected (Figure 3.17). Regarding dog D1, which received a similar 
vector dose as the medium vector dose used in mice, revealed comparable genome copy 
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numbers, but the transgene expression levels measured by ELISA were 10-times lower than 
that in mice. This is probably due to the difference of the biological properties between these 
two species. Thus, the physiological cFIX levels can not be directly compared. Although the 
exact genome status (e.g. percentage of episomal/circular/integrative molecules) of each 
vector is not clear at the time, the relative higher levels of cFIX cDNA compared to SB cDNA 
can be another indirect evidence for somatic integration, as the original vector infusion in 
mice was with a ratio of 3 to 1 between the two vectors HC-AdV-cFIX and HC-AdV-SB and 2 
to 1 between the two vectors in treated dogs.  
 
3.3.3. Acute liver toxicity  
It has been shown that similar to early generation adenoviral vector, systemic 
administration of HC-AdV also resulted in activation of an acute inflammatory response 
indicated by the dramatic and prolonged increases in transaminases (Muruve et al., 1999; 
Schnell et al., 2001; Brunetti-Pierri et al., 2005; Brunetti-Pierri et al., 2004). Therefore, in the 
present study, several markers for activation of the acute inflammatory response were 
measured at various time points post injection.  
Limited toxicity studies were performed by monitoring alanine aminotransferase (ALT) 
levels in mouse serum samples of treated mice to detect acute toxicity associated with 
administration of HC-AdVs. For all study groups, ALT levels were measured one day before 
injection and one day post-injection. ALT levels in these mice were slightly elevated 
compared to the levels before injection, especially for mice which received the high dose 
virus infusion (Figure 3.18.a), but remained in the normal range for all treated mice (20–80 
U/l). To conduct a long term survey for liver toxicity, ALT levels in one group were measured 
for one week post-vector injection and the levels decreased to similar levels as before vector 
injection (Figure 3.18.b).  
To monitor indirectly hepatocytes‟ damage, and to measure liver toxicity caused by 
CCl4 administration, ALT levels before and after CCl4 injection were measured. Serum 
transaminase levels dramatically increased to up to 600 U/l at day 1 after CCl4 
administration but declined to a normal range one week later (Figure 3.18.b). 
To investigate whether vector related toxicity occurred in the hybrid-vectors treated 
dogs, several laboratory measurements were performed. Aspartate aminotransferase (AST, 
normal range, 12–118 U/l) and ALT (normal range, 15–66 U/l) levels in plasma of dogs D1, 
D2, and D3 were monitored, which are used as the markers for acute liver toxicity. It was 
found that ALT and AST levels were elevated in dog D2, whereas transaminase levels for 
dogs D1 and D3 remained in a normal range (Figure 3.19.a-b). Quantification of alkaline 
phosphatase levels (ALP) revealed that this parameter was increased in dog D2, whereas 
levels stayed in a normal range for dogs D1 and D3 (Figure 3.19.c). Notably, elevated ALP 
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Figure 3.18: Alanine transaminase (ALT) levels. (a) ALT levels in serum samples of mice from 
different experiment groups. Samples were measured 1 day before- and 1 day post-virus injection 
(n=5). (b) ALT levels in long term observation. Serum samples were measured 1 day before-, 1 day 
post- and 7days post-virus injection and the time points around CCl4 administration (n=5). The grey 
shadow shows the normal ALT range for mice (20–80 U/l). (U/I)=units per liter.  
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levels have been shown to be associated with certain medical conditions, like drug 
intoxication and tissue damage.  In concordance with these results, the most significant drop 
of platelets was observed in dog D2 (Figure 3.19.d). Furthermore, all other monitored 
parameters like hematocrit, hemoglobin and total protein in blood remained in a normal 
range for dogs D1 and D3 (data not shown). 
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Figure 3.19: Acute toxicity profiles of treated hemophilia B dogs. Plasma samples of dogs D1 
(HSB5 / low dose), D2 (HSB5 / high dose) and D3 (mSB) were collected at indicated time points and 
analyzed for markers related with acute liver toxicity. (a) Alanine aminotransferase levels (ALT; 
normal range: 12 – 118 U/L) were measured as well as (b) aspartate aminotransferase levels (AST; 
normal range: 15 – 66 U/L) and (c) alkaline phosphatase levels (normal range: 5 – 131 U/L). In 
addition (d) the number of platelets (normal range: 200,000 – 500,000 / mm
3
) was quantified for all 
three dogs. HSB5, hyperactive Sleeping Beauty transposase; mSB, inactive transposase. 
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3.4. Exploration of the potential of a hyperactive human coagulation factor IX 
variant (hy-hFIX) in gene therapy application 
Gene therapy has shown great potential for hemophilia treatment in preclinical and 
clinical studies. However, the spontaneously potent innate inflammatory and immune 
responses caused by the high vector dose that is necessary for an efficient therapeutic 
effect, remain an obstacle for successful treatment in patients (Manno et al., 2006). The 
discovery and application of coagulation factors with enhanced activity hold a promise to 
overcome this limitation, because it would permit administration of lower vector doses and 
the therapeutic index could be increased (Dooriss et al., 2009; Pipe, 2010).  
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Based on the structural homologies of human coagulation factor IX and factor X 
genes, Brandstetter group generated several hyperactive FIX variants. These recombinant 
FIX (rhFIX) proteins expressed in E. coli revealed 103-fold increased amidolytic activity in in 
vitro FIX substrate binding assays (Hopfner et al., 1997; Sichler et al., 2003). However, these 
rhFIX variants used were truncated because they only encoded the second epidermal growth 
factor domain, the activation peptide, and the catalytic domain of human FIX. Therefore, I 
wanted to generate a full-length hFIX cDNA for one hyperactive variant (K265T/Y345T) to 
evaluate its therapeutic potential (Figure 1.5). 
 
3.4.1. Investigation of the hyperactive coagulation variant in a plasmid-based 
context 
3.4.1.1. Subcloning of a full-length hyperactive coagulation factor encoding sequence  
A full length hFIX was generated using an over-lapping PCR strategy with the 
primer pairs (hFIX-forw, hFIX-OL1, hFIX-OL2 and hFIX-rev) described in Table 2.2. Two 
plasmids, pET22b which contained the original truncated hFIX variant (K265T/Y345T) 
(Hopfner et al., 1997) and a pAAV-EF1a-FIX plasmid containing the wild-type hFIX (Nakai et 
al., 2001) were used for the over-lapping PCR amplification. The 1.4kb full-length hFIX cDNA 
of hyperactive variant (hy-hFIX) and wild-type (wt-hFIX) were then extracted from an agarose 
gel and subcloned into the pTOPO vector. These pTOPO plasmids containing wt- or hy-hFIX 
were checked by DNA-sequencing and restriction enzyme analysis. 
 
3.4.1.2. Examination of transcription and expression in tissue culture 
To initially determine the transcription and expression of the newly-generated hFIX 
variants, the full length hy-hFIX and the wt-hFIX encoding sequences were cloned into the 
pZAC vector carrying a CMV promoter resulting in pZAC-CMV-(wt/hy)-hFIX. These plasmids 
together with the pAAV-EF1a-FIX plasmid which served as a positive control were 
transfected into a human hepatoma cell line (Huh7) using FuGENE 6 transfection reagent. 
The transfected cells were incubated for 48 hours prior to measuring mRNA transcription and 
protein expression. Herein, the supernatant was collected to analyze hFIX expression by 
ELISA, and the cell pellets were treated with TRIZOL reagent for RNA isolation and reverse 
transcription PCR (RT-PCR). As shown in Figure 3.20.a, transcription of the hFIX transgene 
was detectable from both wt- and hy-hFIX containing pZAC plasmids as well as the positive 
control plasmid pAAV-EF1a-FIX using the primer pair hFIX-forw and hFIX-OL1. For protein 
detection as measured by ELISA, 60-80 ng/ml hFIX level in cell culture supernatant was 
detected (Figure 3.20.b).  
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Figure 3.20: Transcription and expression of hFIX in tissue culture. (a) Reverse transcription 
PCR to check transcription of hFIX. Primer pairs hFIX-forw and hFIX-OL1 were used to amplify a 500 
bp DNA fragment. The red arrow indicates the correct PCR products (~500 bp). (b) ELISA to check 
transgene expression. wt-hFIX: supernatant from the cells transfected with the plasmid pZAC-CMV-
wt-hFIX; hy-hFIX: supernatant from the cells transfected with the plasmid pZAC-CMV-hy-hFIX; PC: 
positive control, supernatant from the cells transfected with the pAAV-EF1a-FIX plasmid; NTC: negative 
control, supernatant from the cells transfected with empty pZAC plasmid; blank: supernatant from the 
cells without transfection. 
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3.4.2. Evaluation of the hyperactive coagulation FIX variant in the context of an 
adenovirus 
After the transcription and expression of the hyperactive hFIX variant was 
confirmed, it is important to measure its functional activity. Furthermore, the transgene 
expression levels in tissue culture from the plasmids were too low for detection using the 
actived partial thromboplastin time assay (APPT) (data not shown). As the adenoviral vector 
is more efficient in cellular transduction and most likely results in higher transgene 
expression levels compared to non-viral vectors, I produced high-capacity adenoviral vectors 
containing the wt-hFIX or hy-hFIX encoding sequences. 
 
3.4.2.1. Generation of high-capacity adenoviral vectors (HC-AdVs) containing the 
human coagulation factor variants 
The pAdFTC vectors containing the hFIX expression cassettes were generated 
according to a standard protocol (Jaeger et al. 2009). Briefly, the 1.4kb wt-hFIX and hy-hFIX 
segments were first sub-cloned into the vector pCI-hAAT-2xMAR, which contains the liver-
specific promoter and enhancer region (ApoE HCR hAAT; 1.3 kb), and stuffer DNA 
fragments (2 x ChMAR: matrix attachment region from chicken lysozyme gene, 2.8 kb of 
each). Subsequently the complete expression cassette and the ChMAR stuffer DNA 
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Figure 3.21: Plasmid constructs to study in vivo efficacy of a hyperactive hFIX expressing 
virus. Plasmids pAdFTC-hAAT-wtFIX and pAdFTC-hAAT-hyFIX were used for production of the 
respective viruses HC-AdV-wt-hFIX and HC-AdV-hy-hFIX. The plasmids carry an ampicillin 
resistance gene (AmpR). 5′- and 3′-ITR: human adenovirus serotype 5 inverted terminal repeats; Ψ: 
packaging signal; IgkMAR: the matrix attachment region of the murine immunoglobulin κ locus; 
HCR: alphoid repeat DNA sequences from human chromosome 17 and a liver-specific enhancer 
(hepatic control region); ChMAR: matrix attachment region from chicken lysozyme gene; hAAT-
wtFIX and hAAT-hyFIX: human alpha-1-antitrypsin-promoter, wtFIX and hyFIX as transgenes, wtFIX 
is the wild type human coagulation factor IX gene, while hyFIX contains two point mutations 
(K265T/Y345T); polyA: SV40 late polyadenylation signal. 
 
ITR Ψ IgkMAR alphoid repeat DNA HCR MCS ITR5‘ 3‘
AmpR
ChMAR hAAT-hyFIX ChMAR
ChMAR hAAT-wtFIX ChMARpolyA
polyA
fragments (9.7 kb) together were cut out from the pCI vector and cloned by the restriction 
enzymes PI-Scel and I-CeuI into the pHM5 shuttle plasmid. The same restriction enzymes 
were then used to clone the hFIX constructs into the adenovirus production plasmid pAdFTC, 
resulting in pAdFTC-hAAT-wtFIX and pAdFTC-hAAT-hyFIX (Figure 3.21). 
The two HC-AdV-hFIX viruses were produced and amplified following a protocol for 
large-scale production of HC-AdV in spinner flasks and subsequent purification by cesium 
chloride (CsCl) ultracentrifugation (Figure 2.1)(Palmer & Ng 2003; Jager et al. 2009). Both 
virus preparations were characterized with respect to total physical titers and infectious titers. 
The physical titers were quantified by OD260nm measurements, while infectious titers were 
determined by quantitative real-time PCR (qPCR) with the primer pairs specific for the hFIX 
cDNA (Table 2.2). For the PCR reaction, the genomic DNA isolated from virus infected 293 
cells was used as template and the human B2M (Beta-2-microgloblin) gene was used as 
internal control.  
 
3.4.2.2. Examination of transgene expression levels in tissue culture 
Transgene expression from the adenoviral vectors HC-AdV-wt-hFIX and HC-AdV-
hy-hFIX was examined in tissue culture. Herein, Huh7 cells were infected with MOIs 10, 100 
and 1000, supernatant was collected 48 hours post-infection and measured for transgene 
expression by ELISA. Unfortunately, hFIX expression (5-24 ng/ml) was only observed after 
infection with HC-AdV-hy-hFIX at all three MOIs. From the HC-AdV-wt-hFIX infected cells, 
transgene expression was undetectable (data not shown). 
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Figure 3.22: Tansgene expression levels and functional activities in one hemophilia B mouse. 
One FIX knock out mouse was transduced with HC-AdV-hy-hFIX encoding mutated hFIX at vector 
doses of 2x10
9
 transducing units (TUs). Plasma samples were collected in 0.1 volume of 3.8% 
sodium citrate at weeks 1, 2, 4 and 6 post-injection. The table shows the plasma hFIX levels at each 
time point, while the figure shows the percentage of FIX antigen (Ag) and activity (C) compared to 
normal human plasma (%). 
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3.4.2.3. Examination of transgene expression and functional activity in hemophilia B 
mice 
Due to the undetectable transgene expression of the HC-AdV containing wt-hFIX, 
only the HC-AdV-hy-hFIX vector was further examined for functional activity. Briefly, FIX 
knock-out mice were transduced at three different vector doses (2x107, 2x108 and 2x109 
transducing units (TUs) per mouse) via tail vein injection. Plasma samples were collected at 
weeks 1, 2, 4 and 6 post-injection for factor IX (FIX) antigen (Ag) and coagulation FIX activity 
(C) determination. FIX antigen was quantified by ELISA while the coagulation activity was 
measured by the actived partial thromboplastin time assay (APPT). Only from the mouse 
which received a vector dose of 2x109 TUs, FIX antigen and activity were detectable (700-
1600 ng/ml and 2.6-8.3%, respectively) (Figure 3.22). Although it shows dose-dependency 
between the hFIX antigen and hFIX activity, the hyperactivity of this hFIX variant 
(K265T/Y345T) still can not be determined from these primary data. This part of the 
experiment related to hemophilia B mice was conducted by our cooperation partner Kazuo 
Ohashi (Institute of Advanced Biomedical Engineering and Science, Tokyo Women‟s Medical 
University, Tokyo, Japan). 
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4. Discussion 
Novel developments in medicine played a crucial role in history, because therapeutic 
advances and successful applications of modern medicine resulted in reduced mortality, 
cured diseases, improved quality of life, and prolonged life span. For instance, emerging 
chemical substances as drugs, such as antibiotics have inhibited many life threatening 
bacterial infections. Later on, with the deeper understanding of many human diseases, other 
molecular forms, such as proteins and peptides were developed as a modern medical 
concept. For instance, the application of insulin for diabetic patients started a new chapter in 
human medicine. Similarly, diseases like hemophilia, a lifelong bleeding disorder which was 
well known as a European royal disease, could be treated by protein replacement therapies 
because plasma concentrates of coagulation factors became available in the 1970s. 
However, soon afterward, the contamination of infectious viruses as hepatitis B and C in the 
concentrates manufactured from pooled plasma obtained from thousands of donors raised 
the risk of this infusion therapy. To be free from blood-transmitted pathogens and to increase 
the worldwide capacity of replacement therapy, the production of recombinant coagulation 
factors was tested and began to be used in the 1990s (Schwartz et al., 1990; Lusher et al., 
1993; White et al., 1997; Roth et al., 2001a). Nevertheless, inhibitors, high costs of the 
products, repeated infusions due to the short half life of the coagulation factors, and the 
limited availability are still factors which raise concerns about this treatment option. 
Therefore, the use of somatic gene therapy for hemophilia attracted researchers‟ attention 
and turned out to be a promising alternative to protein replacement therapy since the early 
1990s (Mannucci and Tuddenham, 2001; Nichols et al., 2009). 
So far, the existing pre-clinical and clinical hemophilia gene therapy trials revealed the 
contradiction in terms of efficiency and safety. For instance, in a recent liver directed 
hemophilia B gene therapy trial utilizing adeno-associated virus serotype 2 (AAV2), the 
therapeutic effects were only observed in patients which received a high vector dose 
infusion, but the successful transduction turned out to be transient, probably due to an 
immune response directed against protein structures of the gene transfer vehicle (Manno et 
al., 2006; Herzog, 2010). In concordance with these studies also in some other pre-clinical 
studies, the application of adenoviral vectors for hemophilia B treatment showed vector dose-
dependent therapeutic effects (Brunetti-Pierri et al., 2005; Brunetti-Pierri et al., 2004; 
Ehrhardt and Kay, 2002; McCormack et al., 2006). 
For viral vectors, there is usually a narrow therapeutic window in which optimal 
effectiveness can be achieved. On the one hand, a high dose vector infusion can lead to an 
improved result, as more recombinant protein is formed. However, this is also associated 
with a higher risk of vector-related toxicity. In addition, a high dose can lead to transduction 
of undesired cells or organs, which could lead to serious safety concerns. On the other hand, 
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side effects after injection of a low vector dose are most likely negligible, but the effects may 
not be therapeutic, because not enough cells were transduced and thus sub-therapeutic 
amounts of the protein are formed (Tao et al., 2001; Morral et al., 2002; Brunetti-Pierri and 
Ng, 2011). Therefore, it is essential to develop other strategies, which enable therapeutic 
effects inside this therapeutic window. 
The effectiveness of the gene-transfer vector is determined by the vector itself as well 
as the transgene to be delivered. In the present study, both determination factors to optimize 
the therapeutic effect have been explored in gene therapeutic studies for hemophilia B.  
 
4.1. Therapeutic effects of the novel adenovirus/transposase hybrid-vectors  
The aim of gene therapy for hemophilia is to deliver the functional transgene (cDNA 
of coagulation factor) into the target tissue of patients for achieving stable and therapeutic 
effects. In the present study, the novel adenovirus/transposase hybrid-vectors showed 
effective therapeutic effects in both small animal (mouse) and large animal (dog) models. 
The adenovirus/transposase hybrid-vector system was initially evaluated in C57Bl/6 
mice in a dose-dependent study. It was found that the serum transgene expression levels 
behaved in a non-linear vector dose-dependent manner (Figure 3.2). When quantifying the 
genome copy numbers of each vector in the treated animals by quantitative real-time PCR, it 
was shown that the genome copies of each vector directly correlated with the infused vector 
doses and transgene expression levels (Figure 3.17). These expression profiles bear 
similarities to the results obtained in previous studies, in which increasing doses of 
adenoviral vectors resulted in a nonlinear increase in transgene expression (Ehrhardt and 
Kay, 2002; Morral et al., 2002; Morral et al., 1998; Tao et al., 2001). 
It is also important to point out that there was toxicity accompanied with the high 
vector dose infusion. In particular, severe toxicity caused the death of mice from the 
transposase group (TcFIX/HSB5) and the control group (TcFIX/Luc) in the high vector dose 
setting (4x109 TUs per mouse). The reasons for this are unclear for the moment. It could be 
speculated that one potential reason may be the helper virus contamination. An important 
feature of these high-capacity adenoviral vectors is the need of helper virus in the vector 
preparation (Jager et al., 2009; Palmer and Ng, 2003). Although Cre recombinase-mediated 
excision of the packaging signal from the helper virus genome is highly efficient, a small 
number of helper virus genomes with retained packaging signals are still packaged into 
capsids, and the helper viruses are not 100% separated from the high-capacity adenoviral 
vector preparations (Palmer and Ng, 2003; Parks et al., 1996; Umana et al., 2001). The HC-
AdVs preparations used in this study, however, only contained a level of <0.03% helper virus 
contamination in the final vector preparations (Figure 3.1). The helper virus (HV, 
AdNG163R-2) used in our high-capacity adenoviral vectors production is a first generation 
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adenoviral vector (FGAdV), which was generated by deletion of the early adenoviral genes 
E1 and E3 (Jager et al., 2009; Palmer and Ng, 2003). Therefore, the high dose mice 
received helper virus at 1.2x106 TUs per mouse (equals to 6x 108 TUs/kg). Such low doses of 
FGAdV are expected to cause no toxicity in mice and large animals (Morral et al., 2002; 
Nunes et al., 1999). Therefore, we believe it is unlikely that the toxicity observed in this study 
was attributable to the contaminating helper virus. Besides helper virus contamination, 
existence of replication-competent adenovirus (RCA) was also excluded from these virus 
preparations.  
Notably, no abnormality was observed in mice which received the high dose in the 
first few days post-injection including the liver alanine aminotransferase (ALT) levels. The 
ALT levels in these mice were slightly elevated compared to the levels before injection 
(Figure 3.18a), but remained in the normal range for all treated mice (20–80 IU/l). Notably, 
the lethal toxicity of the high vector dose infusion caused the death of nine mice on day 5-9 
post-injection, and three mice even died 2 weeks post-injection. This time period was 
probably after transgene expression or activation of an adaptive immune response. C57Bl/6 
mice at 6-8 weeks of age were used for this study, which were in a good health status at the 
experiment time period. We do not know whether these mice had pre-existing anti-human 
Ad5 antibodies or whether any foreign gene products (SB, Flp, cFIX and Luciferase) caused 
toxicity. This needs to be further analyzed. In contrast to the toxicity observed in this study, 
numerous previous studies have shown that systemic administration of HC-AdVs led to 
dose-dependent acute toxicity (Hartman et al., 2008). Those toxicities were observed shortly 
after vector injection (<48hrs) consisting of activation of the innate inflammatory immune 
responses (Brunetti-Pierri et al., 2004; Schiedner et al., 2003; Zang et al., 2001; Croyle et al., 
2005). The single clinical trial of intravascular administration of HC-AdV into a human patient 
with a dose of 4.3 x 1011 VPs/kg resulted in very low FVIII levels (approximately 1%), and 
was also accompanied with transient inflammatory response with hematologic and liver 
abnormalities (Chuah et al., 2004).  
Furthermore, the dose chosen in my study, even the high dose (4x109 TUs per 
mouse, equals to 2x1011 TUs/kg), is comparable to or even lower than those used in the 
other studies. For instance, 5.6x1012 VPs/kg of the gutless adenovirus HC-AdV-LacZ was a 
safe dose in baboons, and 7.5 × 1012 VPs/kg of the apoE expressing HC-AdV or 3x1011 
particles per mouse of a VLDLR expressing HC-AdV were safe doses in mice (Brunetti-Pierri 
et al., 2005; Oka et al., 2001; Kim et al., 2001). However, the methods used to titrate the 
high-capacity adenoviral vectors vary in different laboratories (Kreppel et al., 2002; Puntel et 
al., 2006). In fact, most studies determined the viral titer expressed in viral particles (VPs) 
and not transducing units (TUs), making the issue more complicated. VPs present the titer in 
the number of viral genomes, while TUs indicate the number of active viruses and their 
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transducing ability (Crettaz et al., 2008). Nevertheless, it is clear from this study that a dose 
of ≥2x1011 TUs/kg of the HC-AdV/SB hybrid-vectors is above the maximum tolerable dose in 
mice. 
On the other hand, as shown in the preclinical model in this study, one hemophilia B 
dog injected with a relatively low vector dose of 9.4 x 1011 VPs/kg (equals to about 4.7x 1010 
TUs/kg) showed long-term phenotypic correction of the clotting disorder (3 years) and 
persistent expression of cFIX (Figure 3.4.a). It is of note, that the adenovirus/transposase 
hybrid-vectors mediated gene transfer in hemophilia B dogs was not as efficient as that in 
mice with respect to cFIX protein expression levels (Figure 3.3). However, long-term (three 
years) phenotypic correction was observed in dog D1, demonstrating an efficient therapeutic 
effect in a large animal model. Moreover, the HC-AdV/SB hybrid-vector system has proved to 
be superior to the episomal adenoviral vectors, in terms of long-term transgene expression. 
For instance, in our historical study systemic administration of a HC-AdV-TcFIX at a nontoxic 
dose (8.6 × 1011 VPs/kg) into hemophilia B dogs only achieved transient phenotypic 
correction (therapeutic levels of cFIX for about 2 months) (Ehrhardt et al., 2003). While 
another study with HC-AdV showed sustained cFIX expression for over a year at a high dose 
(3 × 1012 VPs/kg), but transient mild liver enzyme elevations and a decrease in platelet 
counts were observed (Brunetti-Pierri et al., 2005). In summary, these results demonstrated 
the advanced features of the adenovirus/transposase hybrid-vector system, which facilitates 
the long-term therapeutic effect by stably inserting the transgene expression cassette into the 
host chromosomes. 
The study performed in large animal models is particularly important because large 
animals like dogs and non-human primates have more biological similarities to human 
patients than mice. This includes inherit diversity, immune response, life span, body weight 
and vector delivery route. Dogs have long been used as a preclinical model for hemophilia 
gene therapy utilizing different viral vector systems. For instance, retroviral and lentiviral 
vectors were explored for hemophilia gene therapy in canine models. Although correction of 
the phenotype and expression of coagulation factors were observed (Kay et al., 1993; Xu et 
al., 2003), further development has been damped by concerns about the risk of insertional 
mutagenesis (Hacein-Bey-Abina et al., 2003). As one of the best studied vectors, adeno-
associated viral vector (AAV) has also shown its promising potential in hemophilia therapy. 
Protocols to use AAV for hemophilia gene therapy were established in several laboratories 
(Snyder et al., 1997; McCown et al., 1996). These approaches were based on two main 
strategies utilizing muscle and liver as target tissues. In case of muscle targeting, infusion of 
an AAV2 throughout the muscle resulted in long-term (> 3 years) FIX expression (circulating 
levels of 4%-14%) in a canine model for hemophilia B, achieving complete correction of the 
bleeding disorder (Arruda et al., 2005). These results were similar to the therapeutic effect 
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observed in the dog D1 of my study. Recently, an 8-year study in inhibitor prone null 
mutation hemophilia B dogs treated with liver directed AAV2-FIX demonstrated long-term 
correction of the hemophilic phenotype with stable FIX activity remained between 4% and 
10% (Niemeyer et al., 2009). However, unlike that in my study, the stable transgene 
expression in these dogs was most likely due to the extra-chromosomal form of AAV, which 
was proved by the AAV integration sites analysis utilizing linear amplification–mediated 
polymerase chain reaction (LAM-PCR) (Niemeyer et al., 2009). Notably, both muscle and 
liver directed AAV deliver strategies have been applied in clinical trials. Briefly, the muscle 
directed hemophilia clinical trial did not reveal detectable coagulation expression, while the 
liver directed gene transfer resulted in transgene expression, but the  therapeutic effect was 
transient (Kay et al., 2000; Manno et al., 2006). 
Development of a new medical agent follows the transition steps first from tissue 
culture to a small animal model, then to large animal or preclinical models, subsequently 
clinical trials and finally into clinical application (Figure 1.8). These transitions are always 
difficult as they force our knowledge from the predictably known into the uncertain. As to 
gene therapy, the successful translation rates from each step turned out to be even lower 
than the traditional medicine (Lowenstein and Castro, 2009). A variety of vectors, which 
demonstrated significant effects in cell culture can not be applied in vivo and a number of 
vectors and approaches that showed promising gene transfer efficiencies in small animals, 
failed to translate the results to large animals as dogs and non-human primates. Given the 
relatively small numbers of hemophilia clinical trials, it is not unexpected that the success 
rate from preclinical model to human beings is marginal. For example, in the case of AAV-
mediated FIX gene transfer to liver, there were completely different outcomes in humans 
(Manno et al., 2006) compared to experimental animals such as mice, rats, hemophilic dogs 
and nonhuman primates. All of these animals treated showed long-term expression of the 
transgene after AAV-mediated gene transfer (Mount et al., 2002; Snyder et al., 1999; 
Niemeyer et al., 2009; Nathwani et al., 2002). Notably, in that clinical trial, detailed analyses 
of the humoral and cellular immune responses found that the AAV capsid, rather than wild-
type FIX was the antigen that was targeted by the host immune response (Manno et al., 
2006). Unlike experimental animals, humans are naturally infected by AAV2 during 
childhood. Therefore, the prior exposure to the virus capsid probably results in the difference 
in the immune responses.  
As speculated already in other studies performed in canines, this study emphasize 
that only a small therapeutic window for HC-AdV may exist. As shown, application of a 
twofold higher viral dose (2.4 × 1012 VPs/kg body weight) resulted in transient albeit complete 
correction of the hereditary genetic disease in dog D2 (Figure 3.4.b). Moreover, increasing 
the viral dose resulted in transient liver toxicity (Figure 3.19) and may present one potential 
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reason for the strong decrease of plasma cFIX levels observed in dog D2. This dose 
threshold effect, for which a linear increase in viral vector dose does not correlate with 
protein expression, was also shown in several other studies in mice (Bristol et al., 2000) and 
non-human primates (Brunetti-Pierri et al., 2005; Brunetti-Pierri et al., 2004). However, the 
minimal dose in mice for achieving long-term transgene expression seems to be lower 
compared to canines. This underscores the species-dependent differences after systemic 
administration of adenoviral vectors and that direct extrapolation across species may not be 
possible. 
In summary, the adenoviral/SB hybrid-vector system was shown to be a promising 
tool for long-term gene-transfer in small animals and in a large animal model. Notably, it was 
the first trial to apply the SB system in a larger animal model. For stable transduction and 
treatment of tissues with a high-cell turn-over rate, our system represents a valuable tool for 
treatment. For instance, treatment of diseases affecting the skin or ex vivo correction of 
hematopoietic stem cells may be feasible utilizing our vector system. 
 
4.2. Integration profile of the novel adenovirus/transposase hybrid-vectors 
Like all medications, viral vectors carry risks, including potential harmful inflammatory 
reactions, germline transmission and insertional mutagenesis. Relevant preclinical tests for 
assessment of these and other potential adverse outcomes play an important role and will 
help us to better understand the potential risks of the respective gene therapy vector.  
Regarding integrating vectors, on the one hand, these vectors can insert the 
transgene expression cassette into the host genomic DNA, thereby facilitating long-term 
stable transgene expression especially in rapidly dividing cells and regenerating tissues. On 
the other hand, any insertion of a foreign DNA fragment into the chromosome could result in 
genotoxicity. From preclinical tests and clinical trials, we learned that the potential risks of the 
integrating vectors depend on their integration profiles (Baum, 2007; Kustikova et al., 2010). 
For instance, gamma retroviruses and derived vectors, which preferentially target regulatory 
sequences, were also shown to be associated with insertional mutagenesis. Transducing 
hematopoietic stem/progenitor cells with gamma retroviral vectors had released most of the 
treated patients (17/20, 75%) from severe immunodeficiency. However, these gamma 
retroviral vectors, which were designed to express the therapeutic transgene interleukin 2 
receptor-γ (IL2RG) caused the case of leukemia in five of the treated patients (Antoine et al., 
2003; Cavazzana-Calvo and Fischer, 2004; Hacein-Bey-Abina et al., 2010). 
To analyze the integration events in the present study, I used a simple method 
(GenomeWalker-based method), which was adopted from a commercially available kit. This 
method was first used for integration site analysis after PhiC31-mediated integration from an 
adenovirus (Ehrhardt et al., 2007). Briefly, this strategy involved a linker ligation-mediated 
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PCR and can be applied for samples isolated from different sources such as cells and 
tissues. Since it does not require any special equipment, it is applicable for every laboratory, 
especially when there is only a relatively small amount of integration events to be analyzed. 
By this method, the transposition events and integration profile after systemic administration 
of the adenovirus/transposase hybrid-vectors in vivo were carefully evaluated. Herein, I 
found that the transposase-mediated integration events from the adenovirus demonstrated a 
near random integration profile among gene and non-gene regions (Figure 3.14). However, 
the chromosomal distribution of these integration events was uneven and was shown to be 
bias towards the X-chromosome in female mice (Figure 3.11). 
 
4.2.1. Sleeping Beauty transposase mediated integration events distributed 
randomly at genomic level 
SB transposase-mediated integration profile has been extensively studied in previous 
studies. In one plasmid-based study, 1336 SB insertions were identified in primary and 
cultured mammalian cells (Yant et al., 2005). As also shown in my study, the SB integrations 
were found to be widely distributed. Although target site preferences showed a small bias 
towards genes and their upstream regulatory sequences, it was much less pronounced and 
was not significantly influenced by transcriptional activity compared to those of most 
integrating viruses, like retroviral and lentiviral vectors (Hematti et al., 2004; Mitchell et al., 
2004), and AAV (Nakai et al., 2005; Nakai et al., 2003). The same random distribution profile 
of SB with respect to genes and intergenic regions was confirmed by another group (Liu et 
al., 2005). Therefore, regarding the integration profile there seems to be no difference in 
plasmid transfection and viral transduction approaches. However, SB has been clearly 
shown to be less effective in terms of cell entry compared to viral vector delivery systems. 
Therefore, it has been proposed that combining the cell entry properties of viruses and the 
integration machinery of SB could be a potential useful toolkit to generate novel vectors for 
sustained transgene expression (Yant et al., 2002; Vink et al., 2009; Peterson et al., 2007; 
Heinz et al., 2011). 
Towards this, several studies have been performed in the past. Adenovirus, herpes 
simplex virus (HSV), retrovirus and lentivirus have been designed as a platform for gene 
insertion by SB transposase. In the HSV/SB hybrid-vector system, only few SB-mediated 
integration sites were identified (Peterson et al., 2007; de Silva et al., 2010). The SB-
mediated integration profile from integrase defective lentivirus (IDLVs) has been analyzed in 
detail, and revealed a profile mimicking SB-plasmid integration. Briefly, in contrast to 70-80% 
frequency of integrase-proficient lentiviral vectors (ILVs)  integration to active transcription 
units, the integration profile of SB transposition from IDLVs ranged from 30-50% within 
RefSeq genes (Vink et al., 2009; Staunstrup et al., 2009; Moldt et al., 2011).  
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In contrast to the lentiviral delivery system, which has an integrative nature, the 
genomes of the adenoviral vectors have been shown to integrate into host chromosomes at 
low frequencies (Harui et al., 1999; Hillgenberg et al., 2001; Stephen et al., 2008). It can be 
speculated that the SB transposon plays the major role in the target-site selection in the 
AdV/SB system. Therefore, in the present study, it is not surprising that the integration profile 
of SB transposition from HC-AdV is still the same or quite similar to that of the plasmid-based 
approaches (Figure 3.14).  
In addition to these chromosomal integration events, 27 extra-chromosomal 
integrations were characterized, which were found to be located in the HC-AdV genome, 
mainly the stuffer DNA sequence and the transgene region (Figure 3.15). In the 30kb HC-
AdV genome, approximately several thousand potential TA sites are present, and only 12 of 
them were hit by transposon integrations. Notably, these sites were located within two hot 
spots: 4 were in the IgkMAR sequence of the stuffer DNA and 8 were within the intron 1 
which was included in the cFIX transgene. In previous studies based on the 
adenovirus/transposase and adenovirus/integrase hybrid-vector systems, integration events 
identified from HC-AdV administrated mice liver also showed transposon jumping into the Ad 
vector itself (Ehrhardt et al., 2007; Yant et al., 2002). 
Extra-chromosomal integrations have also been described earlier in SB-mediated 
integration from plasmids (Yant et al., 2005). Herein, 41 extra-chromosomal integrations 
were identified from mouse liver and human cell lines after SB transposition in the plasmid 
context. These events were located in two small regions of the target plasmid. One 
corresponded to the promoters while the other was the polyadenylation signal region (Yant et 
al., 2005). In other integrating vector systems like retroviral and lentiviral vectors, or the 
combining of self-inactivating retroviral vector (SIN-RVs) and integrase-defective lentiviral 
vectors (IDLVs) with SB, although >1000 of integrations have been identified, extra-
chromosomal integrations have not been reported (Beard et al., 2007; Hematti et al., 2004; 
Wu et al., 2003; Deichmann et al., 2007; Gabriel et al., 2009; Paruzynski et al., 2010).  
Nevertheless, findings in this study from AdV systems emphasize that the integration not 
only takes place in the host chromosomes but it can also occur between the vectors, even at 
high frequencies. For instance, a likelihood of 20% for the adenovirus/transposase hybrid-
vectors was observed in the present study. How and when these integrations happened in 
the AdV/SB system is at the moment unknown. However, it can be speculated that these 
extra-chromosomal integrations will probably influence the therapeutic efficacy of these 
vectors by decreasing the effective chromosomal integration. 
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4.2.2. Sleeping Beauty transposase mediated integration events distributed 
unevenly at chromosomal level 
One major feature identified for the AdV/SB hybrid-vectors is that the chromosomal 
distribution of integrations was biased towards the X-chromosome in female mice. In total 
three female mice were analyzed, two with high vector dose infusion (f1 and f2, 4x109 TUs 
per mouse) and one with medium dose (f3, 8x108 TUs per mouse). High percentages of 
integrations were found to be located in the X-chromosome in these mice (47% for f1, 37% 
for f2 and 26% for f3) (Figure 3.11). Interestingly, when I tried to analyze the integration 
profile in male mice, which received a medium vector dose (m1 and m2, 8x108 TUs per 
mouse), no clear chromosomal preferences were observed (Appendix Figure 2.d, 2.e). 
Whether the integration pattern differs because of the fact that female mice contain two X-
chromosomes while male mice only contain one, is not clear, at the time.  
The data of the present study is not in line with results obtained by Yant and 
colleagues. In that study it was found that plasmid-based SB insertions were distributed 
evenly at the chromosomal level, and the X-chromosome even seemed to be somewhat 
disfavored (Yant et al., 2005). Some other studies analyzed the integration profile of SB 
transposition from integrase defective lentiviral vectors (IDLVs) and self-inactivating retroviral 
vectors (SIN-RVs). These analyses in human cell lines did not demonstrate any 
chromosomal preferences at a higher resolution of more than 1000 events (Moldt et al., 
2011; Staunstrup et al., 2009; Vink et al., 2009). However, these vector systems were not 
checked with respect for the integration profile in vivo. Therefore, it could be speculated that 
the differences in integration profiles may be due to the experimental settings. It may be 
possible that SB-mediated integration combined with adenoviral transduction of hepatocytes 
and coexpression of Flp recombinase in the target cell might have caused a difference in the 
integration mechanism compared to non-viral or in vitro approaches. In contrast, in another 
study using an adeno/AAV hybrid-vector system, three (12 in total) X-chromosomal 
integration events were identified by ligation-mediated PCR (LM-PCR) from mice (Recchia et 
al., 2004). However, the authors did not further characterize whether the integrase protein 
(Rep) or the AdV itself caused the bias. Moreover, the small amount of integration events 
was not convincing enough to make decisions on the chromosomal distribution.  
Another factor that may influence the chromosomal location is the stuffer DNA 
contained in the HC-AdV genome. Many HC-AdVs contain noncoding “stuffer” DNA to 
maintain the size of the vector DNA within appropriate virion packaging limits. Previous 
studies showed that the nature of the stuffer sequence not only affects the replication and 
production of the HC-AdVs, but also has a significant effect on the function of the vector 
(Sandig et al., 2000). An HC-AdV vector containing 22 kb of eukaryotic DNA has been shown 
to express a transgene to a higher level and for a longer duration than a vector containing 22 
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kb of prokaryotic DNA, both in vitro and in vivo (Parks et al., 1999). A HC-AdV containing a 
21.5-kb human β-globin locus control region (LCR) derived from the β-globin minilocus 
revealed a 25% integration frequency within the genomic globin LCR (Wang and Lieber, 
2006). As to the stuffer DNAs used in the HC-AdVs of this study, it includes a 16.2-kb human 
centromeric fragment and a murine IgκMAR. Although this centromeric region and the 
IgkMAR are not presented on the murine X-chromosome, and sequence homology was not 
found either, it is likely that the vector backbone DNA might influence the integration pattern. 
However, it remains to be determined whether these elements caused the bias towards X-
chromosomal distribution of integration events in the present study. 
It is of note, that the integration sites obtained in other studies were analyzed by 
different methods. For example, in the plasmid-based SB integration study, a plasmid rescue 
method was used (Yant et al., 2005). That method relies on self-ligation of the digested 
flanking DNA, and depends on antibiotic selection in bacteria (Rutledge and Russell, 1997).  
Utilizing this strategy, AAV integration junctions were first analyzed from AAV vector 
transduced Hela cells (Miller et al., 2002; Rutledge and Russell, 1997). Recently, SB and 
PhiC31 mediated integration profile were also determined by plasmid rescue as well as 
integration of AAV in mouse liver (Ehrhardt et al., 2006; Nakai et al., 2005; Yant et al., 2005). 
Compared to the GenomeWalker-based method used in my study, this method has the 
advantage to track the flanking genomic DNA from both sides of the integrated cargo in 
parallel. Thereby, it is possible to analyze the chromosomal deletions and potential 
rearrangements. However, as the selection depends on the antibiotic resistance gene 
expressed from the transgene cargo, this method is not applicable for most kind of gene 
transfer applications, when the transgene is a functional gene like a coagulation factor gene 
(cFIX) used in my study.  
Another method called linear amplification–mediated PCR (LAM-PCR) is the most 
advanced and widely used approach especially in clinical studies. So far, it has been used 
for most of lentiviral and retroviral vector studies. This method combines the linear 
amplification of the target DNA with solid-phase second-strand synthesis. Therefore, the 
sensitivity, specificity and efficacy is considered to be very high (Schmidt et al., 2009; 
Schmidt et al., 2002). It was shown that LAM-PCR has the ability to characterize highly 
complex samples with multiple target sequences and sensitivity down to the single-cell level 
(Schmidt et al., 2007). Recently, Schmidt and colleagues further developed this linear 
amplification–mediated PCR to nonrestrictive LAM-PCR (nrLAMPCR), which allows the 
comprehensive genome-wide detection of existing integration sites without the use of any 
restriction enzyme (Gabriel et al., 2009; Paruzynski et al., 2010). These modifications ensure 
a unidirectional ligation of the linker to the PCR products. Importantly, this approach solved 
the problem of bias of the integration sites caused by the choice of the restriction enzyme(s) 
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(Gabriel et al., 2009; Paruzynski et al., 2010). Although not as sensitive as LAM-PCR, 
nrLAMPCR obviously increased the integration sites retrieval, and identifies variable 
amplicon sizes of sequences around integration sites. 
In summary, the integration events identified might be method-dependent. For 
example, in the present study, due to the restriction enzymes used, only the sites that 
located near certain enzymes could be rescued by the GenomeWalker-based method. 
Moreover, this GenomeWalker-based method may not be sensitive enough to identify a high 
amount of events compared to a method like LAM-PCR.  
 
4.2.3. The potential genotoxicity associated with the novel adenovirus/transposase 
hybrid-vectors  
Cancer caused by insertional mutagenesis has been one major concern. Animal 
models and unfortunately also clinical trials have revealed that the genomic risk associated 
with insertional mutagenesis originating from integrating vectors can be fatal (Li et al., 2002; 
Baum et al., 2006; Ott et al., 2006; Lai et al., 2010). Therefore, I have begun to evaluate the 
cancer-causing-potential of the novel HC-AdV/SB hybrid-vector system. 
From all 136 integration events identified in mice, 10 were located in or near (±5kb) 
cancer-related genes (CRGs) (Table 3.1). Of these CRGs, three genes (GPC3 and CASK 
from f1; ITCH from f2) which can be related to hepatocellular carcinoma (HCC) are of high 
consideration. GPC3 is member of the glypican-related integral membrane proteoglycan 
family (GRIPS). Proteins of this family may play a role in the control of cell division and 
growth regulation (Zittermann et al., 2010; Suzuki et al., 2010). Therefore, the insertional hit 
in this gene would not be the „original sin‟ to develop cancer, but may change the regulation 
function of this cancer-suppressing gene. The CASK gene encodes a calcium/calmodulin-
dependent serine protein kinase, and belongs to the membrane-associated guanylate kinase 
(MAGUK) family of scaffolding molecules, which are associated with intercellular junctions 
(Hsueh, 2009; Hsueh et al., 2000). Since the CASK encoding protein is essential for gene 
ontology features (cell adhesion and protein phosphorylation), it may be speculated that the 
insertion of foreign DNA may affect the cellular fate. The ITCH gene encoded protein is a 
closely related member of the NEDD4-like protein family. This family of proteins are E3 
ubiquitin-ligase molecules and regulate key trafficking decisions, including targeting of 
proteins to proteosomes or lysosomes (Fang et al., 2002). Moreover, E3 ligase ITCH is 
upregulated in anergic T cells (Gronski et al., 2004). Development of cancer is seen as a 
failure of the immune system to control tumor growth. Therefore, the loss-of-function 
mutation in ITCH could decrease the T cells viability. 
Integration events in or near cancer-related genes have been found from integrating 
viral vectors like retroviral vectors (Li et al., 2002; Hacein-Bey-Abina et al., 2003) and 
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lentiviral vectors (Themis et al., 2005), as well as AAV (Donsante et al., 2007), and have 
been proven to be related to cancer induction. A recent study analyzed the integration profile 
from three mostly used non-viral integrating vectors, Sleeping Beauty (SB), Tol2, and 
piggyBac (PB) transposon systems. After transfection of human primary T cells, 10 cancer-
related genes were found as targets from the 96 selected T cell colonies. Interestingly, these 
cancer-related genes were only found from Tol2 and PB mediated integrations, none from 
SB-mediated integration events. The authors concluded that Tol2 and PB more likely 
promote clonal expansion than SB (Huang et al., 2010a). Also in other studies, which 
analyzed SB-mediated integrations (Yant et al., 2005; Staunstrup et al., 2009; Moldt et al., 
2011), cancer-related gene targeting was not yet reported.   
Since at least 1% of the gene repertoire may be involved in the various forms of 
cancer, transgene integration has a relatively high potential to affect genes regulating cell 
growth and survival (Kustikova et al., 2010). However, the induction of cancer by a single 
insertional mutagenesis may not have a high impact, as cancer is a multi-step process that 
requires quite specific forms of oncogene collaboration (Hanahan and Weinberg, 2000). This 
assumption was supported by a recent study, which assessed the potential for AAV vector 
genotoxicity in a murine model. After 18 months of follow-up, AAV injected mice did not show 
a significantly higher rate of hepatocellular carcinoma compared with controls. Although 1029 
integrants were identified, no integration events were identified as causing increased 
oncogene expression (Li et al., 2011). 
Another concern from this study is that high genome copy numbers of transposase 
encoding vector (Hc-AdV-HSB5/mSB) were detected in the hybrid-vectors administrated 
mice (Figure 3.17). Long-term high level SB transposase expression may cause transposon 
moving, potentially resulting in an increase of the cancer forming potential. However, the 
frequency of SB mobility from mammalian cell chromosomes was turned out to be very low 
(10-4 to 10-6 events per transfected cell) (Luo et al., 1998; Yant and Kay, 2003; Yant et al., 
2004). Meanwhile, in the vector design, a phospho-glycerate kinase promoter (PGK) is used 
to control the expression of SB transposase (Figure 3.1). This PGK promoter is relatively 
weak but constitutively expressed. Therefore, the expression of transposase is probably not 
high but still existing. Of cause this prediction needs to be confirmed by the analyses of 
transcription and expression levels of SB. A recent study examined Sleeping Beauty 
transposase after trans delivery in primary human T cells. They also found an unexpectedly 
high copy number of Sleeping Beauty transposase but low frequency of persistent 
expression (Huang et al., 2010b). 
Nevertheless, the present analyses gave the primary insight to the cancer-causing-
potential of the adenovirus/transposase hybrid-vectors in liver. Data from this study showed 
integration events into cancer-related genes, but it remains unknown whether this may alter 
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the expression of these genes or neighboring cancer-related genes. Therefore, it would be of 
high interest to investigate whether the cancer-related genes in or near the integration sites 
are transcriptional activated or suppressed. 
 
4.3. Improving gene therapy efficiency through engineered transgene expression 
cassettes  
In this study, I aimed at increasing the efficacy and safety of hemophilia B gene 
therapy by using gene transfer vectors that express a catalytically enhanced FIX molecule. 
The rationale was that such variant could increase the therapeutic index of the vector by 
permitting a therapeutic outcome at lower viral vector doses. This is important because viral 
vector-mediated toxicity is dose dependent, as shown in the present and other studies 
(Brunetti-Pierri et al., 2004).  
In this study I evaluated vectors expressing one previously described bioengineered 
FIX molecule (K265T/Y345T) in both tissue culture and in a murine model for hemophilia B. 
Although transgene expression has been observed in a plasmid context in transfected Huh7 
cells, this recombinant coagulation factor was not able to show higher clotting activity in FIX-
deleted plasma compared to the wild type protein (data not shown). In a hemophilia B 
mouse, the tail vein injection of 2x109 transducing units of a high-capacity adenoviral vector 
containing this human coagulation factor variant (HC-AdV-hyhFIX) resulted in 700-1600 
ng/ml FIX antigen levels and 2.6-8.3% clotting activity (Figure 3.22). 
The initial study showed that Y94F, K98T and Y177T substitutions in a Gla-EGF1 
domain-truncated FIXa increased the cleavage rate of the FXa-specific chromogenic 
substrate d-Nle-Gly-Arg-pNA 7000-fold (Sichler et al., 2003). However, the effects of the 
mutations on FIX activity in the model systems are different from those observed in plasma. 
One recent study constructed five pre-described full-length FIX mutants with amino acid 
exchanges in the catalytic domain of FIX and characterized their activity in FX activation in 
model systems and in plasma (Hartmann et al., 2009). Similar to our result, it was found that 
these mutants showed no or marginally improved catalytic properties in FX activation by the 
intrinsic tenase complex (FIXa-FVIIIa-Ca (2+)-phospholipid). As to the activation of the 
natural substrate FX, the Y94F and K98T substitutions (chymotrypsinogen numbering 
Y94F/K98T equals to Y259F/K265T by the normally used FIXa numbering) enhanced the 
catalytic efficiency of FX activation approximately two-fold (only in the absence of FVIIIa). 
Unexpectedly, the catalytic efficiency even decreased (both with and without FVIIIa) when 
the Y177F (equals to Y345T in our study) substitution was introduced into FIXa-Y94F/K98T. 
The activity of this FIX mutant (FIXa-Y94F/K98T/Y177F) was even lower than that of plasma-
derived FIXa (Hartmann et al., 2009). A potential explanation could be that these hyperactive 
mutants evaluated from model systems may impair their FVIII binding activity. Therefore, the 
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enhancement of FXIa-catalyzed activation of the FIX mutants determined in model systems 
are not representative of those clotting activities measured in plasma when FVIII is 
presented. This could be one reason for the fact that I did not observe expected higher 
clotting activity in plasma assay from the pre-described hyperactive-hFIX mutant. 
There are recent studies which applied hyperactive factor IX in a gene therapy 
setting, such as FIX-R338A (Schuettrumpf et al., 2005), R338A+FIXVIIEGF1 (Brunetti-Pierri et 
al., 2009) and FIX-V86A/E277A/R338A (Lin et al., 2010). These in vitro screen-generated 
mutants with improved catalytic activity were shown to increase the therapeutic index of 
hemophilia B gene therapy. Importantly, all these mutants included an essential mutation at 
amino acid position 338. This residue change has not only been shown to increase the 
catalytic activity from recombinant FIX (R338A) (Chang et al., 1998), but also in a clinical 
study. In that study, a thrombophilia patient with FIX containing a gain-of-function mutation 
(R338L), revealed approximately eight times increased clotting activity compared to the 
normal factor IX protein (Simioni et al., 2009). Arginine at position 338 and these in the near 
region are highly conserved in factor IX from mammals (Czapinska and Otlewski, 1999), and 
this region of the protein is important for substrate (factor X) binding. Stop-codon mutations 
at R338 are common in hemophilia B, but there is only one missense mutation (R338P) at 
this position in hemophilia B identified (Bottema et al., 1993; Ketterling et al., 1994; P.M. 
Green, 2004) (The Haemophilia B Mutation Database – version 13, 
http://www.kcl.ac.uk/ip/petergreen/haemBdatabase.html). Therefore, the R338 substitution is 
an essential candidate when developing hyperactive FIX mutants. My primary evaluation of a 
hFIX variant which combining the R338A substitution to the hFIX-K265T/Y345T mutant 
(result in hFIX-K265T/Y345T/ R338A) showed enhance activity than that without R338A in 
tissue culture (data not shown). 
Last but not least, although our study needs further investigation, it is believed that 
the idea to use bioengineered FIX molecules with enhanced activity still holds great promise. 
In the gene therapy context, use of such molecules would greatly improve safety and efficacy 
by permitting the administration of lower vector doses for achieving a therapeutic benefit. For 
example, the innate inflammatory immune response directed towards to Ad-based vectors is 
strongly dose dependent (Morral et al., 2002; Brunetti-Pierri et al., 2004) and therefore, any 
reduction in vector dose would greatly increase the vectors‟ therapeutic index.  
 
4.4. Outlook and future perspectives 
The adenovirus/transposase hybrid-vector system is a valuable tool for direct in vivo 
gene therapy based on the SB transposase. However, the treatment of hemophilia B dogs 
revealed a narrow therapeutic window for this system. To face the challenge to translate from 
preclinical studies to the clinics, the system needs to be further optimized. In general there 
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are two directions for improving the system. On the one hand, the efficiency of each single 
component of the hybrid-vector system could be improved. For instance, the integrating 
machinery (SB) used in this hybrid-vector system could be optimized with respect to activity. 
Although this HSB5 has been shown to be hyperactive compared to the former version SB11 
(Yant et al., 2004), even more advanced versions emerged in the last years, like SB100X 
that displayed 100 times higher transposase efficiency in tissue culture and SB100Xo, a 
codon-optimized version of SB100X that adapted to optimal tRNA usage for Homo sapiens 
(Mates et al., 2009; Galla et al., 2011). It may be speculated that the application of the more 
efficient transposases will significantly increase the integration efficiency as well as the 
therapeutic effect. Besides the efficiency, the specifity of the transposase could be another 
important aspect to be improved. Most of the unwanted side effects are due to the off-target 
integrations, therefore, a transposon designed to integrate specifically into „safe‟ harbors, 
could decrease the risk of genotoxicity. On the other hand, the transgene expression 
cassettes could be optimized. As discussed, the utility of a hyperactive enzyme (FIX) may 
represent a potential solution to increase the therapy effect. For instance, it would be 
interesting to further explore the effect of the single mutant R338A/L (Chang et al., 1998; 
Simioni et al., 2009) in the functional improvement of the current hFIX variants 
(K265T/Y345T), or even in the cFIX context. Furthermore, the selection of different introns 
could highly increase the transgene expression levels (Kurachi S Fau - Furukawa et al., 
1995; Sam et al., 2010). Also, the stuffer DNA contained in the HC-AdV genome has been 
shown to play a critical role in the virus production and transgene expression, as well as in 
integration.  
Another important challenge which needs to be addressed in the future is the 
complexity of the design of this adenovirus/SB transposase hybrid-vector system. The co-
delivery of the transposon-donor and -actor vectors makes the efficiency of somatic 
integration highly dependent on entry of these two vectors into one cell. In absence of either 
FLP or SB, the system does not mediate integration. Therefore, the ratio between 
transposons and SB transposase proteins should be optimized including the ratio between 
vectors and the promoters driving the transcription of SB transposase and Flp recombinase. 
Alternatively, utilizing an inducible system for expression of the integration machinery might 
reduce genotoxic and immunogenic side effects and may decrease an overproduction 
inhibition effect. In the further, it could be attractive to explore a “one vector-strategy” 
including all components for somatic integration (therapeutic DNA and the respective 
recombinase) in one vector genome is an option to overcome the necessity of co-
transduction of one cell with two vectors.  
Furthermore, to characterize the AdV/SB integration profile in more detail, it would be 
beneficial to apply a more sensitive method, like nonrestrictive linear amplification–mediated 
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PCR (nrLAM-PCR) (Gabriel et al., 2009; Paruzynski et al., 2010)(Gabriel, R, 2009; 
Paruzynski A. 2010) to analyze a large amount of integration events. The present study was 
the first to show an unevenly chromosomal distribution after SB-mediated integration, and 
this X-chromosome biased distribution needs to be further explored at a higher resolution of 
integration events. Furthermore, it would be helpful to compare the different methods of 
integration site analyses, to evaluate whether the integration preference for the X-
chromosome was method-dependent. Moreover, cancer-related genes in or near integration 
sites were identified and raise concern about the cancer-causing-potential of SB 
transposase. Thus, it will be of interest to analyze the transcription and expression levels of 
these cancer-related genes, to determine at which degree the integrations events influences 
the respective target site. In addition, regarding the extra-chromosomal integrations, we do 
not know the mechanism of these unwanted vector rearrangements. It would be interesting 
to further evaluate these integrations, to get a clearer view of the adenovirus/transposase 
hybrid-vectors for in vivo application. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary 
 
95 
 
Summary 
Gene therapy can be used to treat devastating inherited diseases, especially 
diseases and patients that are not suitable for a conventional cure. The blood clotting 
disorder hemophilia is one of the most extensively studied monogenetic diseases in gene 
therapeutic approaches. Several viral vectors were tested for the treatment of hemophilia B. 
The administration of an episomal adenoviral vector at non-toxic dose showed effective 
phenotypic correction, but the therapeutic effect was only transient. Therefore, the 
combination of non-viral integration machineries for somatic integration with adenoviral 
vectors for efficient delivery offers a promising alternative for achieving persistent transgene 
expression. Towards this end, the delivery of the Sleeping Beauty transposase (SB) 
integration machinery via high-capacity adenoviral vectors (HC-AdVs) has demonstrated 
efficient hepatocyte-directed gene transfer and long-term coagulation factor IX expression in 
vivo.  
However, the safety issues of this adenoviral vector/Sleeping Beauty transposase 
(AdV/SB) hybrid-vector system, especially the vector dose-effect and genotoxicity were not 
addressed yet. Thus, I evaluated this hybrid-vector system in both mice and a canine model 
for hemophilia B with different vector dose settings, and analyzed the integration profile in 
respect to genotoxicity after systemic administration. 
First of all, the viral vector preparations involved in the AdV/SB hybrid-vector studies 
were analyzed regarding physical and infectious titers. To avoid toxic side effects, the helper 
virus (HV) contamination levels were quantified and the potential existence of replication-
competent adenovirus (RCA) in final vector preparations was excluded by quantitative real-
time PCR. Only the HC-AdV preparations with high amounts of transducing units (107-108 
TUs/µl), low HV contamination levels (<0.03%) and undetectable RCA were subsequently 
used for in vivo studies. 
My study showed that this AdV/SB hybrid-vector system can result in significantly 
stabilized transgene expression in rapidly dividing hepatocytes in both male and female 
mice, as well as in a canine model for hemophilia B (three years). Notably, I demonstrated 
that the efficiency of the hybrid-vector system in terms of long-term transgene expression 
occurred in a dose-dependent manner. This phenomenon was confirmed at the molecular 
level by determining vector genome copy numbers of the AdV/SB hybrid-vectors in liver of 
treated animals. Furthermore, it was found that the toxicity profile of the hybrid-vector was 
also dose-dependent.  
Regarding genotoxicity, the SB transposition events from the adenoviral vector were 
identified and analyzed at chromosomal level. For integration site analysis, I first established 
a PCR-based method for high-throughput analysis of integration events. Utilizing this 
method, I identified a total of 163 SB transposase-mediated integration events from five 
Summary 
 
96 
 
transduced mice liver and 9 events from dog. Herein, similar to previously published plasmid-
based studies, a fairly random integration pattern with respect to genes (exons and introns) 
and intergenic regions was observed for the adenovirus hybrid-vector. Unexpectedly, the 
chromosomal distribution displayed a bias towards the X-chromosome in female mice. 
Moreover, some extra-chromosomal integration events were observed, most likely due to 
vector rearrangements. Furthermore, 10 integration events were located in and near cancer-
related genes, but the cancer-causing-potential of SB remains to be analyzed.   
Besides the vector itself, the transgene can significantly influence the outcome of a 
gene therapeutic approach. To increase the therapeutic index of hemophilia B gene therapy 
utilizing adenoviral vectors, a previously described hyperactive human coagulation factor IX 
variant (hFIX-K265T/Y345T) was evaluated. However, the exploration did not reveal the 
expected hyperactive effect. Nevertheless, the utility of an improved transgene expression 
cassette represents a promising strategy for optimized gene therapeutic approaches. 
In summary, this thesis provides novel insights into the adenovirus/SB transposase 
hybrid-vector system and demonstrates that this integrating adenoviral vector system 
presents a promising tool for gene therapy especially in regenerating tissues.  
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Zusammenfassung 
Gentherapie ist eine vielversprechende Methode um schwerwiegende Erbkrankheiten 
zu behandeln, vor allem jene, die nicht durch eine konventionelle Behandlung therapiert 
werden können. Eine der am meisten untersuchten monogenetischen Erkrankungen in 
gentherapeutischen Ansätzen ist die Hämophilie B, die auf einer Störung der Blutgerinnung 
basiert. Diverse virale Vektoren wurden bereits für die Behandlung von Hämophilie B 
getestet. Die Verabreichung einer nicht toxischen Dosis eines episomalen, adenoviralen 
Vektors zeigte hierbei eine signifikante phänotypische Verbesserung, der therapeutische 
Effekt war jedoch nur transient. Deshalb bietet die Kombination aus nicht-viralen 
Integrationssystemen für somatische Integration zusammen mit einem adenoviralen Vektor 
für einen effizienten Transport in die Zelle eine vielversprechende Alternative für anhaltende 
Transgenexpression. Diesbezüglich demonstrierte die Integrationsmaschinerie der Sleeping 
Beauty Transposase (SB) in Kombination mit einem gen-deletierten, adenoviralen Vektor 
(HC-ADV) effizienten Hepatozyten-Gentransfer und langfristige Faktor IX Expression in vivo. 
Allerdings wurde bisher die Eigenschaft dieses adenoviralen Vektor/Sleeping Beauty 
Transposase (AdV/SB)-Hybrid-Vektor-Systems, vor allem im Hinblick auf die Vektor-Dosis 
und Genotoxizität nicht untersucht. Im Rahmen dieser Arbeit wurde dieses Hybrid-Vektor-
System sowohl in Mäusen als auch im Hunde-Modell für Hämophilie B angewandt. Dabei 
wurde die Vektor-Dosis variiert und das Integrationsprofil in Bezug auf Induktion von 
Genotoxizität nach systemischer Applikation analysiert. 
Zunächst wurden die viralen Vektoren der AdV/SB-Hybrid-Vektor-Studien hinsichtlich 
physischem- und infektiösem Titer untersucht. Um toxische Nebenwirkungen zu vermeiden 
wurde zudem die Helfer-Virus (HV) Kontamination quantifiziert und die Existenz von 
replikationskompetenten Adenoviren (RCA) in dem endgültigen Vektor-Präparat wurde 
ausgeschlossen. Die HC-AdV Präparate mit hohen Mengen an transduzierenden Einheiten 
(107-108 TUs/µl), geringer HV Kontamination (<0.03%) und nicht nachweisbaren RCA 
wurden anschließend in den in vivo-Studien eingesetzt. 
Weiterhin konnte gezeigt werden, dass das AdV/SB-Hybrid-Vektor-System  die 
Transgenexpression in sich schnell teilenden Hepatozyten in männlichen und weiblichen 
Mäusen, sowie in einem Hunde-Modell für die Hämophilie B signifikant steigert. Die 
Dosisabhängigkeit des Hybrid-Vektors konnte im Bezug auf langfristige Transgenexpression 
in dieser Arbeit demonstriert werden. Dieses konnte außerdem auf molekularer Ebene durch 
die Bestimmung der Kopienzahl der Vektorgenome in der Leber der behandelten Tiere 
bestätigt werden. Darüber hinaus wurde gezeigt, dass auch das Toxizitätsprofil des Hybrid-
Vektors dosisabhängig ist. 
In Bezug auf Genotoxizität wurden die SB vermittelten Transpositionsereignisse 
ausgehend von dem adenoviralen Vektor identifiziert und auf chromosomaler Ebene 
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untersucht. Die Analyse der Integrationsorte erforderte die Etablierung einer PCR-basierten 
Methode für eine Hochdurchsatz-Analyse. Mit Hilfe dieser Methode konnten insgesamt 163 
SB Transposase-vermittelte Integrationsereignisse aus fünf Mäusen und neun Ereignisse in 
der transduzierten Hundeleber identifiziert werden. Hierbei konnte, vergleichbar mit den 
zuvor veröffentlichten Plasmid-basierten Studien, ein zufälliges Integrationsmuster in Bezug 
auf Gene (Exons und Introns) und intergenische Regionen beobachtet werden. Dennoch 
zeigte die chromosomale Verteilung eine Tendenz zu dem X-Chromosom in weiblichen 
Mäusen. Darüber hinaus wurden einige extra-chromosomale Integrationsereignisse 
beobachtet, vermutlich aufgrund von Vektorumlagerungen. Außerdem konnten 10 
Integrationsereignisse in der Nähe von Krebs-Genen lokalisiert werden. Das tumorigene 
Potential dieser Integrationen bleibt zu untersuchen. 
Neben dem Vektor kann auch das Transgen selbst das Ergebnis einer Gentherapie 
beeinträchtigen. Zur Optimierung der Hämophilie B-Gentherapie, wurde im Rahmen dieser 
Arbeit eine zuvor beschriebene hyperaktive Faktor IX-Variante (hFIX-K265T/Y345T) 
charakterisiert. Die Analysen zeigten jedoch nicht die erwartete hyperaktive Wirkung des 
Blutgerinnungsfaktors. Dennoch stellt die Verbesserung der Transgen-Expressionskassette 
eine vielversprechende Strategie für eine optimierte gentherapeutische Anwendung dar. 
Zusammenfassend vermittelt diese Arbeit neue Einblicke in das Adenovirus/SB 
Transposase Hybrid-Vektor-System und zeigt, dass ein integrierendes System basierend auf 
einem adenoviralen Vektor besonders in regenerativen Geweben ein vielversprechendes 
Werkzeug für die Gentherapie ist. 
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5. Appendix 
5.1. Molecular size marker 
 
 
5.2. Abbreviations 
AAV Adeno-associated virus 
Ad5 wt  Adenovirus serotype 5 wild type 
Ad Adenovirus 
AdV Adenoviral vector 
ALT  Alanine transferase 
Amp
R
 Resistance against ampicillin 
ApoE Apolipoprotein E 
APPT Actived partial thromboplastin time assay 
bp Base pairs 
cDNA  Complementary DNA 
cFIX Canine blood coagulation factor IX 
CIP Calf intestine phosphatase 
CMV Cytomegalovirus 
CsCl Cesium chloride 
DNA Desoxy ribonucleic acid 
dNTPs  Desoxy nucleoside triphosphates (dATP, dCTP, dTTP, dGTP) 
dATP  Desoxy adenosine triphosphate 
dCTP  Desoxy cytidine triphosphate 
dGTP  Desoxy guanosine triphosphate 
dTTP  Desoxy thymidine triphosphate 
 
 
Appendix Figure 1: DNA markers for agarose gel. (a) peqGOLD 1kb DNA marker. This 
molecular marker was used for approximate determination of DNA fragments on 1% agarose gels. 
The sizes of the single bands are indicated. Size range: 250bp to 10000bp. (b) peqGOLD 100bb 
DNA marker. This molecular marker was used for approximate determination of DNA fragments on 
1.5-2% agarose gels. The sizes of the single bands are indicated. Size range: 100bp to 1000bp. 
Pictures obtained from peqlab Biotechnology GmbH.  
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DMSO  Dimethyl sulfoxide 
ds Double-stranded 
EDTA Ethylene diamine tetra acetic acid 
ELISA Enzyme Linked Immunosorbent Assay 
EtBr Ethidium bromide 
FBS  Foetal bovine serum 
Flp Flippase recombination enzyme 
FRT Flippase Recognition Target 
Gen
R
 Resistance against geneticin 
hAAT  Human alpha-1-antitrypsin 
HC-AdV High-capacity adenoviral vector 
HCR Hepatic control region 
hFIX  Human blood coagulation factor IX 
hFVIII   Human blood coagulation factor VIII 
HIV      Human immunodeficiency virus  
Hyg
R
 Resistance against hygromycin B 
HSV Herpes simplex virus 
IDLVs Integrase-defective lentiviral vectors 
IRs    Inverted repeats  
ITR Inverted terminal repeat 
Kan
R
 Resistance against kanamycin 
kb Kilo base pairs 
LB Luria Bertani 
MAR  Matrix attachment region 
MCS  Multiple cloning site 
mg milligram 
ml millilitre 
MLV   Murine leukemia virus 
MOI  Multiplicity of infection (VPs/cell) 
mRNA Messenger RNA 
ng nanogram 
nM nanomolar 
OD260nm  Optical density at 260 nm 
ORF Open reading frame 
ori Origin of replication 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PGK Phospho-glycerate kinase promoter 
phiC31 Bacteriophage integrase 
p.i. post infection 
polyA Polyadenylation signal 
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rAdV Recombinant adenoviral vectors 
RNA Ribonucleic acid 
RT Room temperature 
SB Sleeping Beauty transposase 
SCID Severe combined immunodeficiency syndromes 
SDS Sodium dodecyl sulfate 
SV40 Simian virus 40 
TA Tyrosin and adenosine dinucleotide 
TAE Tris-acetate-EDTA 
TBS Tris-buffered saline 
TBS-T  TBS-Tween 20 
TE Tris-EDTA 
TP Terminal protein 
TRIS Tris-(hydroxymethyl)-ammonium methane 
TUs Transducing units 
VPs Viral particles 
WBCT Whole blood clotting time 
ZFNs Zinc-finger nucleases 
Ψ   Packaging signal 
°C Degree Celsius 
 
 
5.3. SB insertion site mapping in mouse genome 
Appendix Figure 2: SB insertion site mapping in mouse genome. The relative positions of 136 
independent integration sites from all 5 mice for SB-mediated transposition from adenovirus construct 
(AdV/SB hybrid-vector system) within the mouse genome were mapped according to BLAST results 
against NCBI mouse genomic DNA database. The red triangles indicate the relative positions of the 
chromosomal transposon integrations observed from mice liver genomic DNA. Figures (a-e) indicate 
each single mouse. (a) f1: female mouse 1. (b) f2: female mouse 2. (c) f3: female mouse 3. (d) m1: 
male mouse 1. (e) m2: male mouse 2. (f) The summary of all integration sites from these 5 mice. 
 
 
 
 
 
 
 
Appendix 
 
102 
 
 
 
 
Appendix 
 
103 
 
 
 
 
 
 
Appendix 
 
104 
 
 
 
 
Appendix 
 
105 
 
5.4. Detailed description of transposition sites in mouse and dog liver genomic 
DNA 
Appendix Table 
Chromosome 
location:  
hit from 
Band located 
gene 
gene  
symbol 
orient- 
ation 
cancer-  
related 
 gene 
distance to genes                           
      Upstream       downstream 
female mouse 1        
chr1: 194422060 1H6 Intragenic Hhat  (+) no   
chr3: 65662292 3 E1 intergenic N/A (-) N/A >> >> 
chr4: 104929873 4C6 intergenic N/A (+) N/A 25 kb >> 
chr5: 92880283  5 E2 Intragenic Scarb2  (+) yes   
chr8: 36919710  8A4 intergenic N/A (-) N/A 30 kb >> 
chr8: 38395562 8A4 intergenic N/A (+) N/A >> >> 
chr8: 50820216  8B1.2 intergenic N/A (+) N/A >> >> 
chr9: 3020270 9A4 intergenic N/A (+) N/A >> >> 
chr9: 42533603 9A5.1 Intragenic Grik4  (+) no   
*chr9: 52086874 9A5.3 intergenic N/A (-) N/A >> >> 
chr10: 35140724   10B1 intergenic N/A (-) N/A 17 kb 9.8 kb down 
after Pm20d1  
chr12: 46830855  12B3 intergenic N/A (+) N/A >> >> 
chr12: 98173577 12E intergenic N/A (+) N/A >> >> 
chr15: 74257858  15D3 intergenic N/A (+) N/A >> >> 
chr16: 70579425 16C2 intergenic N/A (+) N/A 10.1 kb >> 
chr18: 11755160 18A1 intergenic N/A (+) N/A >> >> 
chr19: 8282601 19A Intragenic D63000-
2G06Rik 
(-) no   
chr19: 36673880   19C2 Intragenic Hectd2  (-) no   
*chr19: 
57747837  
19D2 Intragenic Atrnl1   (+) no   
chr19: 58649662 19D2 intergenic N/A (-) N/A 21 kb >> 
chrx: 3833873 XA1.1 intergenic N/A (+) N/A >> >> 
chrx: 10225114  XA1.1 intergenic N/A (+) N/A >> >> 
chrx: 13341506 XA1.1 Intragenic Cask   (-) yes   
chrx: 15843807 XA1.2 intergenic N/A (-) N/A >> >> 
chrx: 33107224 XA3.2 intergenic N/A (+) N/A >> >> 
chrx: 44119865  XA4 intergenic N/A (+) N/A >> >> 
chrx: 49859131 XA5 Intragenic Gpc3  (-) yes   
chrx: 53163914 XA5 Intragenic Gm8015 (-) no   
chrx: 89237584 XC1 intergenic N/A (-) N/A >> 22.9 kb 
chrx: 105294595  XD intergenic N/A (+) N/A >> >> 
chrx: 105740425 XD intergenic N/A (-) N/A >> >> 
chrx: 106723407 XD intergenic N/A (+) N/A >> >> 
chrx: 108319959 XE1 intergenic N/A (+) N/A 513 bp up 
to Cylc1 
>> 
chrx: 115229175 XE1 intergenic N/A (+) N/A >> >> 
chrx: 121295716  XE3 intergenic N/A (+) N/A 46 kb >> 
chrx: 130860559 XE3 intergenic N/A (-) N/A 9.3 kb up 
to Arl13a 
7.3 kb down 
after Trmt2b 
chrx: 139540810 XF2 intergenic N/A (+) N/A 1.58 kb 
up to 
Rgag1 
>> 
chrx: 146195524 XF3 intergenic N/A (-) N/A >> 29 kb 
        
female mouse 2        
chr1: 40405475 1B Intragenic Il1rl2  (+) no   
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 Appendix Table continued 
Chromosome 
location:  
hit from 
Band located 
gene 
gene  
symbol 
orient- 
ation 
cancer-  
related 
 gene 
distance to genes 
chr1:40405964 1B Intragenic Il1rl2  (-) no   
chr1: 133682925 1 E4 intergenic N/A (-) N/A >> >> 
chr2: 154999131 2H1 Intragenic Itch  (-) yes   
chr3: 23027811 3A3 intergenic N/A (+) N/A >> 30 kb 
chr4: 45756871 4B1 intergenic N/A (+) N/A 2 kb up  
to Igkj5  
845bp down to  
Igk-C  
chr4: 71120349 4C2 intergenic N/A (-) N/A 24 kb >> 
chr4:83033499 4C3 intergenic N/A (-) N/A >> >> 
chr5: 75314112  5C3.3 intergenic N/A (+) N/A >> >> 
chr6: 70675170 6C1 intergenic N/A (-) N/A >> >> 
chr7: 79596448  7D1 intergenic N/A (+) N/A 9.8 kb up 
to 60S 
ribosomal 
protein 
L21-like 
12kb 
 
chr8: 7133849  8A1.1 intergenic N/A (+) N/A >> >> 
chr9: 3000960 9A4 intergenic N/A (+) N/A >> >> 
chr9: 84714017 9E 2 intergenic N/A (-) N/A >> >> 
chr10:89748283  10C2 Intragenic Anks1b  (-) no   
chr10: 
120789794 
10D2 intergenic N/A (-) N/A >> >> 
chr11: 18486121  11A3.1 intergenic N/A (+) N/A >> >> 
chr15: 20903343 15A2 intergenic N/A (-) N/A >> >> 
chr16: 16052282  16A2 Intragenic 231000-
8H04Rik  
(-) no   
chr19: 14809979  19A intergenic N/A (-) N/A >> >> 
chr19: 37444874   19C2 intergenic N/A (+) N/A 35 kb 6.2 kb down 
after Kif11 
chr19: 43843935  19C3 intergenic N/A (-) N/A 1.1 kb up 
to Cutc 
(cancer 
relative 
gene) 
12 kb 
 
chrx:  7224956   XA1.1 intragenic Syp  (+) no   
chrx: 12660407 XA1.1 intergenic N/A (-) N/A >> 11 kb 
chrx: 27868001, 
27207021, 
26778136 
XA3.1 
 
intergenic N/A (+) N/A 38 kb >> 
chrx: 32650536, 
29173628, 
24543339 
XA3.2 
 
intergenic N/A (-) N/A 21 kb >> 
chrx: 35713786 XA3.3 intergenic N/A (-) N/A 26 kb 43 kb 
chrx: 37563854  XA3.3 intergenic N/A (-) N/A >> >> 
chrx: 66650755 XA7.1 Intragenic Aff2  (-) no   
chrx: 67224297  XA7.1 intergenic N/A (-) N/A 25 kb >> 
chrx: 83829163 XC1 intergenic N/A (+) N/A >> >> 
chrx: 128596826 XE3 intergenic N/A (-) N/A >> >> 
chrx: 138187413 XF1 intergenic N/A (+) N/A 27 kb >> 
chrx: 138774886 XF2 Intragenic Acsl4   (-) yes   
chrx: 153941500 XF4 intergenic N/A (-) N/A 11 kb 47 kb 
        
female mouse 3        
chr1: 109939552 1E2.1 intergenic N/A (+) N/A >> >> 
chr2: 46430608  2B intergenic N/A (+) N/A >> >> 
chr2: 48181018  2B intergenic N/A (+) N/A >> >> 
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 Appendix Table continued 
Chromosome 
location:  
hit from 
Band located 
gene 
gene  
symbol 
orient- 
ation 
cancer-  
related 
 gene 
distance to genes 
        
chr3: 96293888  3F2.1 intergenic N/A (-) N/A >> >> 
chr4: 92665103 4C5 intergenic N/A (-) N/A >> >> 
chr4: 9790374 4A1 intragenic Gdf6   (+) no   
chr6: 139086159 6G1 intergenic N/A (-) N/A >> >> 
chr7: 48894699  7B3 intragenic Zfp788  (+) no   
chr10: 96805748 10C3 intergenic N/A (-) N/A >> >> 
chr11: 72029791 11B4 intragenic 4930563-
E22Rik 
(+) no   
chr12: 76703967   12C3 intergenic N/A (-) N/A 8.5 kb up 
to 
Ppp2r5c  
29 kb 
chr13: 
115413189 
13D2.2 intergenic N/A (-) N/A >> >> 
chr17:65504778 17E1.1 intergenic N/A (-) N/A >> >> 
chr17: 81325464  17 E3 Intragenic C230072-
F16Rik  
(-) no   
chrx: 21056881  XA2 intergenic N/A (-) N/A >> 6.1 kb down 
after Agtr2 
chrx: 90090876 XC2 intergenic N/A (+) N/A >> >> 
chrx: 119198273 XE3 intergenic N/A (+) N/A >> >> 
chrx: 152507426 XF4 intergenic N/A (+) N/A >> >> 
chrx: 152683688 XF4 intergenic N/A (-) N/A >> >> 
        
male mouse1        
*chr1: 37535572 1B intragenic Mgat4a   (+) yes   
chr2: 98502694  2E 1 intergenic N/A (+) N/A >> 9.8 kb down 
after Rngtt 
chr4: 33387605 4A5 intergenic N/A (-) N/A >> >> 
chr5: 21504508 5A3 intragenic Reln    (+) no   
chr5: 114227669 5F intragenic Iscu  (+) no   
chr6: 70675372 6C1 intergenic N/A (-) N/A >> >> 
chr6: 81394562  6C3 intergenic N/A (+) N/A >> >> 
chr7:22185492 7A3 intergenic N/A (-) N/A >> 5.9 kb down 
after Tmcc3 
chr7: 22668522 7A3 intergenic N/A (-) N/A >> >> 
chr10: 93971778 10C2 intergenic N/A (-) N/A >> >> 
chr11: 
116280651 
11 E2 intergenic N/A (-) N/A 6.5 kb up 
to Rnf157  
14 kb 
chr11: 21917357 11A3.1 intragenic Ehbp1  (-) yes   
chr12: 8130076 12A1.1 intergenic N/A (+) N/A >> >> 
chr12: 
102730920 
12E intergenic N/A (-) N/A >> >> 
chr13: 95763763 13D1 intragenic Wdr41  (+) no   
chr14: 
106831507 
14E2.3 intergenic N/A (+) N/A 15 kb >> 
chr15: 11026633 15A1 intergenic N/A (-) N/A >> >> 
chr15: 11540100 15A1 intragenic Adamts12  (+) no   
chr16: 67498961 16C2 intergenic N/A (-) N/A >> >> 
chr17: 26693467 17A3.3 intergenic N/A (+) N/A >> 4.57 kb down 
after Ergic1 
chrx: 8673141 XA1.1 intergenic N/A (+) N/A >> 8.3 kb down 
after 
4930402K13Rik 
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 Appendix Table continued 
Chromosome 
location:  
hit from 
Band located 
gene 
gene  
symbol 
orient- 
ation 
cancer-  
related 
 gene 
distance to genes 
        
chrx: 20425116 XA1.3 intergenic N/A (-) N/A >> 1.99 kb down 
after Araf 
(cancer relative 
gene) 
chrx: 22444327 XA2 intergenic N/A (-) N/A >> >> 
male mouse 2        
chr1: 48600054 1C1.1 intergenic N/A (-) N/A >> >> 
chr2: 21992479 2A3 intergenic N/A (-) N/A 1.5 kb 
after 
Gm13337 
>> 
*chr4: 29830686 4A4 intergenic N/A (-) N/A >> >> 
*chr4: 61508632 4B3 intergenic N/A (-) N/A >> >> 
chr4: 71120369 4C2 intergenic N/A (-) N/A >> 12 kb 
chr5: 36106310 5B3 intragenic Ablim2  (+) yes   
chr6: 65335553 6C1 Intragenic C130060-
K24Rik 
(-) no   
chr8: 18575969 8A1.2 intergenic N/A (-) N/A >> >> 
chr11: 18486436 11A2 intergenic N/A (+) N/A >>  
chr11: 18486585 11A3.1 intergenic N/A (-) N/A >> >> 
chr11: 
118496485 
11 E2 intragenic D11Bw-
g0517e  
(+) no   
chr12: 10642739 12A1.1 intergenic N/A (-) N/A >> >> 
chr13: 63684106 13B3 intergenic N/A (-) N/A >> 17 kb 
*chr13: 
71245313 
13C1 intergenic N/A (+) N/A >> >> 
chr13: 71245898 13C1 intergenic N/A (-) N/A >> >> 
chr13: 82419479 13C3 intergenic N/A (-) N/A >> >> 
chr15: 56690742 15D1 intergenic N/A (-) N/A >> >> 
chr16: 58651148 16C1.2 intergenic N/A (-) N/A >> >> 
chr16: 85890787 16C3.3 Intragenic Adamts5  (-) no   
chrx: 57950898 XA6 intergenic N/A (-) N/A >> >> 
chrx: 63637490 XA7.1 intergenic N/A (-) N/A >> >> 
        
Dog D1        
chr4: 65779013 N/A intergenic N/A (-) N/A >> >> 
chr5: 13684258 N/A intergenic N/A (-) N/A 28 kb 36 kb 
#chrx: 42244951 N/A intragenic Synap-
tophysin  
(+) no   
chrUn: 
59183592 
N/A intergenic N/A (+) N/A >> >> 
 
*integration events were found twice; # integration events were found several times. 
 >> Integration events were more than 50 kb way from genes. 
Only genes that were <10 kb from integration events were checked for cancer relation. 
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